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CHAPTER I 
 
INTRODUCTION 
 
 
Addiction is a chronic, relapsing disorder for which strikingly few effective 
therapies exist, and there are no FDA-approved pharmacotherapies for 
psychostimulant addiction.  There is an immense need to identify the 
neurobiological underpinnings of stimulant addiction and develop efficacious 
pharmacotherapies to compliment the current mainstay treatment of 
behavioral/cognitive therapy.  Several theories of addiction exist.  However, the 
propensity of drug-associated cues to increase neuronal activity (Childress et al., 
1999; Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002; Rebec and Sun, 
2005; Maas et al., 1998) and elicit drug-craving and seeking (Grant et al., 1996; 
Bonson et al., 2002; Ehrman et al., 1992) suggests a considerable contribution of 
maladaptive associative learning processes in the underlying neuropathology of 
addiction.  The association between the rewarding effects of abused substances 
and contextual cues can be profound and long-lasting.  Even after long-periods 
of abstinence, cues associated with drug-use can precipitate drug-craving, drug-
seeking and relapse to drug-taking (Ehrman et al., 1992; Hartz et al., 2001; 
O'Brien et al., 1992).  In the laboratory, conditioned place preference (CPP) is 
demonstrated by rodents (Tzschentke, 1998; Tzschentke, 2007) and humans 
(Childs and deWit H., 2009) whereby subjects will choose to spend time in a 
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context previously associated with a rewarding substance; a behavior which is  
thought to reflect the increased salience attributed to drug-associated cues. Thus 
CPP is a valuable research tool to evaluate the neuronal adaptations associated 
with drug-induced associative learning and provides a means to evaluate the 
utility of potential pharmacotherapies to reduce the salience of drug-associated 
cues.   
 
Methamphetamine (Meth) is a powerful psychostimulant which reliably produces 
CPP (Tzschentke, 2007; Tzschentke, 1998).  This behavior reflects molecular, 
cellular, and circuit adaptations that occur as a consequence of repeated 
psychostimulant administration (Hyman et al., 2006; Nestler, 2004) as well as the 
adaptations that underlie acquisition, maintenance, and expression of the Meth-
context association (Alberini, 2009; Bailey et al., 1996).  Human imaging studies 
demonstrate that basal neuronal activity is decreased in the cortex after chronic 
cocaine use (Bolla et al., 2004; Goldstein and Volkow, 2002; Volkow et al., 
1992).  However, the brain is hyper-responsive to stimuli, including unconditioned 
stimuli (subsequent drug-injections) (Sax and Strakowski, 2001; Pierce and 
Kalivas, 1997; McDaid et al., 2007; McDaid et al., 2006b) as well as conditioned 
stimuli (e.g., drug-associated cues) (Hotsenpiller et al., 2001; Rebec and Sun, 
2005; Rebec and Sun, 2005; Hotsenpiller and Wolf, 2002).  This hyper-
responsivity may be a mechanism underlying cue-induced drug-craving and -
seeking in humans (Childress et al., 1999; O'Brien et al., 1998; Childress et al., 
1999; Ehrman et al., 1992) and rodents (Crombag et al., 2008).   While the 
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hyper-excitable brain state is likely the consequence of maladaptations in a 
number of neurotransmitter systems such as down-stream signaling proteins, 
gene expression patterns, and neuronal function, decreased function of the γ-
amino butyric acid (GABA) system, the major inhibitory neurotransmitter in the 
central nervous system, may significantly contribute to the hyper-responsive 
brain state.  The metabotropic GABAB receptor (GABABR) system is down-
regulated by psychostimulant administration.  Such down-regulation includes 
decreases in GABABR expression (Frankowska et al., 2008b; Frankowska et al., 
2008a), G-protein expression (i.e., Gi/o) (Nestler et al., 1990), and functional 
coupling of the receptor to the G-protein (Xi et al., 2003; Zhang et al., 2000).  
However, it is not clear if this down-regulation occurs at a time when Meth-
conditioned behaviors are expressed or if a decrease in GABABR signaling 
during withdrawal might contribute to the maintenance of the mal-adapted brain 
state and behaviors.  This dissertation project evaluated GABABR 
expression and distribution at a time when rats demonstrate Meth-induced 
behaviors (e.g., CPP).   
 
The GABABR system has recently emerged as a potential therapeutic target for 
drug addiction (Brebner et al., 2002; Cousins et al., 2002; Rose and Grant, 2008; 
Xi and Gardner, 2008).  Pharmacological augmentation of GABABR signaling 
inhibits the development and expression of many psychostimulant-induced 
behaviors including CPP (Li et al., 2001), conditioned locomotion (Hotsenpiller 
and Wolf, 2003), motor sensitization (Bartoletti et al., 2005; Bartoletti et al., 2004; 
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Frankowska et al., 2009; Lhuillier et al., 2007), and self-administration (Brebner 
et al., 2005; Campbell et al., 1999; Filip et al., 2007; Filip and Frankowska, 2007; 
Ranaldi and Poeggel, 2002; Roberts et al., 1996; Roberts and Andrews, 1997; 
Shoaib et al., 1998; Smith et al., 2004; Weerts et al., 2007).   These results 
demonstrate a role of the GABABR in drug-induced processes, but to better 
emulate the clinical scenario we wanted to determine the capacity of GABABR 
ligands to modify the maintenance of a previously established psychostimulant-
induced behavior.  To date, only Bartoletti and colleges have demonstrated the 
capacity of the GABABR agonist baclofen to inhibit the maintenance of a 
previously established psychostimulant-induced behavior; they demonstrated 
that 10 once-daily injections of baclofen inhibited the maintenance of 
amphetamine-induced motor sensitization (Bartoletti et al., 2004).  We proposed 
that pharmacologically augmenting GABABR signaling would disrupt 
mnemonic processes necessary to maintain and subsequently express 
previously acquired Meth-induced CPP.  Furthermore, during the hours, days, 
and weeks following psychostimulant administration and memory acquisition, the 
brain is highly dynamic with withdrawal-time-dependent effects being observed in 
the GABABR system (Zhang et al., 2000; Jayaram and Steketee, 2005) and 
withdrawal time-dependent behavioral effects are reported in humans (McGregor 
et al., 2005).  Thus, we hypothesized that withdrawal time dependent effects 
on GABABR expression/distribution and/or function may be reflected as a 
change in the capacity of GABABR ligands to disrupt the maintenance of 
Meth-induced associative learning.      
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Baclofen is a direct-acting (i.e., orthosteric) GABABR agonist, and it produces 
substantial undesirable side effects, including sedation and motor impairment, 
that may limit its clinical usefulness (Cryan et al., 2004; Jacobson and Cryan, 
2005; Heinzerling et al., 2006; Ling et al., 1998; Shoptaw et al., 2003).  Positive 
allosteric modulators (PAMs) of the GABABR provide an alternative means to 
augment GABAergic signaling.  GABABR PAMs do not directly activate 
receptors; instead they increase the efficacy of endogenous GABA (Bettler et al., 
2004; Urwyler et al., 2001; Urwyler et al., 2005; Gjoni et al., 2006).  This 
dependence on endogenous GABA release makes PAMs regionally and 
temporally specific in contrast to direct acting GABABR agonists which bind to 
and activate all GABABRs regardless of endogenous GABAergic tone.  These 
attributes of PAMs result in fewer unwanted side effects than those typically 
observed with direct acting agonists, like baclofen (Cryan et al., 2004).  
Substantiating the idea that these drugs may be useful for addiction therapy, 
PAMs have been shown in laboratory rodents to successfully reduce cocaine 
self-administration (Smith et al., 2004) and prevent molecular adaptations 
resulting from psychostimulant administration (Lhuillier et al., 2007).  We 
hypothesized that systemic administration of the GABABR PAMs would 
antagonize the maintenance of Meth-induced CPP without the side effects 
associated with the GABABR agonist baclofen.   
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One region that might be particularly important in mediating the effects of 
systemically administered GABABR ligands is the medial dorsal thalamus (MDT).  
The MDT expresses moderate to high levels of GABABR (Margeta-Mitrovic et al., 
1999; Charles et al., 2003) and via afferent and efferent projections modulates 
and is modulated by brain regions important for the regulation of 
psychostimulant-induced behaviors and mnemonic processes.  Indeed, baclofen 
(Romanides et al., 1999) or lidocaine (Floresco et al., 1999) injected into the 
MDT inhibits working memory.  The role of the MDT in the maintenance of 
psychostimulant-induced associative learning is unclear.  To fill this gap, the 
present dissertation project evaluated the role of GABABRs in the MDT as 
critical regulators of the maintenance of Meth-induced CPP. 
 
A stand alone pharmacotherapy may not be the most effective approach to 
reduce the propensity of cue-elicited relapse; likewise, behavioral/cognitive 
therapy (i.e., extinction therapy) has not been particularly efficacious in reducing 
relapse in abstinent drug-dependent humans (Conklin and Tiffany, 2002) or in 
rodent models of addiction (Crombag and Shaham, 2002; Di Ciano P. and 
Everitt, 2004).  There is convincing evidence which suggests that combining 
extinction therapy with a pharmacotherapy may be more efficacious in reducing 
cue-elicited responses in humans (O'Brien et al., 1990) and rodents (Heinrichs et 
al., 2010) than with either strategy alone.  Thus, we proposed that the 
GABABR agonist, baclofen would promote extinction training. 
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These experiments will 1) shed light on the role of GABABRs in the maintenance 
of Meth-induced associative learning, 2) provide insight into the role of the MDT 
in the maintenance of associative memories, and 3) evaluate the utility of 
GABABR activators to reduce the salience of psychostimulant-associated cues.     
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CHAPTER II 
 
LITERATURE REVIEW 
 
Methamphetamine Addiction 
Meth, a highly addictive psychostimulant, is one of the most abused substances 
world-wide (United Nations Office on Drugs and crime, 2009) with Meth use 
disturbingly high in certain regions in the United States including Hawaii, San 
Diego, Los Angeles, San Francisco, and Phoenix (National Institute on Drug 
Abuse, 2009).  The euphorogenic effects of amphetamines (including Meth), is 
the consequence of elevated extracellular concentrations of the monoamines 
serotonin (5-HT), dopamine (DA), and norepinephrine (NE) (Baumann et al., 
2002b; Baumann et al., 2002a; Kuczenski et al., 1995; Melega et al., 1995; 
Rothman et al., 2001).  The massive increase in synaptic monoamine 
concentrations is achieved via multiple mechanisms including inhibition of 
reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin 
(SERT) as well as the vesicular monoamine transporter 2 (VMAT-2) (Amara and 
Kuhar, 1993; Rothman and Baumann, 2003; Rudnick and Clark, 1993; Sulzer et 
al., 2005).  These mechanisms of Meth function to increase monoamine 
concentrations in the synapse.  By virtue of Meth increasing the synaptic 
concentrations of the monoamines Meth can be considered an indirect agonist at  
DA, NE, and 5-HT receptors.  In addition, Meth decreases monoamine  
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concentration of monoamines achieved as a consequence of these multiple 
mechanisms exceeds that achieved by, e.g., cocaine which only inhibits reuptake 
transporters (i.e., DAT, NET, SERT) (Hyman and Malenka, 2001).  Thus, the 
effects of Meth are more profound and long lasting than those observed after 
cocaine administration (Fowler et al., 2008) which is thought to underlie the 
extraordinarily high abuse liability of Meth. 
 
Withdrawal from psychostimulant administration 
The massive efflux of synaptic monoamines observed during psychostimulant 
administration activates a number of neurotransmitter receptors to initiate a 
cascade of down-stream signaling events that result in neuronal adaptations 
which change over the course of hours, days, and weeks after exposure (Zhang 
et al., 2001; Ernst and Chang, 2008; McGregor et al., 2005; Camp et al., 1997; 
McDaid et al., 2006b; Zhang et al., 2000; Jayaram and Steketee, 2005).  These 
adaptations can persist long after terminating psychostimulant use, and thus may 
underlie the subjective states (e.g., negative affect) that occur during withdrawal 
as observed by McGregor and colleagues in Meth withdrawn addicts (McGregor 
et al., 2005).  Studies demonstrate that basal neuronal activity is decreased in 
the cortex during withdrawal from chronic cocaine use in humans (Bolla et al., 
2004; Goldstein and Volkow, 2002; Volkow et al., 1992) and after 
psychostimulant administration in rodents (Kalivas and Hu, 2006), however the 
brain is hyper-responsive to stimuli including re-exposure to cocaine or cocaine-
associated cues (Hotsenpiller et al., 2001; Rebec and Sun, 2005; Rebec and 
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Sun, 2005; Hotsenpiller and Wolf, 2002; Febo et al., 2004; Ferris et al., 2005; 
Sun and Rebec, 2006; Kalivas and Hu, 2006).  As withdrawal time and 
contextual cues are important factors in determining neuronal function, brain 
state, and subjective behavioral effects, a better understanding of the underlying 
neuronal adaptations may aid in developing anti-addiction pharmacotherapies.   
 
Psychostimulant-induced associative learning 
Persistent adaptations in neuronal function likely contribute to the behavioral 
hallmarks of withdrawal from drug addiction including compulsive drug-seeking, 
the inability to stop using the drug even when desired, and high propensity to 
relapse to drug-use even after long-periods of withdrawal (American Psychiatric 
Association, 2000).  There are several theories why individuals exhibit these 
behaviors; however, the association which forms between the drug 
(unconditioned stimulus) and contextual cues (conditioned stimulus) appears to 
be a credible candidate.  Repeated administration of psychostimulants creates 
persistent molecular and cellular adaptations (Everitt and Wolf, 2002; Hyman and 
Malenka, 2001; Hyman et al., 2006; Nestler, 2004).  The stimulant-induced 
effects are similar to those that are engaged during mnemonic processes (i.e., 
learning and memory) (Abel and Kandel, 1998; Bailey et al., 1996).  These 
overlapping mechanisms (Hyman et al., 2006; Kelley, 2004) include effects on 
kinases (e.g., PKA) (Chen et al., 2009; Selcher et al., 2002) and transcription 
factors (e.g., CREB) (Carlezon et al., 2005; Lonze and Ginty, 2002).  Adaptations 
such as these may contribute to cue-elicited neuronal hyper-responsivity 
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observed in brain regions such as the prefrontal cortex (especially the 
orbitofrontal and anterior cingulate cortices), amygdala, and thalamus (Childress 
et al., 1999; Childress et al., 2008; Kilts et al., 2001; Kilts et al., 2004; Brown et 
al., 1992; Zombeck et al., 2008; Ciccocioppo et al., 2001; Rhodes et al., 2005; 
Franklin and Druhan, 2000), cue-induced drug-craving (Ehrman et al., 1992; 
Hartz et al., 2001; O'Brien et al., 1992), and drug-seeking (Ciccocioppo et al., 
2001; Filip and Frankowska, 2007).   Drug-induced associative learning (i.e., 
drug-induced conditioned place preference, CPP) is the process where an 
association is learned between the unconditioned stimulus (e.g., the 
psychostimulant) and the context (e.g., place) where the drug was administrated, 
i.e., the conditioned stimulus) wherein drug-free laboratory animals (Tzschentke, 
1998; Tzschentke, 2007) and humans (Childs and deWit H., 2009) tend to spend 
more time in a previously drug-paired context than in one not associated with the 
rewarding effects of abused substances.  Conditioned place preference can be 
induced with a wide range of substances including the Meth (Tzschentke, 1998; 
Tzschentke, 2007).  Thus, CPP is an efficient and effective means to model the 
enhanced salience of Meth-associated cues (i.e., the increased significance 
attributed to Meth-associated cues) that occurs during addiction. 
 
Memory that results from associative learning processes (such as that engaged 
during CPP) can be divided into short-term (also known as working memory) and 
long-term memory.  Short- and long-term memories involve distinct processes.  
Long-term memory requires a complex interplay of kinases and protein 
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transcription in order for learned events to be consolidated, retained, and 
subsequently recalled.  Processes necessary for consolidation of long-term 
memory (events which occur soon after learning) and reconsolidation (events 
necessary to retain a memory following recall) also involve kinases (e.g., PKA) 
and protein expression in a time dependent manner within particular brain 
regions such as the hippocampus, frontal cortex, and amygdala (McGaugh, 
2000).  Recall (also known as memory expression) requires glutamate receptors.  
The maintenance phase of long-term memory is a relatively un-explored area, 
and while it is clear that memory maintenance is highly dynamic (Abel and 
Kandel, 1998; Alberini, 2009; Bailey et al., 1996), the exact mechanisms remain 
to be elucidated. 
 
Associative learning established during CPP can be broken down into several 
distinct phases including development, maintenance, and expression.  The 
development of CPP refers to the time when the association between the drug 
and the context memory is being acquired (i.e., during conditioning) and 
expression is when the learned association is recalled and is demonstrated 
behaviorally.  The maintenance of CPP refers to the time between when the 
drug-cue memory is acquired and when it is subsequently recalled.  This 
dynamic phase is a potential point of therapeutic intervention to disrupt unwanted 
memories after they have been established.  This disruption can occur as a result 
of a pharmacologic intervention modifying processes that are necessary to 
maintain memory or via extinction training wherein an unwanted memory is 
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replaced or over ridden by a new memory.  Applications of these memory 
maintenance disrupting approaches are considered in this dissertation. 
 
The GABAB receptor and psychostimulant administration 
GABA is the major inhibitory neurotransmitter in the central nervous system.  
Ionotropic GABAA receptors mediate fast, robust neuronal inhibition via activation 
of chloride channels whereas GABABRs modulate neuronal activity via G-protein 
(Gi/o)-dependent mechanisms including inhibition of high voltage activated 
calcium (Ca++) channels, activation of inwardly rectifying potassium channels 
(GIRKs), and inhibition of cAMP production (Bowery, 1993; Mott and Lewis, 
1994).  These mechanisms blunt both pre- and post-synaptic neuronal activity.  
In order for the GABABR to efficiently mediate these inhibitory effects, the 
GABABR must function as an obligate heterodimer complex containing both the 
GABABR1 and the GABABR2 receptor (Jones et al., 1998; Kaupmann et al., 
1998; Kuner et al., 1999; White et al., 1998).  The GABABR1 receptor subtype 
cannot be trafficked to the neuronal surface due to the presence of an 
endoplasmic reticulum (ER) retention signal.  This ‘signal’ is found in both 
isoforms of the GABABR1, the GABABR1a and the GABABR1b, which differ from 
each other by the presence or absence of a sushi domain.  Dimerization of the 
GABABR1 with the GABABR2 masks the ER retention signal which allows the 
receptor dimer to traffic to the neuronal surface (Jones et al., 1998; Kaupmann et 
al., 1998; Kuner et al., 1999; White et al., 1998).  Following insertion, the 
GABABR1 is responsible for binding to the ligand whereas the GABABR2 is 
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responsible for binding of the receptor to the G-protein.  Thus, both GABABR 
subunits are necessary for ligand-mediated signal transduction (Bettler et al., 
2004; Bowery et al., 2002).   
 
Psychostimulant-induced brain adaptations are highly dynamic and contribute to 
withdrawal-time and context-dependent brain states, which involve multiple 
neurotransmitter systems and downstream signaling molecules (Nestler, 2001; 
Chao and Nestler, 2004).  One component contributing to the maladapted brain 
state may be the GABABR system.  Specific adaptations are influenced by 
neuronal phenotype, number of drug exposures, and withdrawal duration; 
however, in general the GABABR system is down-regulated after psychostimulant 
administration in a brain region and withdrawal-time dependent manner.  The 
down-regulation includes decreased GABABR expression (Frankowska et al., 
2008b; Frankowska et al., 2008a), decreased G-protein expression (Gi/o) (Nestler 
et al., 1990; Striplin and Kalivas, 1993), and decreased GABABR/G-protein 
coupling (Kushner and Unterwald, 2001; Zhang et al., 2000).  Furthermore, 
increased basal GABAergic tone (Jayaram and Steketee, 2005; Xi et al., 2003) 
and evoked GABA release (Bustamante et al., 2002) is observed after 
psychostimulant administration which would be consistent with the apparent 
down-regulation of the GABABR system if the brain is attempting to blunt 
neuronal activity (i.e., return the brain to a pre-psychostimulant state).  
Decreased function of the GABABR system may contribute to the hyper-excitable 
brain state observed in subjects during re-exposure to drug stimuli. 
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Withdrawal from psychostimulant administration results in region-specific 
changes in brain states that vary during the hours, days, and weeks following 
psychostimulant administration.  Examples include, decreased Gi/o G-protein 
expression at 14 days, but not at one day, of withdrawal from repeated cocaine 
administration (Striplin and Kalivas, 1993), functional coupling of the GABABR to 
the G-protein is decreased in the cortex at 14 days withdrawal from repeated 
amphetamine, an effect that is not observed at one day withdrawal (Zhang et al., 
2000), and extracellular GABA concentrations are elevated at one and seven, but 
not 28 days of withdrawal from repeated cocaine administration (Jayaram and 
Steketee, 2005).  These studies demonstrate withdrawal time-dependent effects 
of psychostimulant administration on the GABABR which may significantly alter 
neuronal excitability.  Furthermore, changes such as these may render the brain 
more vulnerable to pharmacological interventions at certain withdrawal times 
than at others.  The studies in this dissertation are designed to evaluate these 
withdrawal phase-dependent effects.   
 
The GABAB receptor: drug-induced behaviors and mnemonic processes 
Pharmacologically augmenting GABABR signaling (via systemic administration of 
a GABABR agonist) blunts psychostimulant-induced behaviors, including CPP (Li 
et al., 2001), motor sensitization (Bartoletti et al., 2004; Frankowska et al., 2009; 
Lhuillier et al., 2007; Hotsenpiller and Wolf, 2003), and self-administration 
(Ranaldi and Poeggel, 2002; Brebner et al., 2005; Campbell et al., 1999; Filip et 
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al., 2007; Roberts and Andrews, 1997; Smith et al., 2004; Weerts et al., 2007).  
These findings lend credibility to the idea that the GABABR system influences 
psychostimulant-induced behaviors.  Furthermore, systemic administration of 
GABABR agonists negatively regulates mnemonic processes (Castellano et al., 
1989; Levin et al., 2004; McNamara and Skelton, 1996; Nakagawa et al., 1995; 
Swartzwelder et al., 1987; Zarrindast et al., 2004; Zarrindast et al., 2001); 
however, memory-improving effects have also been observed (Georgiev et al., 
1988; Saha et al., 1993).  Therefore, it is not clear what effect pharmacological 
augmentation of GABABR signaling might have on the maintenance of learned 
associations between Meth and the contextual cues. 
 
The GABABR modulates neuronal excitability, signal transduction, and protein 
expression; thus, changes in the GABABR system will significantly affect brain 
function.  Effects on neuronal excitability are mediated by G-protein-dependent 
activation of inwardly rectifying K+ channels and inhibition of high voltage 
activated Ca++ channels (i.e., P/Q- and N-type) (Bowery, 1993; Mott and Lewis, 
1994).  The GABABR is located both pre- and post-synaptically (Bowery, 1993; 
Chen et al., 2004; Wirtshafter and Sheppard, 2001) regulating neuronal activity 
and the release of other neurotransmitters including dopamine (Gong et al., 
1998; Kalivas, 1993; Santiago et al., 1993a; Santiago et al., 1993c; Smolders et 
al., 1995), and glutamate (Bonanno et al., 1997; Huston et al., 1990).  Dopamine 
and glutamate are critical regulators of drug-induced behaviors, and learning and 
memory.  In addition, GABABRs negatively regulate protein expression and 
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signal transduction via a G-protein-dependent mechanism (e.g., inhibition of 
cAMP) to regulate the activity of the transcriptional regulator cAMP response 
element binding protein (CREB) (Barthel et al., 1996; Bettler et al., 2004; Mott 
and Lewis, 1994; Lhuillier et al., 2007; Yin et al., 2006).  In addition, a G-protein-
independent mechanism exists wherein transcription factors (e.g., ATF4/CREB2) 
bind directly to the carboxyl terminus of the receptor (Bettler et al., 2004; White et 
al., 2000; Nehring et al., 2000).  Thus, processes that are critical for the 
maintenance of Meth-induced behaviors may be disrupted by pharmacologically 
augmenting GABABR signaling.   
 
GABAB receptor positive allosteric modulators 
Stimulation of the GABABR by the direct acting agonist baclofen causes 
significant side effects including hypothermia, sedation, and motor impairment 
(Cryan et al., 2004; Jacobson and Cryan, 2005; Heinzerling et al., 2006; Ling et 
al., 1998; Paredes and Agmo, 1995; Shoptaw et al., 2003).  Baclofen binds to the 
orthosteric site, which is located in the large extracellular region of the receptor, 
and activate all GABABRs regardless of endogenous GABAergic tone.  In 
contrast, positive allosteric modulators (PAMs) of the GABABR bind to a 
transmembrane site of the receptor which is distinct from the orthosteric binding 
site.  Binding of the PAM to the transmembrane site has minimal or no effect on 
GABABR signaling in the absence of an agonist.  Rather, PAMs induce a 
conformational change which enhances coupling of the receptor to the G-protein 
as well as increases the affinity of the receptor for the ligand (i.e., agonist 
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binding).  Consequently, PAMs increase the potency and maximum efficacy of 
endogenous GABA (Bettler et al., 2004; Gjoni et al., 2006; Urwyler et al., 2001).  
The enhancement of GABABR signaling only in brain regions / active synapses 
where GABA is endogenously released likely underlies the fact that these drugs 
have fewer side effects than baclofen and therefore may be an alternative to 
baclofen (Bettler et al., 2004; Cryan et al., 2004; Paredes and Agmo, 1995).  
Furthermore, the desensitization that can occur during baclofen administration is 
not observed with PAMs (Gjoni and Urwyler, 2009; Gjoni and Urwyler, 2008).  
Modulation of GABABRs may be a way to modify the maintenance of CPP 
without the associated side effects of direct acting agonists such as baclofen. 
 
The medial dorsal thalamus: drug-induced behaviors and mnemonic 
processes 
Mnemonic processes engage numerous brain regions; however, those which 
have been very well characterized are the hippocampus (HC) and the prefrontal 
cortex (PFC).  The HC is critically involved in the early phases of memory 
consolidation.  Memories are subsequently transferred to the PFC for long-term 
storage.  Other regions have also been implicated in learning and memory 
processes such as the amygdala and the more recently identified medial dorsal 
thalamus (MDT).  The thalamus has typically been considered a relay region 
between the limbic system and the cortex; however, recently the role of the MDT 
has been recognized as an important regulator of learning and memory.  The 
MDT is connected with the PFC, NAc, and VP via glutamatergic (Pirot et al., 
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1994; Kuroda et al., 1995; Kuroda et al., 1998) and GABAergic projections 
(Churchill et al., 1996b; Groenewegen, 1988; Mogenson et al., 1987; Zahm et al., 
1996) via efferent and afferent projections.   A primary source of glutamatergic 
afferents to the PFC (a region important for executive control and memory) is the 
MDT (Giguere and Goldman-Rakic, 1988; Pirot et al., 1995).  Based on this 
anatomy it is not surprising that the MDT is important for associative processes.  
Oyoshi et al. revealed that the MDT (particularly the medial portion) is engaged 
during conditioned associative tasks (Oyoshi et al., 1996).  Furthermore, lesions 
of the MDT inhibit the acquisition of sucrose-induced CPP (McAlonan et al., 
1993) 
 
The thalamus, including the MDT, expresses moderate to high levels of 
GABABRs (Margeta-Mitrovic et al., 1999; Charles et al., 2003).  Following at least 
10 days of stable cocaine self-administration, GABABR expression is significantly 
reduced throughout the rat brain including in the MDT (Frankowska et al., 2008b; 
Frankowska et al., 2008a).  Although this change occurs as a consequence of 
cocaine self-administration it is not clear if it is driving the self-administration 
behavior.  Studies have shown that modifying GABABR signaling within the MDT 
modifies behavior; augmenting GABABR signaling within the MDT by intra-
cerebral injections of baclofen dose-dependently increases spontaneous motor 
activity (Churchill et al., 1996a) and disrupts working memory (Floresco et al., 
1999; Romanides et al., 1999).  The status of GABABRs in the MDT at a time 
when Meth-induced associative learning is expressed is unknown.  Furthermore, 
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the effect of locally augmenting GABABR signaling during the maintenance of 
Meth-induced associative learning has not been explored.  The experiments in 
this project fill in these gaps in the literature. 
 
Significance and therapeutic implications 
Addiction is a chronic and relapsing condition.  Costs associated with addiction 
are an enormous burden on society and the families of the addicted individual.  
Thus, there is a huge incentive to determine the underlying neuronal adaptations 
and develop effective therapies to reduce the propensity of cue-elicited relapse.  
Currently, there are no FDA-approved pharmacotherapies for Meth addiction and 
the incidence of relapse is remarkably high following behavioral/cognitive 
therapy.  Relapse to using abused drugs remains a major challenge for abstinent 
addicts.  Therefore, determining a way to reduce the salience of drug-associated 
memories will be of value to reduce cue-elicited relapse and we propose that the 
GABABR may be viable pharmacotherapy target. 
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CHAPTER III 
RATIONALE FOR EXPERIMENTAL DESIGN 
AND METHODOLOGY 
The studies contained in this dissertation are designed to explore the role of the 
GABABR in the maintenance of Meth-induced learned associations.  Several 
different CPP paradigms were used to evaluate treatment duration and 
withdrawal-time dependent effects of GABABR ligands on the maintenance of 
Meth-induced CPP.  We further explored combining a GABABR pharmacotherapy 
with extinction training as a potential means to rapidly mitigate the maintenance 
and subsequent expression of learned associations between the rewarding 
effects of Meth and contextual cues.  To better understand the underlying 
adaptations contributing to Meth-induced behaviors, the expression and 
distribution of the GABABR were evaluated at a time when Meth-induced 
behaviors were exhibited.   An explanation of selected methodologies is provided 
below. 
  
Associative learning is a biological imperative from an evolutionary standpoint.  
Animals and humans learn to avoid harmful and stressful situations (conditioned 
place aversion, CPA) and to seek out beneficial and pleasurable experiences 
(conditioned place preference, CPP).  The CPP task measures the associations 
that develop between the unconditioned stimulus (e.g., rewarding properties of 
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psychostimulants) and the unconditioned stimulus (e.g., contextual cues) (Bardo 
et al., 1995; Tzschentke, 1998; Tzschentke, 2007).  Place conditioning is a 
relatively easy, high-throughput method and it is becoming increasingly used for 
evaluations in laboratory rodents; however, the conditioning apparatus, 
methodological details, statistical analysis, and even terminology are highly 
variable.  The merits of the selected CPP paradigms included in this dissertation, 
and why these paradigms were selected, are detailed below. 
 
General Methods  
Animals 
Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-300g at the 
start of the study were acclimated to the vivarium for at least five days prior to the 
onset of the experiments.  Rats were housed in pairs in a climate-controlled 
environment (23-25º) on a 12 hr light/dark cycle, and allowed ad libitum access to 
food and water.  Cage mates were given identical pharmacological treatments.  
Housing facilities are accredited through the Association for Assessment and 
Accreditation of Laboratory Animal Care, and all experiments were carried out in 
accordance with the conditions set forth by the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals (National Research Council, 
1996) and with the approval of the Loyola University Medical Center or Rush 
University Medical Center Institutional Animal Care and Use Committee. 
 
Drugs 
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(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile 
saline and administrated as 1mg/ml/kg as the base.  Saline was administered as 
1ml/kg.  All injections were given intraperitoneally (i.p.).   
  
Apparatus for Assessing Conditioned Place Preference 
The test room was dimly lit (54-108 lux) with white noise continuously present 
(white noise generator, San Diego Instruments, San Diego, CA).  The CPP 
apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by 
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large 
conditioning chambers (25cm x 30cm x 30cm) separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct, yet neutral, visual 
and tactile cues.  Time spent in each chamber and motor activity was monitored 
via two sets of photobeams (24 in the horizontal and 12 in the vertical plane).   
 
The rats were transported from the vivarium to the test room at least 30min prior 
to the start of the experiment.  A 30min pre-test, was used to determine initial 
chamber bias and these data were used to assign a Meth-paired chamber (half 
were Meth-paired in the chamber in which the greatest amount of time was spent 
during the pre-test and half in the chamber in which the least amount of time was 
spent during the pre-test).  Conditioning was initiated two to three days later.  
During the conditioning phase, Meth conditioned rats were given a Meth injection 
(1mg/kg, i.p.) every other day (days 1, 3, and 5) and immediately placed into the 
appropriate chamber for 45min.  On the alternate days (5-day protocol: 2 and 4, 
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6-day protocol: 2, 4, and 6), rats were given a saline injection (1ml/kg, i.p.) and 
immediately placed into the opposite chamber for 45min.  Saline conditioned rats 
were given a saline (1ml/kg) for all conditioning sessions.  A drug-free CPP test 
was performed three days after the last conditioning session (5-day protocol, day 
8; 6-day protocol, day 9; termed CPP Test 1).  This was accomplished by placing 
rats into the center chamber and the sliding doors were immediately removed 
allowing free access to the entire CPP box.  The test session lasted 30min and 
time spent in each chamber was determined.   
 
Elevated Plus Maze 
The elevated plus maze (EPM) consisted of two sets of perpendicular arms (50.2 
x 10.8cm) located 91.4cm above the floor.  The intersection of the arms was 10.8 
x 10.8cm.  Closed arms had black plastic walls that were 40cm in height on 
either side and open arms had no walls.  Time spent in each arm and number of 
arm entries were (closed vs. open) over 5min were recorded by three trained 
observers which were averaged to obtain the value for each rat.  EPM 
experiments were conducted under red light conditions.   
 
In order to examine the effects of acute Meth (1mg/kg) administration on anxiety, 
a Meth injection was administered 30min prior to the EPM test session.  Rats 
were then pre-tested, conditioned, and tested as described previously.  One day 
later, rats were given a drug-free EPM test to determine if Meth-conditioning 
altered anxiety. 
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Statistics 
Conditioned Place Preference: For the pre-test data, time spent in each chamber 
was compared using a Paired t-test.  CPP was defined as spending significantly 
more time in the chamber paired with Meth- vs. time spent in the same chamber 
during the pre-test or spending significantly more time in the chamber paired with 
Meth- vs. time spent in the saline-paired chamber.  These within group analyses 
were conducted using a Paired t-test.  Between group analyses were conducted 
using a Student‟s t-test.   Elevated Plus Maze: Time spent in each arm as well as 
number of arm entries were compared between Meth- and saline-rats using a 
Student‟s t-test. 
 
All data are presented as mean ± standard error of the mean (SEM).  Statistical 
outliers were determined as those rats that spent greater than two standard 
deviations above or below the mean time spent in any chamber or arm.  
 
Results 
Conditioned place preference apparatus: Non-biased vs. biased 
Typically, a CPP apparatus consists of two- or three-chambers (three chambers 
includes a small, center chamber which connects the two conditioning 
chambers); each of which contain distinct contextual cues.  Studies used in the 
current project used a three-chamber apparatus (Accuscan Instruments, Inc; 
Columbus, OH); opaque Plexiglas sliding doors separated the two large 
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conditioning chambers (25cm x 30cm x 30cm) from the small center chamber 
(13cm x 30cm x 30cm).  For rodents, conditioning typically utilizes visual and 
tactile cues although other sensory modalities may be used (e.g., olfactory cues).  
The conditioning apparatus can be configured such that naïve animals spend 
approximately equal amounts of time in each chamber (unbiased apparatus) or 
unequal amounts of time in each chamber (biased apparatus).  This 
determination is often made prior to initiating the study in order to establish 
„baseline‟ behavior, and is termed the pre-test.  There is some argument that pre-
tested rodents are slower at acquiring the learned association (Tzschentke, 
1998), as this presents an opportunity for the animals to become familiar with the 
environment; however, including a pre-test has not impacted the ability of rats to 
successfully acquire and express Meth-induced CPP (Chapters IV-IX). 
 
The interpretation of the behavior observed during the pre-test deserves 
consideration.  Typically, the rats initially explore the new environments 
presented by the CPP box, and then, as they become familiar with the 
surroundings, they may elect to spend more time in one environment over the 
other.  The affinity for a particular context often can be ethologically explained, 
i.e., rats prefer dark places and avoid brightly lit places, and the literature 
typically refers to this as a “preference” for dark places and an “aversion” to the lit 
places.  Thus, choice of contextual cues (aversive vs. neutral) may contribute to 
the development of a biased vs. a non-biased apparatus.  Stimuli such as bright 
lights are typically avoided by rodents; light/dark box studies demonstrate that 
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rodents will chose to spend more time in a dark environment compared to one 
that is brightly lit (Bourin and Hascoet, 2003; Costall et al., 1989; Ramos, 2008).  
In a CPP apparatus with black and white walls (e.g., Med Associates CPP 
apparatus) the natural tendency of rodents to spend time in the chamber with the 
black walls is often deterred by the addition of a bright light in that chamber; thus, 
creating an apparatus in which subjects spend approximately equal amounts of 
time in each chamber (Carlezon, 2003).  In this example, the addition of the 
aversive stimuli of the bright light produces a non-biased apparatus.  We contend 
that use of aversive stimuli in the CPP paradigm may compromise the ability to 
interpret behavioral outcomes by introducing the confounding factor of anxiety; 
thus the preference that develops following conditioning may reflect a reduction 
in anxiety rather than rewarding properties of the drug per se.  Thus, a better 
approach may be to use contextual cues which are inherently neither preferred 
nor aversive in rodents, termed neutral contextual cues.   
 
The use of neutral cues (stimuli which are inherently neither aversive nor 
preferred by rodents) such as vertical vs. horizontal stripes and non-noxious 
textured floors (see Fig. 1), typically will not produce a group preference for either 
chamber; however, individual rats may have a preference for one chamber (Shen 
et al., 2006).  This point is illustrated in Fig. 2.  As a group, 55 rats did not 
demonstrate a significant preference for Chamber A (vertical stripes on walls with 
a textured floor with an overturned paint dish glued in the middle) or Chamber B 
(horizontal stripes on walls with a textured floor with a flat, rectangular piece of 
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Plexiglas glued to the center of the floor with only a minimal amount of time being 
spent in the center compartment (solid color walls with a smooth slightly raised 
platform floor) (Fig. 2A, 818±49s vs. 855±51s; paired t-test, p>0.05); however, 
individual rats tended to spend more time in one chamber relatively to the other 
(Fig 2B; approximately 65% vs. 27%).  As the time spent in one compartment vs. 
another was random (i.e., some rats spent more time in chamber A and others in 
chamber B, Fig 2B), this behavior is difficult to interpret in ethological terms.  One 
theory, is that the rats may be exploring the CPP apparatus until they are 
sufficiently habituated at which time they stop exploring resulting in significantly 
more time being spent in that chamber.  While individual rats had a bias for one 
chamber or the other, as a group there was no chamber bias; thus, the CPP 
apparatus used for studies in this project were conducted in a non-biased 
apparatus in the sense that all rats do not prefer one chamber over the other.  
 
The use of a non-biased vs. a truly biased apparatus can significantly impact 
behavioral outcomes.  For example, Cunningham and colleagues manipulated 
the conditioning apparatus such that rats had either no preference (non-biased) 
or a strong preference (biased) for one chamber (Cunningham et al., 2003).  The 
use of either the biased or non-biased apparatus can significantly influence 
behavioral outcomes.  This factor is discussed below in the use of a non-biased 
or biased experimental design. 
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Conditioned place preference experimental design: Non-biased vs. Biased 
design and other considerations 
Non-biased vs. biased CPP design refers to the chamber in which animals are 
paired with the drug based on initial chamber preference (determined by a pre-
test).  One method statistically „neutralizes‟ chamber bias by using a 
counterbalanced drug-paired chamber assignment, wherein half of the animals 
are assigned to be drug-paired in the initially preferred and others in the non-
preferred chamber (Carlezon, 2003).  Counterbalancing creates approximately 
equal (not statistically different) times being spent in the drug-paired and non-
drug-paired chamber prior to conditioning; however, this approach can introduce 
considerable variability when animals have strong unconditioned chamber bias 
making it difficult to assess small shifts in preference.  In contrast, a biased 
design assigns all animals to be drug-paired in the initially preferred or non-
preferred chamber.  This methodology has been thoroughly discussed in several 
publications (Brielmaier et al., 2008; Cunningham et al., 2003; Roma and Riley, 
2005; Hinson et al., 1991).     
 
The use of a non-biased vs. a biased apparatus and experimental design can 
significantly impact behavioral outcomes.  For example, Cunningham and 
colleagues manipulated the conditioning apparatus such that rats had either no 
preference (non-biased apparatus) or a strong preference (biased apparatus) for 
one chamber (Cunningham et al., 2003).  Rats were randomly assigned to 
receive ethanol in the non-biased apparatus and either the initially preferred or 
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non-preferred chamber in the biased apparatus. This study determined that 
ethanol-induced CPP can be produced in the non-biased apparatus, however, 
when individual rats express a strong initial preference for a chamber during the 
pre-test (defined as a large difference in time spent in one chamber relative to 
the other) as occurs in a biased apparatus, significant CPP is achieved only in by 
pairing ethanol with the initially non-preferred chamber (Cunningham et al., 
2003).  This effect is likely due to the ceiling effect that can occur when a strong, 
initial preference is present prior to conditioning.  Similar findings are reported 
with clonidine (Cervo et al., 1993), cocaine (Nomikos and Spyraki, 1988), 
cocaethylene (Schechter, 1995), heroin (Schenk et al., 1985), and nicotine 
(Calcagnetti and Schechter, 1994).   Furthermore, conditioned place aversion 
(CPA) can only be produced when rats are paired with the hallucinogenic drug 
LSD in the initially preferred chamber (Meehan and Schechter, 1998).  These 
findings have been corroborated by our laboratory with Meth-induced CPP.  
Although we do not have a true “biased apparatus” and the rats randomly spent 
more time in one chamber or the other (Fig 2B), thus individual rats have a 
strong unconditioned bias.  Here, rats were pre-tested and assigned to receive 
Meth in a counterbalanced manner (wherein half of the rats were assigned to 
receive Meth in the initially preferred chamber and others in the initially non-
preferred chamber) and subsequently conditioned for five-days with 1mg/kg Meth 
(Fig 3A).  Using this non-biased design we observed that conditioning produced 
CPP when all rats (n=45) were evaluated as a group; time spent in the Meth-
paired chamber was significantly greater during the CPP test compared to the 
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same chamber during the pre-test (Fig 3B, designated Non-Biased 
Counterbalanced; n=45, paired t-test, p<0.001).  However, splitting these rats 
into those paired in the initially non-preferred and preferred chambers revealed 
that only those rats Meth-paired in the initially non-preferred chamber 
demonstrated significant CPP (time spent in the Meth-paired chamber during the 
CPP test compared to the same chamber during the pre-test) (Fig 3B; 
designated Biased Non-preferred; n=23; paired t-test, p<0.001).  In contrast, 
evaluation of data collected from rats paired in the initially preferred chamber 
revealed that time spent in the Meth-paired chamber was decreased, not 
increased, after Meth-conditioning (Fig 3B; designated Biased Preferred; n=22; 
paired t-test, p<0.05) indicating a ceiling effect that may occur when a strong 
unconditioned bias is present.  These results indicate that it is not appropriate to 
Meth-pair rats in the preferred chamber in a biased apparatus.      It also should 
be noted that analyzing this same data set by comparing time spent in the saline- 
and Meth-paired chambers for the non-biased and biased (Biased Preferred and 
Biased Non-Preferred) all resulted in positive CPP (Fig 3C).  However, it should 
be noted that this outcome likely does not reflect learning (CPP) in all treatment 
groups.  Rather, the CPP data achieved for the Biased Preferred rats looks 
remarkably similar to that achieved during the pre-test thus this reflects the 
unconditioned preference rather than a learning phenomenon.  Thus, this 
underscores the notion that multiple methods of analysis should be used to verify 
CPP results as the use of a non-biased vs. biased apparatus and design may 
influence the behavioral outcomes and appropriate methods of analysis.   
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A controversial aspect of the biased design is the potential contribution of anxiety 
associated with pairing in the initially non-preferred chamber may have on 
behavioral outcomes.  These concerns arise as a result of complex issues 
regarding the motivational states associated with the initially non-preferred 
context (Schenk et al., 1985), especially if the non-preferred context can be 
ethologically defined (e.g., in a bright chamber).  Data obtained from the biased 
design can be interpreted in two ways 1) the preference is the result of the 
association between the rewarding properties of the drug or 2) the preference is 
achieved as a result of anti-anxiety properties of the drug (i.e., initial anxiety for 
the non-preferred chamber is overcome).  There are several lines of evidence 
that belay the concern that CPP is the result of anxiolytic, rather than rewarding, 
properties.  Regarding the first concern, psychostimulants are not anxiolytic but 
rather are anxiogenic particularly after repeated administration (Cancela et al., 
2001; Olausson et al., 2000).  For example, the anxiogenic drugs 
methamphetamine, amphetamine, and MDMA induce CPP (Daza-Losada et al., 
2007; Lin et al., 1999; Tzschentke, 1998).  We observed that Meth (1mg/kg) 
administration did not alter anxiety as measured on the elevated plus maze (time 
spent in open vs. closed arms or number of open vs. closed arm entries, Fig 4B 
and 4C, time spent in each arm as well as number of arm entries were compared 
between Meth- and saline-rats using a Student‟s t-test, p>0.05) when 
administered 30min prior to the elevated plus maze test (time during peak 
psychomotor effects).  Furthermore, assessment of anxiety on the elevated plus 
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maze failed to reveal an anxiogenic or anxiolytic effect following repeated 
administration of methamphetamine which was sufficient to produce a 
conditioned place preference when evaluated within 24hr of the drug-free 
conditioned place preference test (Fig 4D & 4E, time spent in each arm as well 
as number of arm entries were compared between Meth- and saline-rats using a 
Student‟s t-test, p>0.05).  The second line of evidence to belay concerns about 
the contribution of anxiety is that anxiolytic drugs do not always produce a 
preference in the CPP paradigm.  Variable doses and paradigms used make it 
difficult to directly compare across studies, but the benzodiazepines diazepam 
and alprazolam produce CPP in some cases (Gray et al., 1999; Le et al., 2002; 
Papp et al., 2002; Walker and Ettenberg, 2003; Walker and Ettenberg, 2001; 
File, 1986) but have no effect on conditioning in others (File, 1986; Matsuzawa et 
al., 2000; Meririnne et al., 1999).  Additionally, serotonergic drugs (venlafaxine 
and paroxetine), which are commonly used to treat anxiety disorders (i.e. 
anxiolytic effects), do not produce CPP (Deslandes et al., 2002; Subhan et al., 
2000; Tzschentke et al., 2006).  Taken together, it is unlikely that a reduction in 
anxiety is the main cause of Meth-induced CPP in the protocol employed for the 
current studies.   
 
 
 
Measuring preference 
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There are several methods to evaluate CPP data; including between and within 
group comparisons.  The selection of a method of analysis and statistical 
approach are dictated by experimental design and hypothesis being tested.  
Between group comparisons allow for direct treatment effects to be evaluated.  
Illustrated in Figures 5 and 6 are data collected from a six-day conditioning 
paradigm (timeline illustrated in Fig 4A) wherein rats were conditioned with either 
Meth or saline.  Between group analyses revealed the following.  Time spent in 
the Meth-paired chamber (day 1, 3, 5 chamber for saline conditioned rats, termed 
“Meth-like chamber”) was significantly greater in Meth-conditioned rats compared 
to saline-conditioned rats (Fig 5A; saline conditioned rats (white bar, n=12); 
Meth-conditioned rats (black bar, n=48); Student‟s t-test, p<0.05).  The second 
method demonstrated that subtracting time spent in the saline-paired chamber 
(day 2, 4, 6 chamber for saline conditioned rats, termed “saline-like chamber”) 
from the time spent in the Meth-like or Meth-paired chamber demonstrated 
significant between group differences  as well (Fig 5B; saline-conditioned rats 
(white bar, n=12); Meth-conditioned rats (black bar, n=47); Student‟s t-test, 
p<0.05).  Finally, time spent in the Meth-like or Meth-paired chamber minus time 
spent in the same chamber during the pre-test revealed significant between 
group differences (Fig 5C; saline-conditioned rats (white bar, n=11); Meth-
conditioned rats (black bar, n=47); Student‟s t-test, p<0.001).  While these 
methods of analysis are visually quite different, all demonstrate significant 
between group differences indicating that Meth conditioning resulted in significant 
CPP.  Within group comparisons are generally employed for evaluating shifts in 
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preference across time.  For example, time spent in the Meth-paired chamber 
before and after pharmacological treatments or before and after extinction 
training.  Among the commonly used methods of analysis to evaluate preference 
within an experimental group include comparing time spent in the Meth-paired 
chamber vs. time spent in the saline-paired chamber (Fig 6A; n=50; Paired t-test, 
p<0.001) and time spent in the Meth-paired chamber across multiple tests for 
preference (e.g., pre-test vs. CPP test) (Fig 8B; n=50; Paired t-test, p<0.001).   
 
The majority of studies in this project assess changes in preference across time 
(i.e., before and after pharmacological treatments in the home cage and before 
and after extinction training); therefore, we chose to evaluate data using a within 
subject analysis.  For example, within group comparison of rats conditioned in a 
five-day conditioning paradigm (Fig 3A) revealed that the Biased Preferred rats 
spent significantly more time in the Meth-paired chamber than in the saline-
paired chamber (Fig 3B; black bars; n=22; paired t-test, p<0.01); however, 
preference evaluated across time (pre-test vs. CPP test) demonstrated that time 
spent in the Meth-paired chamber decreased after conditioning (Fig 3A; black 
bars; n=22; paired t-test, p<0.05).  This observation underscores the importance 
of validating behavioral outcomes with more than one statistical approach in 
order to avoid type I and type II error.  While not presented in this dissertation, all 
data sets were analyzed with several different statistical methods to verify the 
behavioral outcomes.  
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Concluding Remarks 
There is a place for the biased design in CPP assessments.  Especially when 
using a CPP apparatus which engenders a strong, unconditioned bias which will 
reduce variability revealing CPP which might otherwise be undetected due to the 
ceiling effect which may occur.  We contend, and here demonstrate, that the 
biased design demonstrates reward-mediated behavior and not necessarily an 
anxiety-reducing phenomenon and thus is appropriate to test the proposed 
hypothesis in the current project. 
 
Rationale for doses used 
Methamphetamine   
In the current series of experiments, 1mg/kg Meth reliably produced persistent 
CPP in several different experimental paradigms independent of conditioning 
protocol used, withdrawal time imposed, or repeated CPP testing.  This outcome 
is in agreement with published studies demonstrating that Meth-induced CPP is 
readily produced with 1mg/kg Meth in both two- and eight-day conditioning 
protocols (Kitanaka et al., 2010; Li et al., 2002; Herrold et al., 2009; Schindler et 
al., 2002).  A dose-response evaluation for Meth-induced CPP was conducted 
and demonstrated that Meth-induced CPP was produced by 0.3mg/kg and 
1mg/kg (as the base) but not 0.1mg/kg in a six-day conditioning protocol; but, the 
persistence of the behavior was more robust in the 1mg/kg conditioned rats (data 
collected by Amy A. Herrold).  Indeed, studies contained in this dissertation 
demonstrate the enduring behavioral effects (i.e., CPP) established with 1mg/kg 
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Meth conditioning (see data contained in Chapters IV-VIII and especially Chapter 
IX).  Furthermore, this dose and dosing paradigm is below that which induces 
neuronal toxicity (e.g., decreased DAT expression and glial fibrillary acid protein 
expression) (Krasnova and Cadet, 2009; McDaid et al., 2006a).   
 
GABAB Receptor ligands   
Baclofen is a well-characterized drug which has been clinically available since 
the 1970‟s.  It has been widely employed as a GABABR agonist ((-) baclofen 
IC50=33μM; (+) baclofen IC50=0.04 μM) (Bowery et al., 1983).  Baclofen has 
been tested as an anti-relapse medication in clinical trials (Brebner et al., 2002; 
Cousins et al., 2002; Heinzerling et al., 2006; Ling et al., 1998; Shoptaw et al., 
2003); however substantial side effects including sedation and motor impairment 
limit the utility of baclofen (Cryan et al., 2004; Heinzerling et al., 2006; Jacobson 
and Cryan, 2005; Ling et al., 1998; Shoptaw et al., 2003).  The dose selected for 
baclofen in the current study (2mg/kg) is below the threshold published in the 
literature to produce significant side effects in rodents; baclofen (2.5 & 5mg/kg) 
inhibits motor behavior, impairs memory, and induced hypothermia (Cryan et al., 
2004).  We have verified that motor performance assessed on the rotarod was 
significantly inhibited by 4mg/kg baclofen (For results see Chapter V).  
Additionally, while 3mg/kg baclofen produced an impairment in spontaneous 
motor activity, the motoric effects of 2mg/kg baclofen did not differ from that of 
vehicle (horizontal activity, photobeam breaks over 75min post-injection for 
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vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388; baclofen 3mg/kg 
(n=6), 1067±258; ANOVA p=0.012, post-hoc Dunnett‟s).   
 
The dose of 2mg/kg baclofen is within the range of doses found to successfully i) 
attenuate the development and expression of Meth-induced CPP when 
administered 30 min prior to each daily conditioning session or CPP test, 
respectively (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001) ii) inhibit the reinstatement of 
nicotine-induced CPP and self-administration when administered 5 min prior to 
testing (0.612, 1.25, 2.5mg/kg, i.p.) (Fattore et al., 2009), iii) reduce cocaine self-
administration when administered 10 min prior to the session (2.5mg/kg, i.p.) 
(Smith et al., 2004), iv) reduce amphetamine self-administration (i.e., break point) 
when administered 30min prior to testing (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 
2005), and v) inhibit the maintenance of amphetamine-induced motor 
sensitization (2mg/kg, i.p.) (Bartoletti et al., 2004).  Plasma and brain 
concentrations of baclofen are reported to be relatively consistent for at least 
180min after a single bolus intravenous (i.v.) injection of baclofen in the rat 
(50mg/kg) (Deguchi et al., 1995) which aligns with enduring effects of GABAergic 
ligands on drug-induced behaviors.  Orally administered baclofen (5mg/kg) elicits 
centrally-mediated events including hypothermia (Cryan et al., 2004) within one 
hour after baclofen administration suggesting that the onset of action is relatively 
short.   
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To evaluate the involvement of GABABRs in the MDT in the maintenance of 
Meth-induced CPP, baclofen was injected directly into the MDT.  The dose of 
0.5nmol/0.5μl/side baclofen was selected because it is within the range of MDT-
injected doses found to be behaviorally relevant to inhibit working memory 
(doses used were 0.03-0.3nmol) (Romanides et al., 1999) and influence motor 
activity (doses used were 0.003-1.0nmol) (Churchill et al., 1996a).  The 
behavioral effects (i.e., motor activity and memory retention) of locally injected 
baclofen can be antagonized by co-administration of GABABR antagonists (i.e., 
CGP35348 or saclofen) (Zarrindast et al., 2002; Churchill et al., 1996a) indicating 
these behavioral effects are the consequence of baclofen acting at the GABABR.   
 
Fendiline.  Fendiline is an L-type Ca++ channel blocker that is used clinically as a  
coronary vasodilator (Bayer and Mannhold, 1987; Nawrath et al., 1998; Tripathi 
et al., 1993) has recently been discovered to function as a GABABR PAM (Ong 
and Kerr, 2005; Ong et al., 2005).  While radioligand binding studies to determine 
the affinity of fendiline for the GABABR have not been published, fendiline was 
found to potentiate baclofen inhibition of neuronal activity (neuronal inhibition 
EC50=20μM) (Chen et al., 2005; Ong et al., 2005).  The GABABR positive 
allosteric modulator fendiline modulates GABABR signaling without the motor 
side effects associated with baclofen as we verified using the rotarod 
assessment for motivated motor behavior (Chapter V).  While motor performance 
was significantly inhibited by 4mg/kg baclofen, the GABABR PAM fendiline 
(5mg/kg) did not affect performance (For results see Chapter V).   The ability of 
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fendiline to modify psychostimulant-induced behaviors remains unknown but the 
dose of 5mg/kg was selected based on studies which show peripheral 
cardiovascular effects (Bayer and Mannhold, 1987).  Fendiline pharmacokinetics 
demonstrate a slow onset of action and a long half-life (Bayer and Mannhold, 
1987).  Adverse behavioral effects (including sedation) were observed with 
30mg/kg fendiline (unpublished data) thus the dose used for the studies in the 
current project was 5mg/kg.   
 
GS39783, and CGP7930. The GABABR PAMs GS39783 and CGP7930 were 
selected based on several criteria: 1) They are positive allosteric modulators of 
the GABABR but with distinct molecular structures.  2) While radioligand binding 
studies to determine the affinity of these ligands for the GABABR have not been 
published, they both enhance the binding of GABABR agonists (i.e., baclofen and 
GABA), decrease the binding of GABABR antagonists, and potentiate the effects 
of baclofen on K+ currents, cAMP production, and neuronal activity (EC50=1μM 
for both ligands) (Urwyler et al., 2004; Chen et al., 2005; Olianas et al., 2005). 3) 
Lack of significant side effects at even 200mg/kg (p.o.) (Cryan et al., 2004).  4) 
The dose of 30mg/kg (i.p.) GS39783 and CGP7930 successfully reduces 
cocaine self- administration when administered 10 min prior to the session (Smith 
et al., 2004).  Finally, 5) while the pharmacokinetics of the PAMs GS39783 and 
CGP7930 have not been published, GS39783 (3mg/kg, i.p.), and CGP7930 
(30mg/kg, i.p.) significantly reduce cocaine self-administration for at least 10hr, 
indicating that these ligands may actively alter brain processes for several hours 
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after a single administration (Smith et al., 2004).  The dose of 30mg/kg for both 
ligands was selected based on their favorable side effect profile and ability to 
alter psychostimulant-induced behaviors. 
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Figure 1.  Illustration of three-chamber CPP apparatus used for studies in the 
current project.  A.  Shows the test procedure before (left) and after (right) the 
dividers have been removed.  B.  Shows the chambers (A & B) used for 
conditioning. 
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Figure 2.  Demonstration of pre-test results generated in our three-chamber CPP 
apparatus.   A. Time spent in each chamber (sec) as an average of a group of 
rats (n=55).  Data analyzed as a paired t-test, p>0.05.  Center chamber was not 
included for statistical analysis and is illustrated for qualitative purposes.  B.  The 
same data illustrated as individual rats.  
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Figure 3.  Non-biased vs. biased conditioned place preference experimental 
design.  A.  Timeline illustrating the five-day conditioning protocol.  Conditioning 
was preceded by a drug-free pre-test followed by five days of conditioning which 
consisted of Meth (1mg/kg)-conditioning interposed by saline (1ml/kg)-
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conditioning, concluding in a drug-free CPP test.  Trtmnt, treatment; Meth, 
methamphetamine; Sal, saline; Ø, no drug.  B.  Within group comparison of time 
spent in the saline- and Meth-paired chambers during the CPP test.  C.  Within 
group comparison of time spent in the Meth-paired chamber during the CPP test 
compared to time spent in the same chamber during the pre-test.  Non-biased 
Counterbalanced (n=45), Biased Preferred (n=23), Biased Non-Preferred (n=22).  
Data were analyzed with a paired t-test for each data set, * p<0.05, ** p<0.01.   
  
46 
 
 
 
 
Figure 4.  Neither acute Meth nor repeated Meth administration had any effect 
on anxiety measured in the elevated plus maze.  A.  Timeline illustrating testing 
and treatment protocol.  B & C.  Effect of acute saline (1ml/kg) or Meth (1mg/kg) 
administration on time spent in the open or closed arms (B) or number of arm 
entries into the open or closed arms (C).  D & E.  Effect of repeated saline 
(1ml/kg) or Meth (1mg/kg) administration in the CPP conditioning paradigm when 
tested in a drug-free state 24hr after testing for CPP on time spent in the open 
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arms (D) or number of arm entries into the closed or open arms (E).  Data were 
analyzed with a Student‟s t-test, p>0.05. 
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Figure 5.  Between group analysis for Meth-induced CPP.  A.  Timeline 
illustrating the six-day conditioning protocol.  A drug-free pre-test was followed by 
conditioning which consisted of Meth (1mg/kg)-conditioning interposed by saline 
(1ml/kg)-conditioning, concluding in a drug-free CPP test.  Trtmnt, treatment; 
Meth, methamphetamine; Sal, saline; Ø, no drug.  B.  Illustrates time spent in the 
Day 1, 3, 5-paired chamber (saline or Meth) for each group during the CPP test.  
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C.  Illustrates time spent in the Day 1, 3, 5-paired chamber minus time spent in 
the Day 2, 4, 6-paired chamber during the CPP test for each group.  D.  
Illustrates time spent in the Day 1, 3, 5-paired chamber during the CPP test 
minus time spent in the same chamber during the pre-test for each group.  Data 
were analyzed with a Student‟s t-test, * p<0.05, *** p<0.001.  White bars indicate 
saline-conditioned rats (they received saline-pairings on all days); black bars 
indicate rats that were conditioned with Meth and learned to associate Meth with 
a particular chamber. 
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Figure 6.  Within group analysis for methamphetamine (Meth) conditioned rats.  
A.  Timeline illustrating the six-day conditioning protocol.  Conditioning was 
preceded by a drug-free pre-test followed by six days of conditioning which 
consisted of Meth (1mg/kg)-conditioning interposed by saline (1ml/kg)-
conditioning, concluding in a drug-free CPP test.  Trtmnt, treatment; Meth, 
methamphetamine; Sal, saline; Ø, no drug.  B.  Illustrates time spent in the 
saline- and Meth-paired chambers during the CPP test.  C.  Illustrates time spent 
in the Meth-paired chamber during the CPP test compared to time spent in the 
same chamber during the pre-test.  Data were analyzed with a paired t-test, 
n=55, p<0.001. 
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CHAPTER IV 
REPEATED BACLOFEN ADMINISTRATION INHIBITS THE MAINTENANCE OF 
METHAMPHETAMINE-INDUCED CONDITIONED PLACE PREFERENCE 
 
Abstract 
Using conditioned place preference (CPP), the present study sought to 
determine if post-conditioning, home cage administration of the GABABR agonist 
baclofen inhibited the maintenance of methamphetamine (Meth)-induced 
associative learning and if this effect depended upon the time period during 
which baclofen was administered.  Male Sprague Dawley rats were conditioned 
with Meth (1mg/kg, i.p.) and saline.  Baclofen (2mg/kg, i.p.) was subsequently 
administered and CPP was tested as follows:  i) Baclofen given for two days 
during early withdrawal from Meth conditioning (protocol days 6 & 7); CPP tested 
one or 11 days later.  ii) Baclofen administered for two days during more 
protracted withdrawal from conditioning (protocol days 16 & 17); CPP tested for 
CPP one day later.  iii) Baclofen given for 10 days (protocol days 9-18); CPP 
tested 3 days later.  These studies revealed that post-conditioning administration 
of 10 once-daily home cage injections of baclofen inhibited the maintenance and 
subsequent expression of Meth-induced CPP.  This inhibitory effect was not 
observed when baclofen was administered for two days independent of when 
those two injections were administered.  These data indicate that the 
maintenance of Meth-induced associative learning can be disrupted by 
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pharmacologically augmenting GABABR signaling for 10 days.  As a reduction in 
the significance of Meth-associated cues is a means to reduce relapse, baclofen 
may be of value for addiction therapy in abstinent Meth-abusing humans. 
 
Introduction 
Re-exposure to drug-paired cues increases neuronal activity in limbic brain 
regions in drug-withdrawn, drug-addicted/dependent humans (Childress et al., 
1999; Childress et al., 2008) and rodents (Brown et al., 1992; Zombeck et al., 
2008; Franklin and Druhan, 2000; Ciccocioppo et al., 2001; Rhodes et al., 2005), 
and can elicit drug-craving and drug-seeking even after long periods of 
withdrawal (O'Brien et al., 1992; Ehrman et al., 1992).  Therefore, disrupting the 
maintenance of the drug-cue association may reduce the propensity of cue-
induced relapse.  Learned associations between the rewarding effects of abused 
substances (unconditioned stimulus) and the context in which the drugs were 
administered (conditioned stimulus) can be produced  in the laboratory using 
conditioned place preference (CPP) in humans (Childs and deWit H., 2009) and 
rodents (Tzschentke, 2007).  Thus, this behavioral paradigm has been widely 
employed to investigate processes engaged during associative learning as well 
as to help identify potential pharmacotherapies for relapse prevention.  There are 
currently no FDA-approved treatments for methamphetamine (Meth) addiction 
and the mainstay behavioral/cognitive therapies might be improved by adding a 
pharmacotherapy.  To best model the human scenario, the potential therapies 
should demonstrate the capacity to reduce/reverse the drug-conditioned effects.  
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Towards that end, we employed Meth-induced CPP in rats and subsequently 
administered repeated post-conditioning, home cage injections of baclofen, a 
GABABR agonist, to determine if it would inhibit the maintenance of Meth-
induced associative learning. 
  
Baclofen has received considerable support as a viable therapy for 
psychostimulant abuse (Brebner et al., 2002; Xi and Gardner, 2008; Rose and 
Grant, 2008; Vocci and Appel, 2007; Cousins et al., 2002).  Neuronal activity is 
negatively regulated by the GABABR (Mott and Lewis, 1994; Bowery, 1993); the 
GABABR decreases release of several neurotransmitters including glutamate 
(Giorgetti et al., 2002; Huston et al., 1990; Bonanno et al., 1997) and dopamine 
(Santiago et al., 1993a; Gong et al., 1998; Kalivas, 1993; Smolders et al., 1995; 
Santiago et al., 1993c).   Moreover, GABABRs modify downstream effectors, 
such as transcription factor activity (Bettler et al., 2004; Mott and Lewis, 1994; 
Barthel et al., 1996), which also underlie psychostimulant-induced neuroplasticity 
(Chen et al., 2009; Nestler, 2001) and mnemonic processes (Wang et al., 2006; 
Quevedo et al., 2004; Bailey et al., 1996; Berke and Hyman, 2000)  Therefore 
the GABABR is positioned to influence many systems critical for the maintenance 
of CPP behaviors.   
 
The GABABR is down-regulated after psychostimulant administration 
(Frankowska et al., 2008b; Kushner and Unterwald, 2001; Zhang et al., 2000) 
and pharmacologically augmenting GABABR signaling inhibits the development 
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and expression of psychostimulant-induced behaviors, including CPP (Li et al., 
2001), motor sensitization (Bartoletti et al., 2005), and self administration (Smith 
et al., 2004; Brebner et al., 2005; Filip et al., 2007; Filip and Frankowska, 2007; 
Ranaldi and Poeggel, 2002).  However, to date only a report from Bartoletti and 
colleagues (Bartoletti et al., 2004) has demonstrated that baclofen inhibits the 
maintenance of a previously established psychostimulant-induced behavior; i.e., 
the maintenance of amphetamine-induced motor sensitization was inhibited by 
baclofen.  Motor sensitization and CPP demonstrate different dose-related 
profiles for amphetamine and engage different brain substrates (Shen et al., 
2006; Rademacher et al., 2006; Shoblock et al., 2003).  Thus, to extend the 
current literature, we determined if baclofen would inhibit the maintenance of 
Meth-induced CPP. 
 
The current study evaluated withdrawal time- and duration-dependent effects of 
baclofen on the maintenance of Meth-induced CPP.  Withdrawal from 
psychostimulants is a dynamic process with different brain states being present 
during the hours, days, and weeks following psychostimulant exposure (Zhang et 
al., 2001; Ernst and Chang, 2008; McGregor et al., 2005; Camp et al., 1997; 
McDaid et al., 2006b; Zhang et al., 2000; Jayaram and Steketee, 2005); thus the 
brain substrate on which baclofen will act will vary greatly depending on the 
withdrawal time.  This includes flux in a number of neurotransmitters (e.g., GABA 
and glutamate) and downstream signaling molecules (e.g., the transcription 
factor CREB).  For example, functional coupling of the GABABR is decreased in 
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the cortex at 14 days withdrawal from repeated amphetamine, an effect that is 
not observed at one day withdrawal (Zhang et al., 2000).  Likewise, the 
transcription factor CREB is differentially regulated after a sensitizing regimen of 
Meth with CREB being elevated at three but not 14 days withdrawal (McDaid et 
al., 2006b).  Thus, the brain state is highly dynamic and baclofen administered 
during one post-conditioning withdrawal time may not necessary be effective 
during another.  The current study evaluated the possibility of “windows of 
opportunity” for baclofen to be effective as well as the possibility of treatment 
duration effects of baclofen on the maintenance of Meth-induced associative 
learning. 
  
Materials and Methods 
Animals 
Male Sprague-Dawley rats (n=94) (Harlan, Indianapolis, IN) weighing 250-300g 
at the start of the study were acclimated to the vivarium for at least five days prior 
to the onset of the experiments.  Rats were housed in pairs in a climate-
controlled environment (23-25º) on a 12 hr light/dark cycle, and allowed ad 
libitum access to food and water.  Cage mates were given identical 
pharmacological treatments.  Housing facilities are accredited through the 
Association for Assessment and Accreditation of Laboratory Animal Care, and all 
experiments were carried out in accordance with the conditions set forth by the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals 
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(National Research Council, 1996) and with the approval of the Rush University 
Institutional Animal Care and Use Committee.  
 
Drugs 
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile 
saline and administrated as 1mg/ml/kg as the base; saline was administered as 
1ml/kg; baclofen (2mg/kg; Sigma, St Louis, MO), and baclofen vehicle (0.9% 
saline; 1ml/kg).  All injections were given intraperitoneally (i.p.).   
 
The 2mg/kg dose of baclofen was selected because it was within the range of 
doses used in laboratory rats to successfully i) attenuate the development and 
expression of Meth-induced CPP when administered 30min prior to each daily 
conditioning session or CPP test, respectively (doses tested were 1.25, 2.5, 
5mg/kg, i.p.) (Li et al., 2001), ii) inhibit the reinstatement of nicotine-induced CPP 
and self-administration when administered 5min prior to testing (0.612, 1.25, 
2.5mg/kg, i.p. were used) (Fattore et al., 2009), iii) reduce cocaine self-
administration when given 10min prior to the session (2.5mg/kg, i.p.) (Smith et 
al., 2004), iv) reduce amphetamine self administration when administered 30min 
prior to testing (doses tested were 1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005), 
and v) inhibit the maintenance of amphetamine-induced motor sensitization 
(2mg/kg, i.p.) (Bartoletti et al., 2004).  In addition, we determined in a pilot study 
that 3mg/kg baclofen reduced motor activity, but no impairment was observed 
with 2mg/kg baclofen (e.g., horizontal activity, over 75min post injection for 
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vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388; baclofen 3mg/kg 
(n=6), 1067±258; one-way ANOVA p=0.012, post-hoc Dunnett’s showed 
significance for 3mg/kg).  
 
Apparatus for Assessing Behavior 
The test room was dimly lit (54-108 lux) with white noise continuously present 
(white noise generator, San Diego Instruments, San Diego, CA).  The CPP 
apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by 
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large 
conditioning chambers (25cm x 30cm x 30cm) separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct visual (vertical vs. 
horizontal lines on walls) and tactile (patterned floor with an overturned paint dish 
glued to the center of the floor or differently patterned floor with a smooth 
rectangle glued to the center of the floor) cues which were randomized for 
visual/tactile cue combinations.  The center chamber had white, solid colored 
walls and a smooth slightly raised platform floor.  Time spent in each chamber 
and motor activity was monitored via two sets of photobeams (24 in the 
horizontal plane and 12 vertical). 
 
Conditioned Place Preference 
Rats were transported from the animal housing room to the adjacent test room at 
least 30min prior to the start of the experiment.  Rats were subjected to a 30min 
pre-test at least 72hr prior to initiating conditioning to determine unconditioned 
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preference.  Pre-test results demonstrated that the box configuration resulted in 
rats spending unequal amounts of time in each chamber (n=94; time spent 
727±38sec vs. 950±39sec, p<0.05); thus, rats were Meth-paired in the chamber 
in which they spent the least amount of time during the pre-test.  As illustrated in 
the experimental timelines (Figs. 9A, 10A, & 11A), conditioning occurred over five 
days; Meth-conditioned rats were given a Meth injection (1mg/kg) every other 
day for three days (days 1, 3, & 5) and a saline injection (1ml/kg) on the alternate 
two days (days 2 & 4).  This five-day conditioning protocol reliably produces 
amphetamine- (Shen et al., 2006; Rademacher et al., 2006) and Meth- (Chapters 
IV& VII and unpublished data) induced CPP.  Moreover, alternating the order of 
Meth administration does not influence preference outcomes and the resulting 
CPP is similar to that obtained with 6-day conditioning protocol (Chapter VI).  
During conditioning, immediately after the injection rats were placed into the 
appropriate chamber of the CPP box for 45min.  After conditioning, three 
experiment-specific protocols were used to determine withdrawal time and 
treatment duration effects of baclofen on Meth-induced CPP, as described below. 
 
Experiment 1: Early Withdrawal (Short vs. Long-Term Maintenance) 
This experiment was designed to ascertain the effects of baclofen on the short-
term maintenance of Meth-induced CPP (see Fig. 9A for experimental time line).  
Rats were assigned to a treatment group based on pre-test outcomes such that 
time spent in each chamber prior to conditioning was approximately equal 
between treatment groups.  Rats were administered two-once daily home cage 
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injections (protocol days 6 & 7) of baclofen (2mg/kg) or baclofen vehicle (1ml/kg); 
one day (protocol day 8) or 11 days (protocol day 18) after the last injection rats 
were tested for CPP in a drug-free state.  For the CPP test, rats were allowed 
free access to the entire CPP box and time spent in each chamber was 
monitored for 30min.   
 
Experiment 2: Protracted withdrawal (Long-Term Maintenance) 
This experiment was designed to ascertain if baclofen effects on the 
maintenance of Meth-induced CPP were withdrawal-time dependent (See Fig. 
10A for experimental time line).  After conditioning, but before the home cage 
treatments were initiated, rats were given a drug-free CPP test to verify the 
development of the preference (Fig 10A; protocol day 11).  Rats that did not 
increase time spent in the Meth-paired chamber on CPP Test 1 compared to the 
same chamber during the pre-test by at least 10% (180sec) were excluded from 
the study.  Culling rats based on the strength of learning (Paolone et al., 2009), 
helps assure that only those rats that clearly acquired the task were used to 
determine the potential for GABABR ligands to subsequently reduce the acquired 
preference.   Rats were assigned to a treatment group such that the magnitude 
of CPP expressed during CPP Test 1 was approximately equal for both treatment 
groups.  Rats were subsequently administered two once-daily home cage 
injections (protocol days 16 & 17) of baclofen (2mg/kg) or baclofen vehicle 
(1ml/kg).  One day after the last home cage injection (protocol day 18), rats were 
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tested in a drug-free state in order to ascertain if preference demonstrated during 
CPP Test 1 could be disrupted.     
 
Experiment 3: Sub-Chronic Baclofen Administration & the Long-Term 
Maintenance of Meth-induced CPP  
This experiment was designed to ascertain if a longer duration baclofen 
treatment would inhibit the maintenance of Meth-induced CPP (see Fig. 11A for 
experimental time line).   Rats were tested in a drug-free state three days after 
conditioning (day 8) and culled using the method described previously to ensure 
robust initial preference.  Rats were assigned to a treatment group such that the 
magnitude of CPP expressed during CPP Test 1 was approximately equal for 
both treatment groups.  Rats were subsequently administered 10 once-daily 
home cage injections (protocol days 9-18) of baclofen (2mg/kg) or baclofen 
vehicle (1ml/kg).  Three days after the last home cage injection (protocol day 21), 
rats were tested in a drug-free state to ascertain if preference demonstrated 
during CPP Test 1 could be disrupted.  This three-day period was imposed to 
allow the sub-chronic baclofen treatment to be cleared from the system prior to 
testing so we could determine baclofen effects on memory maintenance.   
 
Statistical Analysis 
CPP was defined as spending significantly more time in the Meth- vs. the saline-
paired chamber.  For Experiment 1, a two-way ANOVA was used (Treatment x 
Chamber) to determine the effect of treatment on preference expressed during 
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the CPP Test.  A two-way repeated measures ANOVA was employed for 
Experiments 2 and 3 (Chamber x Test) to evaluate the changes in preference 
that occurred before and after home cage treatments (i.e., CPP Test 1 vs. CPP 
Test 2).  For all experiments, a post-hoc Newman-Keuls test was conducted.  
Similar approaches were used by Stewart and colleagues (Paolone et al., 2009; 
Botreau et al., 2006).  Time spent in the center compartment was not used for 
CPP statistical analysis but we verified that time spent in the center chamber was 
not different between treatment groups or during any test within a treatment 
group (Student’s t-test or repeated measures ANOVA, respectively).  All data are 
presented as mean ± standard error of the mean (SEM).  Statistical outliers, 
determined as those rats that spent greater than two standard deviations above 
or below the mean time spent in any chamber, were not included for analysis.  
 
Results 
Experiment 1: Early Withdrawal (Short vs. Long-Term Maintenance) 
To determine if processes engaged soon after conditioning could be inhibited by 
baclofen, two once-daily, post-conditioning, home cage injections of baclofen or 
vehicle were administered on protocol days 6 & 7 (Fig. 9A) and the rats were 
tested one day later (protocol day 8).  Baclofen did not inhibit the maintenance 
and subsequent expression of Meth-induced CPP in either protocol.  A two-way 
ANOVA revealed a significant effect of Chamber (F(1,54)=33.86, p<0.0001) with a 
non-significant effect of Treatment (F(1,54)=0, p=0.996) and Treatment x Chamber 
interaction (F(1,54)=1.83, p=0.182).  A post-hoc Newman-Keuls test revealed 
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significantly more time was spent in the Meth-paired chamber compared to the 
saline-paired chamber for vehicle (Fig. 9B, n=14, p<0.001) and baclofen (Fig. 9B, 
n=15, p<0.01) treated rats.  Time spent in the middle chamber was not 
significantly different between treatment groups (Student’s t-test, p>0.05).  Thus, 
two injections of baclofen administered on the days soon after Meth conditioning 
failed to alter the expression of CPP one day. 
 
To determine if the time between baclofen administration and CPP testing altered 
the ability of baclofen to disrupt the preference for the Meth-associated context, 
another group of Meth-conditioned rats, administered baclofen (2mg/kg) or 
baclofen vehicle (1ml/kg) on days 6 and 7, were tested for the expression of the 
preference on day 18.  Similar to those tested one day after baclofen, these rats 
successfully expressed CPP (time spent Meth-paired chamber, 1141±46sec vs. 
time spent in the saline-paired chamber, 455±45sec; paired t-test, p<0.0001).  
Findings from these two experiments converge to demonstrate that two injections 
of baclofen given soon after conditioning (i.e., protocol days 6 and 7) did not 
inhibit the expression of Meth-induced CPP one or 11 days later. 
 
Experiment 2: Protracted withdrawal (Long-Term Maintenance) 
In this experiment, CPP Test 1 was incorporated on protocol day 11 (see Fig. 
10A) in order to verify that rats successfully developed the preference for the 
Meth-paired chamber prior to administration of the home cage treatments and 
then to allow identification of the strongest learners to provide a more rigorous 
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evaluation of the ability of baclofen to reduce this learning.  As a group, the 30 
rats tested expressed CPP (time spent Meth-paired chamber, 896±48sec; vs. 
saline-paired chamber, 758±48sec; paired t-test, p<0.05); however, six out of 30 
rats did not increase time spent in the Meth-paired chamber on CPP Test 1 by 
10% (180s) more than time spent in the same compartment during the pre-test, 
thus they were not tested for antagonism by baclofen. 
 
To determine if baclofen administered during a later withdrawal time (protocol 
days 16 & 17) would disrupt previously acquired place preference when CPP 
expression was tested one day later (day 18).  Vehicle treated rats (Fig 10B, n=9) 
expressed a preference for the Meth-paired chamber before (protocol day 11) 
and after the two home cage vehicle injections (protocol day 18).  Two-way 
repeated measures ANOVA revealed a significant effect of Chamber 
(F(1,16)=19.832, p=0.0004) as well as a significant Chamber x Test interaction 
(F(1,16)=4.528, p=0.049) with no effect of Test (F(1,16)=0.020, p=0.889).  A post-
hoc Newman-Keuls revealed significantly more time was spent in the Meth-
paired chamber compared to the saline-paired chamber for both tests (p<0.01).  
This indicates that the acquired preference demonstrated during CPP Test 1 was 
not diminished on CPP Test 2 (day 18); therefore, repeated CPP testing, 
intervening home cage injections, or withdrawal time did not alter subsequent 
expression of place preference.  The baclofen treatments resulted in similar 
outcomes obtained with vehicle; i.e., preference maintained after two once-daily 
injections of baclofen (Fig. 10C, n=13).  A two-way repeated measures ANOVA 
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revealed a significant effect of Chamber (F(1,24)=17.483, p=0.0003) with no effect 
of Test (F(1,24)=0.072, p=0.790) or Chamber x Test interaction (F(1,24)=0.122, 
p=0.730).  A post-hoc Newman-Keuls test revealed significant CPP during CPP 
Test 1 (p<0.01) and CPP Test 2 (p<0.05).  For each test, time spent in the middle 
chamber did not significantly change for either treatment group (Student’s t-test, 
p>0.05).  Thus, findings from Experiments 1 and 2 indicate that two once-daily 
injections of baclofen independent of when they are administered (days 6 & 7 vs. 
16 & 17) or tested (day 8 or 18) failed to alter the expression of CPP induced by 
a five-day Meth conditioning protocol. 
 
Experiment 3: Sub-Chronic Baclofen Administration & the Long-Term 
Maintenance of Meth-induced CPP 
As a group, the 32 rats tested expressed CPP during Test 1 (time spent Meth-
paired chamber, 999±43sec vs. saline-paired chamber, 645±44sec; paired t-test, 
p<0.0001); however, four out of 32 did not increase time spent in the Meth-paired 
chamber on CPP Test 1 by 10% (180s) more than time spent in the same 
compartment during the pre-test thus they were not used to evaluate antagonism 
by baclofen.   
 
In this Experiment, a three day period was imposed between the last home cage 
injection to allow baclofen to be cleared from the system prior to testing for 
preference,   to clearly delineate between baclofen effects on maintenance 
(tested in a drug-free state) vs. baclofen effects on expression (baclofen present 
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during the CPP test).  Post-conditioning administration of the vehicle (days 9-18) 
did not impact the ability of rats to express a preference for the Meth-paired 
chamber (Fig. 11B, n=12).  Two-way repeated measures ANOVA revealed a 
significant effect of Chamber (F(1,22)=27.298, p<0.0.0001) but no effect of Test 
(F(1,22)=0.051, p=0.823) or Chamber x Test interaction (F(1,22)=0.103, p=0.751).  A 
post-hoc Newman-Keuls test revealed significant preference for both CPP tests 
(Fig. 11B; p<0.01).  This demonstrated that the acquired preference 
demonstrated during CPP Test 1 was not diminished on CPP Test 2 (day 21); 
therefore, repeated CPP testing, intervening home cage injections, and 
withdrawal time did not alter subsequent CPP.  In contrast, CPP that was 
observed during CPP Test 1 was not maintained after 10 days of home-cage 
baclofen injections (Fig. 11C, n=13).  Two-way repeated measures ANOVA 
revealed a significant effect of Chamber (F(1,24)=20.814, p=0.0001) and a 
Chamber x Test interaction (F(1,24)=5.742, p=0.025) but no effect of Test 
(F(1,24)=0.009, p=0.926).  A post-hoc Newman-Keuls test reveled significant 
preference for CPP Test 1 (p<0.01) but not for CPP Test 2 (p>0.05).  These 
findings demonstrate that sub-chronic treatments with baclofen can disrupt the 
maintenance of Meth-induced CPP.  The inability of rats to express a preference 
for the Meth-paired chamber did not reflect motor deficits engendered by the 
repeated baclofen treatment for activity during CPP Test 2 was statistically 
indistinguishable between vehicle (n=12) and baclofen (n=13) treated rats.  
(Horizontal Activity; vehicle, 3281±291 vs. baclofen, 3390±193, Student’s t-test, 
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p>0.05.  Vertical Activity; vehicle, 593±76 vs. baclofen, 554±59, Student’s t-test, 
p>0.05.)  
 
Discussion 
Results from this study revealed that 10 once-daily home cage injections of 
baclofen inhibited the maintenance of Meth-induced CPP.  The critical feature of 
this effect appeared to be the sub-chronic exposure as opposed to time during 
which baclofen was administered or when the CPP was tested, for baclofen 
given during the first two or last two days of this treatment period were 
ineffective, and place preference was sustained whether CPP testing occurred 
one or 11 days after the last injection.  These findings suggest that persistent 
adaptations engendered by repeatedly augmenting GABABR signaling (i.e., for 
more than two days) was sufficient to disrupt processes necessary to maintain 
Meth-induced associative learning.   
 
Psychostimulant-induced brain adaptations are complex, involving multiple 
neurotransmitter systems and downstream signaling molecules (Nestler, 2004; 
Nestler, 2001; McDaid et al., 2006b; McDaid et al., 2007).  Contributing to the 
dysregulated brain state during withdrawal from repeated psychostimulant 
administration is a decrease in the expression of GABABRs (Frankowska et al., 
2008b) as well as a reduction in functional coupling of the receptor to the G-
protein (Zhang et al., 2000; Kushner and Unterwald, 2001).  Withdrawal from 
repeated psychostimulant exposure is a dynamic process with different brain 
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states occurring in the hours, days, and weeks after terminating psychostimulant 
administration.  For example, functional coupling of the GABABR is decreased in 
the nucleus accumbens and increased in the cortex at 14 days withdrawal from 
repeated amphetamine, an effect that is not observed at one day withdrawal 
(Zhang et al., 2000).  The time dependent nature of these changes may translate 
into periods of time when the brain is more vulnerable, or sensitive, to 
pharmacological interventions.  In the current study, two once-daily injections 
administered during the two days following conditioning (protocol days 6 & 7) or 
delayed by 10 days (protocol days 16 & 17) were not able to reveal withdrawal 
time-dependent effects.   This indicates that the brain state during early vs. more 
protracted withdrawal does not impact the ability of two once-daily treatments of 
baclofen to disrupt the maintenance of Meth-induced CPP.   Rather, our findings 
point to the duration of the baclofen treatment being a critical factor in disrupting 
maintenance previously acquired place preference.   
 
The maintenance of psychostimulant-induced behaviors is relatively unexplored; 
the current study has demonstrated for the first time that 10 once-daily injections 
inhibit the maintenance of Meth-induced associative learning.  To the best of our 
knowledge, no literature has demonstrated baclofen effects on memory 
maintenance; however, memory acquisition and expression are sensitive to 
pharmacological disruption by baclofen (Nakagawa et al., 1995; McNamara and 
Skelton, 1996; Castellano et al., 1989; Swartzwelder et al., 1987; Zarrindast et 
al., 2002; Zarrindast et al., 2004; Levin et al., 2004; Li et al., 2001; Stackman and 
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Walsh, 1994).  A single study by Bartoletti and colleagues has demonstrated that 
10 injections of 2mg/kg baclofen inhibit the maintenance of amphetamine-
induced motor sensitization (Bartoletti et al., 2004).  As a collective, these 
findings suggest that 10 injections of baclofen target a mechanism that is 
engaged during Meth-induced CPP (current results) and amphetamine-induced 
behavioral sensitization (Bartoletti et al., 2004).     
 
Ten once-daily baclofen injections have influenced the expression of these 
psychostimulant-induced behaviors by a number of mechanisms.  Repeated 
administration of an agonist may result in receptor down-regulation and/or 
desensitization.  A single baclofen administration (5-30mg/kg) has been reported 
to dose-dependently decrease GABABR expression in gerbil brain when 
measured 2hr after the injection (Park et al., 2004); however, mRNA expression 
of the GABABR is not altered by a tolerance-inducing baclofen administration 
protocol (2 x daily 5mg/kg, x 7 days) in rat spinal cord (Sands et al., 2003).  
Chronic baclofen administration (10mg/kg x 21 days) can functionally down-
regulate GABABR responses in rat spinal cord (Malcangio et al., 1995).  
Therefore, in the current study we cannot determine if a change in GABABR 
expression may have contributed to the observed behavioral results; however 
based on previous studies which either blunt or augment neuronal activity it 
seems unlikely that reducing inhibitory GABAergic tone would inhibit the 
maintenance of Meth-induced CPP.  Other candidate mechanisms may involve 
downstream consequences of repeated (i.e., > 2 injections) GABABR activation.  
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GABABR negatively regulate signal transduction, ion channel function and gene 
transcription, via inwardly rectifying potassium channels (GIRKs), calcium 
channels, and cAMP (Bettler et al., 2004; Mott and Lewis, 1994; Barthel et al., 
1996).  Indeed, increasing the dose and/or duration of baclofen administration 
appears to have a more profound effect on the downstream consequences of 
GABABR activation.  No changes in neuropeptide gene expression (e.g., 
preprodynorphine and preproenkephalin) were observed with a single systemic 
injection of 2.5mg/kg baclofen; however, a single large systemic dose (10mg/kg) 
increases c-Fos expression in specific brain regions (van Nieuwenhuijzen et al., 
2009) and seven injections (10mg/kg) alter the expression and activation of the 
transcription factor cAMP response element binding protein (CREB) (Yin et al., 
2006).  Activation (i.e., phosphorylation) of transcription factors in limbic brain 
regions is a molecular consequence of psychostimulant administration (McDaid 
et al., 2006b; Carlezon et al., 2005; Olson et al., 2005; Berke and Hyman, 2000; 
Chen et al., 2009; Nestler, 2001) and is also involved in learning in memory 
processes (Wang et al., 2006; Bailey et al., 1996; Berke and Hyman, 2000; 
Alberini, 2009).  The GABABR activation pharmacologically antagonizes events 
leading to changes in the transcription factor CREB (Yin et al., 2006; Lhuillier et 
al., 2007) and also normalizes downstream consequences of changes in gene 
transcription including ΔFosB (Lhuillier et al., 2007) and neuropeptide gene 
expression (Zhou et al., 2004).  Thus, changes in the function of transcription 
factors provides an overlapping mechanism by which baclofen can alter the 
maintenance of memory and psychostimulant-induced behaviors.   
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Conclusion 
In summary, we have found that pharmacologically augmenting GABABR 
signaling for 10 days inhibited brain mechanisms necessary to maintain and 
subsequently express Meth-induced associative learning.  The results of these 
experiments provide insight into the role of the GABABR in memory processes 
engaged during the maintenance of Meth-induced CPP and may be of value as 
an addiction therapy for abstinent, Meth abusing individuals an effect which may 
be independent of when the treatment is initiated. 
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Figure 7.  Maintenance of Meth-induced CPP was not altered by two-once daily 
injections of baclofen administered during the early post-conditioning phase.  A.  
Illustration of Experiment 1 treatment protocol.  M, methamphetamine (1mg/kg); 
S, saline (1mg/kg); Ø, no drug; V, baclofen vehicle (0.9% saline, 1ml/kg); B, 
baclofen (2mg/kg).  Data were analyzed with a two-way ANOVA followed by a 
post-hoc Newman-Keuls which compared time spent in the Meth- (filled bar) and 
saline- (open bar) paired chambers (significance denoted by *** p< 0.001 or ** p< 
0.01).  The center compartment (hatched bar) was not included for statistical 
comparisons.  B.  Rats that received two post-conditioning vehicle injections 
expressed a preference for the Meth-paired chamber one day later (protocol day 
8, left set of bar graphs; n=14).  Rats that received two injections of baclofen also 
expressed CPP (right set of bar graphs; n=15).   
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Figure 8.  Maintenance of Meth-induced CPP was not inhibited by two once-daily 
home cage injections of baclofen initiated during the late post-conditioning 
phase.     A.  Illustration of Experiment 2 treatment protocol.  M, 
methamphetamine (1mg/kg); S, saline (1mg/kg); Ø, no drug; V, baclofen vehicle 
(0.9% saline, 1ml/kg); B, baclofen (2mg/kg).  Data were analyzed with a two-way 
repeated measures ANOVA followed by a post-hoc Newman-Keuls which 
compared time spent in the Meth- (filled square) and saline- (open square) paired 
chambers (significance denoted by ** p<0.01 or * p<0.05).  The center 
compartment (filled triangle) was not included for statistical comparisons.  B.  
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Rats assigned to the baclofen vehicle (n=9) expressed CPP on both test days 
(CPP Test 1 & CPP Test 2).  C.  Rats that received baclofen treatment (n=13) 
also expressed a preference for the Meth-paired chamber on both test days 
(CPP Test 1 & CPP Test 2). 
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Figure 9.  Meth-induced CPP was inhibited by 10 once-daily injections of 
baclofen.   A.  Illustration of Experiment 3 treatment protocol.  M, 
methamphetamine (1mg/kg); S, saline (1mg/kg); Ø, no drug; V, vehicle (0.9% 
saline, 1ml/kg); B, baclofen (2mg/kg).  Data were analyzed with a two-way 
repeated measures ANOVA followed by a post-hoc Newman-Keuls which 
compared time spent in the Meth- (filled square) and saline- (open square) paired 
chambers.  (significance denoted by ** p<0.01).  The center compartment (filled 
triangle) was not included for statistical comparisons.  B.  Rats assigned to 
receive baclofen vehicle (n=12) expressed CPP during both CPP tests (CPP Test 
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1 & CPP Test 2).  C. Rats that received baclofen treatments (n=13) expressed a 
preference for the Meth-paired chamber during CPP Test 1 but the preference 
was no longer evident during CPP Test 2 (p>0.05). 
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CHAPTER V 
POST-CONDITIONING ADMINISTRATION OF THE GABAB RECEPTOR 
POSTITIVE ALLOSTERIC MODULATOR / Ca++ CHANNEL BLOCKER 
FENDILINE ANTAGONIZES THE MAINTENANCE AND  
EXPRESSION OF METHAMPHETAMINE-INDUCED 
 CONDITIONED PLACE PREFERENCE 
Abstract 
The current study evaluated the potential of fendiline, a GABABR positive 
allosteric modulator and L-type calcium channel blocker, to inhibit the 
maintenance and expression of learned associations between methamphetamine 
(Meth; the unconditioned stimulus) and a unique environmental context (a 
conditioned stimulus).  Meth (1mg/kg)-induced associative learning was 
established using a six-day conditioned place preference (CPP) paradigm, and 
fendiline or its vehicle was administered at various post-conditioning times.  The 
dose selected for fendiline (5mg/kg) did not inhibit motivated motor behavior 
assessed on the rotarod nor produced rewarding or aversive effects on its own 
as determined with the CPP/CPA task.  In rats demonstrating Meth-induced 
CPP, two once-daily injections of fendiline did not influence the maintenance of 
place preference when tested in a drug-free state regardless of the post-
conditioning phase or the length of time between terminating the fendiline 
treatments and the test for preference when tested.  In contrast, 10 once-daily 
fendiline treatments were successful in inhibiting the maintenance of the 
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preference.  Following re-conditioning, an injection of fendiline administered 
immediately prior to the CPP test revealed that expression of Meth-induced CPP 
was inhibited in rats with a treatment history of 10 fendiline injections and rats 
that received two injections of fendiline corresponding to the last two days of the 
10 day treatment.  These experiments reveal duration-dependent effects of 
fendiline on the maintenance of Meth-induced CPP and withdrawal time-after 
fendiline treatment-dependent effects of fendiline on the expression of Meth-
induced CPP.  As a reduction in the significance of Meth-associated cues is a 
means to reduce relapse, fendiline, or other drugs with similar chemical 
properties may be of value for addiction therapy in abstinent Meth-addicted 
humans. 
 
Introduction 
During repeated psychostimulant administration, associations are made between 
the rewarding effects of the stimulant and the context in which the drug was 
administered.  After terminating the drug treatments, the brain is hyper-
responsive to subsequent re-exposure to psychostimulant-paired cues 
(Hotsenpiller et al., 2001; Rebec and Sun, 2005; Rebec and Sun, 2005; 
Hotsenpiller and Wolf, 2002).  This hyper-responsivity may be an underlying 
mechanism contributing to cue-induced drug-craving and seeking in humans 
(Childress et al., 1999; O'Brien et al., 1998; Childress et al., 1999; Ehrman et al., 
1992) and rodents (Crombag et al., 2008).   This behavior can be observed in the 
laboratory using conditioned place preference (CPP) (Childs and deWit H., 2009; 
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Tzschentke, 2007; Tzschentke, 1998).  CPP provides a useful means to explore 
the potential for pharmacotherapies to reduce cue-elicited drug-craving and –
seeking in the abstinent addict.  The current study is focused on 
methamphetamine (Meth).    Meth is a potent and highly abused psychostimulant 
for which no FDA-approved pharmacotherapy is available, therefore; there is a 
large unmet need to develop an anti-relapse therapy for Meth addiction. 
 
The maladapted brain state that occurs after repeated psychostimulant 
administration is the consequence of several factors, including a down-regulation 
of the GABABR system (Frankowska et al., 2008b; Kushner and Unterwald, 
2001; Zhang et al., 2000) and an up-regulation of L-type calcium channels 
(Shibasaki et al., 2010; Ford et al., 2009; Nasif et al., 2005a; Nasif et al., 2005b; 
Hu, 2007).  The inhibitory effects of the GABABR are mediated by inhibition of 
high voltage-activated Ca++ channels (Mott and Lewis, 1994; Bowery, 1993) thus 
this provides a unique opportunity for GABABRs to blunt the neuronal excitability 
that occurs as a consequence of the up-regulated Ca++ channels.  The GABABR 
and the L-type calcium channel have received attention as possible targets for a 
pharmacotherapy for addiction (Brebner et al., 2002; Xi and Gardner, 2008; Rose 
and Grant, 2008; Vetulani, 2001).  The GABABR agonist baclofen inhibits the 
maintenance and expression of amphetamine-induced behavioral sensitization 
(Bartoletti et al., 2004; Bartoletti et al., 2005), the expression of Meth-induced 
CPP (Li et al., 2001), and decreases Meth (Ranaldi and Poeggel, 2002), 
amphetamine (Brebner et al., 2005) and cocaine self-administration (Filip et al., 
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2007; Filip and Frankowska, 2007).  A drawback to the practical application of 
direct acting GABABR agonists, such as the baclofen, is sedation and motor 
impairment (Cryan et al., 2004; Ling et al., 1998; Shoptaw et al., 2003; 
Heinzerling et al., 2006).  Positive allosteric modulators (PAMs) of the GABABR 
selectively augment GABABR-mediated signaling by acting only where 
endogenous GABA is already bound to the GABABR (Bettler et al., 2004; Urwyler 
et al., 2001; Gjoni et al., 2006; Urwyler et al., 2005).  This action affords PAMs 
considerable regional and temporal specificity compared to direct acting agonists 
such as baclofen.  Consequently, GABABR PAMs present fewer negative side 
effects than those associated with direct (orthosteric) acting agonists like 
baclofen.  Furthermore, the receptor desensitization and down regulation that 
occurs with direct agonists is not observed with PAMs (Gjoni and Urwyler, 2008) 
which is an additional therapeutic advantage as long-term treatment would likely 
be necessary for an anti-addiction therapy.  Like baclofen, GABABR PAMs (i.e., 
CGP7930 and GS39783) reduce the maintenance of Meth-induced CPP (Voigt et 
al., unpublished data), cocaine self-administration (Smith et al., 2004; Filip et al., 
2007) and cocaine- and cue-induced reinstatement of cocaine-seeking (Filip and 
Frankowska, 2007).  Attenuation of stimulant-induced behaviors is also observed 
with L-type calcium channel blockers which inhibit the expression of nicotine- 
(Biala, 2003), Meth-, and cocaine-induced CPP (Suzuki et al., 1992), cocaine-
induced behavioral sensitization (Martin-Iverson and Reimer, 1994), and 
attenuates drug-primed reinstatement of nicotine self-administration (Biala and 
Budzynska, 2008).  Collectively, these studies demonstrate that GABABR PAMs 
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and L-type calcium channel blockers modulate stimulant-mediated behaviors.  
The capacity of these targets to modify the maintenance and expression of Meth-
induced behaviors was to date, unknown, and thus, is the focus of the current 
study.   We consider the dual actions of fendiline, a GABABR PAM (Ong and 
Kerr, 2005; Ong et al., 2005; Chen et al., 2005) and L-type calcium channel 
blocker (Tripathi et al., 1993; Nawrath et al., 1998; Bayer and Mannhold, 1987) to 
be particularly interesting which compelled us to evaluate the ability of fendiline 
to mitigate previously acquired CPP.   
 
Psychostimulant administration initiates a cascade of down-stream signaling 
events which change over the course of hours, days, and weeks following the 
last exposure (Zhang et al., 2000; Zhang et al., 2001; Camp et al., 1997; Ernst 
and Chang, 2008; Jayaram and Steketee, 2005; McDaid et al., 2006b).  For 
example, functional coupling of the GABABR is observed at 14 but not one day 
withdrawal from repeated amphetamine administration (Zhang et al., 2000).  
Changes such as these are manifested as different phases of withdrawal which 
have been observed during the three weeks following the cessation of Meth use 
(McGregor et al., 2005).  The dynamic brain state present after psychostimulant 
administration presents an opportunity during which the brain may be more 
sensitive or vulnerable to disruption of mechanisms necessary to maintain and 
subsequently express psychostimulant-induced behaviors.  The current study, 
evaluated the post-conditioning time and duration-dependent effects of fendiline 
on the maintenance and expression of Meth-induced CPP.    
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Materials and Methods 
Animals 
Male Sprague-Dawley rats (n=118, Harlan, Indianapolis, IN) weighing 225-250g 
at the start of the study were acclimated to the vivarium for at least five days prior 
to the onset of the experiments.  Rats were housed in pairs in a climate-
controlled environment on a 12hr light/dark cycle and allowed ad libitum access 
to food and water.  Cage mates were given identical pharmacological treatments.  
Housing facilities are accredited through the Association for Assessment and 
Accreditation of Laboratory Animal Care, and all experiments were carried out in 
accordance with the conditions set forth by the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals (National Research Council, 
1996) and with the approval of the Rush University Medical Center Institutional 
Animal Care and Use Committee.  
 
Drugs 
Conditioning: (+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 
0.9% sterile saline and administrated as 1mg/ml/kg (calculated as the base) and 
saline was administered as 1ml/kg.  Home Cage Treatment: Fendiline [N-(3,3-
diphenylpropyl)-α-methylbenzylamine] (Sigma, St. Louis, MO) 5mg/ml/kg or 
fendiline vehicle (25% EtOH) 1ml/kg.  Rotarod: Fendiline 5mg/ml/kg; fendiline 
vehicle 1ml/kg; (+/-)baclofen 4mg/kg/ml (a direct GABABR agonist, Sigma, St. 
Louis, MO); baclofen vehicle (0.9% saline) 1ml/kg; and positive control 
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pentobarbital 10mg/kg/ml (an agonist of ionotropic GABAA receptors; Ovation 
Pharmaceuticals, Inc., Deerfield, IL).  All injections were given intraperitoneally 
(i.p.).   
 
The 5mg/kg dose of fendiline was selected for CPP experiments based on 
literature demonstrating that this dose provides improved cardiovascular function 
(e.g., antihypertensive effects) while having a favorable side effect profile in 
humans (Bayer & Mannhold 1987) and pilot studies conducted in our laboratory 
(a higher dose of 30mg/kg resulted in adverse side effects in rodents).  For 
example, 4mg/kg baclofen was selected as a GABABR positive control for a 
rotarod motor-control study because it was within the range of doses previously 
used in laboratory rats to successfully attenuate psychostimulant-induced 
behaviors including Meth-induced CPP (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001) 
and amphetamine self-administration (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 
2005).  As another positive control, we conducted a pilot study to verify that the 
10mg/kg pentobarbital dose was below that which is necessary to induce 
anesthesia or inhibit the righting reflex but was sufficient to induce motor slowing.  
 
Experiment 1: Assessment of motivated motor function 
Rotarod assessments were used to ascertain the effects of treatments used in 
the CPP protocols on motivated motor function requiring a high degree of motor 
coordination.  The rotarod apparatus (San Diego Instruments, San Diego, CA) 
consisted of four animal lanes (each 11cm wide).  The drum (7cm diameter) was 
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positioned to achieve a 46cm fall height.  The rotating drum was accelerated 5-
40rpm over 5min.  Previously Meth-conditioned rats were trained until all rats met 
the criterion of remaining on the rotarod for a minimum of 3min.  On the test day, 
a test compound was administered and latency to fall from the apparatus (sec) 
was measured at the following time points: 0 (immediately prior to injection), 20, 
40, 60, 180, 360min, and 24hr after the injection.  A repeated measures design 
was used (all rats were evaluated with each test compound).  Rats were 
“retrained” on the apparatus 24hr prior to each test to ensure that minimum 
criterion  (i.e., had to remain on the rotarod apparatus for a minimum of 3min) 
was maintained across multiple tests.   
 
Conditioning apparatus 
The test room was dimly lit (54-108 lux) with white noise (white noise generator, 
San Diego Instruments, San Diego, CA) continuously present.  The CPP 
apparatus (AccuScan Instruments, Inc., Columbus, OH) (63cm x 30cm x 30cm) 
consisted of three chambers divided by Plexiglas sliding doors; two large 
conditioning chambers (25cm x 30cm x 30cm) were separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct visual and tactile 
cues (chamber A, vertical lines on walls and an overturned paint dish glued to the 
center of a randomly patterned floor; chamber B, horizontal lines on walls and a 
square patterned floor; center chamber, no stripes on walls and a smooth, 
slightly raised platform floor).  Time spent in each chamber and motor activity 
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was monitored via two sets of photobeams (24 in the horizontal plane and 12 
vertical in the vertical plane). 
 
Experiment 2: Assessment of fendiline in conditioned place 
preference/conditioned place aversion 
This experiment was designed to test rewarding or aversive properties 
associated with fendiline.  The timeline is illustrated in Fig. 12.  The rats were 
transported from the animal housing room to the adjacent test room at least 
30min prior to the start of the experiment.  Rats were subjected to a 30min pre-
test at least 72hr prior to initiating conditioning to determine unconditioned 
preference.  Pre-test results verified that the box configuration did not engender a 
bias for either chamber; however individual rats tended to spend more time in 
one chamber or another other so rats were counterbalanced; half received 
fendiline in the initially preferred chamber and half in the initially non-preferred 
chamber.  This experimental design was employed because it was unclear if 
fendiline would produce a preference (CPP) or an aversion (conditioned place 
aversion, CPA) the counterbalanced design allows for detection of both; 
accordingly rats which spent more than 75% of the pre-test in one chamber were 
excluded from further analysis (2 out of 10 rats from the study).  Conditioning 
occurred over 10 days; two conditioning sessions took place each day.  Each 
morning, rats were injected with vehicle (25% EtOH 1ml/kg i.p.) and immediately 
placed in one CPP chamber for 45min; 4hr later, the other chamber was paired 
with fendiline (5mg/kg i.p.)  for 45min.  Three days following the final conditioning 
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session rats, were given a drug-free CPP test.  The three day period between 
conditioning and the CPP test was imposed to allow for fendiline to be cleared 
from the system prior to testing for preference.  For the 30min CPP test, rats 
were allowed free access to the entire CPP apparatus and time spent in each 
chamber and motor activity was monitored.   
 
Experiments 3-5: Methamphetamine-induced conditioned place preference 
Rats were pre-tested as described above, and were paired with Meth in the 
chamber in which they spent the least amount of time during the pre-test.  As 
illustrated in the experimental timelines (Fig. 12B & 12C), conditioning occurred 
over six days; Meth-conditioned rats were given a Meth injection every other day 
for three days and a saline injection on the alternate three days.  During 
conditioning, rats were placed into the appropriate chamber of the CPP box 
immediately after the injection (Meth or saline) for 45min.  A 30min, drug-free 
CPP test was conducted three days after the last conditioning session (day 9).  
Rats that did not increase time spent in the Meth-paired chamber on CPP Test 1 
compared to the same chamber during the pre-test by at least 10% (180s) were 
excluded from the study.  Culling rats based on the strength of learning, as 
previously employed (Paolone et al., 2009), helps assure that only those rats that 
clearly acquired the task (i.e., made the association between drug and context) 
were used to determine the potential for GABABR ligands to subsequently reduce 
the acquired preference.  Rats were assigned to a treatment group such that the 
magnitude of preference expressed during CPP Test 1 was approximately equal 
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for all treatment groups.  The effects of fendiline on the maintenance (tested in a 
drug-free state) and expression (tested immediately after a fendiline injection) 
were tested in specific protocols described below. 
 
Experiment 3 was designed to ascertain if early post-conditioning treatments of 
fendiline were sufficient to disrupt the short-term maintenance of previously 
acquired CPP when measured in a drug-free state.  To do so, Meth-conditioned 
rats were injected in the home cage, once-daily for two days (on protocol days 10 
& 11; refer to Fig 12B) with 5mg/kg fendiline or its vehicle.  Rats were tested 
three days after the last home cage treatment using the method described 
previously.  The three day drug-free period was imposed to allow fendiline to be 
removed from the system prior to testing for preference.  Experiment 4 was 
designed to determine fendiline effects on the long-term maintenance of Meth-
induced CPP when measured in a drug-free state.  For this experiment, Meth-
conditioned rats received one of the following four post-conditioning treatments to 
determine the influence of post-conditioning time and treatment duration: (1) 10 
days of fendiline vehicle, (2) 10 days of fendiline, (3) two days of fendiline 
followed by eight days of vehicle, or (4) eight injections of vehicle followed by two 
days of fendiline.  Rats were tested for CPP expression in a drug-free state three 
days after the last home cage treatment (day 22), as in Experiment 3.  We then 
used these rats to test the effects of fendiline on CPP expression when tested 
immediately after a fendiline injection, as well as to ascertain if a fendiline history 
influenced outcomes of this assessment (Experiment 5).  To do so, 7-10 days 
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after CPP Test 2, the rats were „re-conditioned‟ for four days (protocol days R1-
R4, Fig 12C) to re-establish preference in all groups and prevent the extinction of 
the preference that can occur due to repeated testing.  Three days after re-
conditioning, rats were given a drug-free CPP test (CPP Test 3, protocol day R7) 
to verify CPP and the 10% criterion for task acquisition was applied.  Three days 
later, an acute injection of fendiline was administered immediately prior to CPP 
Test 4 (protocol day R10) and preference was determined as in CPP Tests 1-3.  
On days when experimental procedures were not conducted (i.e., intervening 
days are not indicated on the experimental timelines in Fig. 12A, B, & C), rats 
remained undisturbed in the home cage. 
 
Statistical Analysis 
Motor Function: Rotarod assessments were conducted using a repeated 
measures ANOVA with the within subject factor of time and the between subject 
factor of treatment followed by a post-hoc Newman-Keuls for between group 
differences at each time point.  Motor activity during CPP Test 4 was assessed 
using a one-way ANOVA followed by a post-hoc Newman-Keuls.  Conditioning: 
Preference or aversion was defined as spending significantly more time in the 
drug-treated or vehicle-treated chamber, respectively.  This comparison was 
accomplished by two-way repeated measures ANOVA (factors were chamber 
and CPP Test) followed by a post-hoc Newman-Keuls test for between chamber 
differences.  All data are shown as mean ± SEM.  Statistical outliers were 
determined as those rats with assessments that were greater than two standard 
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deviations above or below the mean.  Using this criterion, 14 rats were removed 
from the studies for being outliers.   
 
Results 
Experiment 1:  Effect of fendiline on rotarod performance 
The rotarod test was used to determine if fendiline (5mg/kg), or its vehicle (25% 
EtOH), induced deficits in motivated motor function task (using the natural fear of 
falling as a motivating factor) that requires a high degree of motor coordination.  
Baclofen (4mg/kg) and pentobarbital (10mg/kg) were used as positive controls.  
All rats (n=10) maintained minimum criterion throughout the repeated testing 
design (refer to methods).  Two-way repeated measures ANOVA revealed a 
significant effect of Time (F(6,270)=3.357, p=0.003) as well as a significant 
Treatment x Time interaction (F(24,270)=3.587, p<0.0001) with a non-significant 
factor of Treatment (F(4,45)=1.367, p=0.260).  As shown in Fig 13, a post-hoc 
Newman-Keuls test revealed that baclofen (p<0.05) and pentobarbital (p<0.01) 
administration significantly impaired motivated motor function compared to the 
saline treatment at 20 and 40min post injection, an effect that was not observed 
with fendiline or its vehicle (p>0.05).  These findings indicate that the 5mg/kg 
dose used to determine if fendiline could produce CPP or CPA (Experiment 2) 
and/or alter the maintenance of Meth-induced CPP (Experiments 3-5) was not 
sufficient to alter even a rigorous motor-function task.  
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Experiment 2: Assessments of fendiline in conditioned place 
preference/conditioned place aversion (Refer to Fig. 12A for timeline) 
An important consideration for medication development targeted toward chronic 
therapy for addiction is to determine potential abuse liability or aversive side 
effects of the putative therapeutic agent.  Thus, we evaluated the capacity of 
fendiline to produce either a preference or an aversion in the conditioning 
protocol using the 5mg/kg dose used in the rotarod task which did not alter motor 
function.  We designed a conditioning paradigm for fendiline that mimicked the 
most robust fendiline treatment protocol to be used to disrupt the maintenance of 
Meth-induced CPP, i.e., 10 once daily injections.  Thus, a morning/afternoon 
conditioning paradigm was employed where saline-pairings were conducted in 
the morning and fendiline-pairings were conducted in the afternoon.  Following 
10 days of twice-daily conditioning, rats demonstrated neither a preference nor 
an aversion for the fendiline-paired chamber (Fig. 14, n=8).  That is, a two-way 
repeated measures ANOVA revealed no significant  effects of Chamber 
(F(1,14)=0.009, p=0.928), Test (F(1,14)=0.004, p=0.949), or Chamber x Test 
interaction (F(1,14)=0.600, p=0.452).   Thus, using the fendiline dose (5mg/kg) 
identified as having no effects on motivated motor behavior (Fig. 13) or rewarding 
or aversive subjective effects (Fig. 14) we sought to determine if post-
conditioning administration of fendiline inhibited the maintenance and 
subsequent expression of Meth-induced CPP.   
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Experiment 3: Effect of fendiline administered during early the post-
conditioning phase on short-term maintenance of Meth-induced preference 
(refer to Fig. 12B for timeline) 
Following conditioning with Meth, preference for the Meth-paired chamber was 
observed before (CPP Test 1) and after (CPP Test 2) two once-daily treatments 
of vehicle (Fig. 15A, n=8) and fendiline (Fig. 15B, n=9).  A two-way repeated 
measures ANOVA revealed the following.  Vehicle-treated rats demonstrated a 
significant Chamber effect (F(1,14)=77.807, p<0.0001) with no effect of Test 
(F(1,14)=0.017, p=0.898) or Chamber x Test interaction (F(1,14)=0.121, p=0.733).  A 
post-hoc Newman-Keuls test revealed a significant preference during CPP Test 1 
and CPP Test 2 (p<0.01).  Likewise, fendiline-treated rats demonstrated a 
significant effect of Chamber (F(1,16)=14.746, p=0.001) with no effect for Test 
(F(1,16)=0.120, p=0.733) or a Chamber x Test interaction (F(1,16)=1.734, p=0.207).  
A post-hoc Newman-Keuls test revealed a significant preference for the Meth-
paired chamber during CPP Test 1 (p<0.01) and during CPP Test 2 (p<0.05).  
Thus, CPP was expressed independent of treatment history; two days of 
fendiline administered during the early post-conditioning phase had no impact on 
the short-term maintenance of Meth-induced CPP. 
 
Experiment 4.  Effects of fendiline administration on the long-term 
maintenance of Meth-induced CPP (Refer to Fig. 12C for timeline) 
To ascertain if increasing the number of fendiline treatments would inhibit the 
maintenance of Meth-induced CPP (tested in a drug-free state), the once-daily 
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injections of fendiline were increased from two to ten.  To verify that Meth-
induced CPP persisted for the duration of the study, we determined that post-
Meth conditioning administration of ten once-daily vehicle injections did not 
impact the ability of rats to express a preference for the Meth-paired chamber 
(Fig. 16A, n=11).  That is, a two-way repeated measures ANOVA revealed a 
significant effect of Chamber (F(1,20)=63.355, p<0.0001) but a non significant 
effect of Test (F(1.20)=0.165, p=0.689) and Chamber x Test interaction 
(F(1,20)=0.284, p=0.600).  This finding indicates the preference exhibited three 
days after conditioning (CPP Test 1) did not diminish for at least 15 days, due to 
repeated CPP testing, or with the home cage vehicle treatments.  In contrast to 
these results, in rats administered ten once-daily treatments of fendiline, the 
preference that was evident during CPP Test 1 was no longer maintained during 
CPP Test 2 (Fig. 16B, n=12).  A two-way repeated measures ANOVA revealed a 
significant effect of Chamber (F(1,22)=11.129, p=0.003) and a significant Chamber 
x Test interaction (F(1,22)=4.800, p=0.039) but no effect of Test (F(1,22)=0.035, 
p=0.853).  A post-hoc Newman-Keuls test revealed significant CPP for Test 1 
(p<0.01) but not for CPP Test 2 (p>0.05).  These results demonstrate that 10 
days of fendiline treatment is sufficient to nullify previously established 
preference.   
 
The positive outcome with ten-days of fendiline led to the question as to whether 
a critical time during this ten-day period could be identified during which the Meth 
memories are particularly vulnerable to fendiline-induced disruptions.  That is, if 
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the behavioral antagonism reflected processes that occurred only at the 
beginning or end of the chronic treatment period.  Thus, we tested the effects of 
two fendiline injections given on days 10 and 11 (2 Day Early Fendiline) or 18 
and 19 (2 Day Late Fendiline).  Neither 2 Day Early Fendiline (Fig. 16C, n=14) or 
2 Day Late Fendiline (Fig. 5D, n=16) influenced the expression of the preference 
on CPP Test 2.   For early fendiline-treated rats, a two-way repeated measures 
ANOVA revealed a significant effect of Chamber (F(1,26)=47.050, p<0.0001) and 
Chamber x Test interaction (F(1,26)=11.056, p=0.003) but no effect of Test 
(F(1,26)=0.003, p=0.956).  Two-way repeated measures ANOVA of data collected 
for the late fendiline-treated rats revealed a significant effect of Chamber 
(F(1,30)=44.607, p<0.0001) with no effect of Test (F(1,30)=0.001, p=0.971) or 
Chamber x Test interaction (F(1,30)=0.863, p=0.360).  A post-hoc Newman-Keuls 
test revealed a significant preference for the Meth-paired chamber during CPP 
Test 1 and CPP Test 2 for both treatment groups (p<0.01).  Thus, while ten days 
of once-daily fendiline injections inhibited the maintenance of Meth-induced CPP, 
this effect did not appear to reflect any particular post-conditioning phase-
dependent phenomenon.  Thus, it appears that the larger number of treatments 
is critical for inhibiting the maintenance of Meth-induced CPP.   
 
To verify the conclusions drawn from the rotarod experiment, we also monitored 
motor activity during the CPP Test 2.  The fendiline treatment which terminated 
three-days prior to CPP Test 2 did not result in any significant changes in motor 
activity for any treatment group (one-way ANOVA, F(3,52)=2.55, p=0.07).  
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Horizontal activity (horizontal beam breaks); 10 Day Vehicle (n=11) 3649±246, 
10 Day Fendiline (n=12) 3373±362, 2 Day Early Fendiline (n=14) 4280±232, 2 
Day Late Fendiline (n=16) 4239±190.   
 
Experiment 5:  Effects of fendiline administered during the test for 
expression of Meth-Induced CPP (Refer to Fig. 12C for timeline).   
Experiment 5 was designed to ascertain if a 5mg/kg fendiline challenge, 
administered immediately prior to the CPP test, inhibited CPP expression 
regardless of the effects fendiline may have had on maintenance.  We also set 
out to determine if fendiline treatment history was an important factor in the 
effects seen with the fendiline challenge.  To accomplish these objectives, all rats 
used for Experiment 4 were re-conditioned (refer to Fig. 12C) to ensure that CPP 
was maintained and expressed by all groups (i.e., to re-establish CPP in the 10 
Day Fendiline-treated group as well as to assure that extinction of the preference 
did not occur during repeated CPP testing required for Experiment 4).  Thus, 
following re-conditioning, all rats were subsequently given a drug-free CPP test 
(CPP Test 3) to verify that the preference was present.  The 10% criterion for 
preference acquisition during CPP Test 3 was applied as described for 
Experiments 3 and 4.    This excluded only 6 rats, and these were distributed 
approximately equally across treatment groups.  Moreover, rats that received the 
10 fendiline injections which did not express a preference during CPP Test 2 
were not impaired in “re-acquiring” a preference for the Meth-paired chamber 
compared to other treatment groups.  Rats which met the criterion were tested 
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three days later, immediately after an injection of vehicle or fendiline.  Meth-
conditioned rats with a vehicle treatment history between CPP Test 1 and CPP 
Test 2, and who demonstrated preference for the Meth context during CPP Test 
3 (i.e., the 10 Day Vehicle group), also showed preference during CPP Test 4 
following an acute challenge of vehicle (Fig. 17A, n=9).  Two-way repeated 
measures ANOVA revealed a significant effect of Chamber (F(1,16)=18.780, 
p=0.001) with no effect of Test (F(1,16)=0.012, p=0.913) or Chamber x Test 
interaction (F(1,16)=0.113, p=0.741).  Indeed, post-hoc Newman-Keuls verified 
significant CPP Test 3 and CPP Test 4 (p<0.01).  Similarly, rats in the 2 Day 
Early Fendiline treatment group expressed preference for the Meth-paired 
chamber during both drug-free CPP Test 3 and fendiline challenged CPP Test 4 
(Fig. 17C, n=12).  Two-way repeated measures ANOVA revealed a significant 
effect of Chamber (F(1,22)=14.315, p=0.001) and no effect of Test (F(1,22)=0.280, 
p=0.602) or a Chamber x Test interaction (F(1,22)=0.634, p=0.434).  A post-hoc 
Newman-Keuls verified the significant preference during both CPP tests 
(p<0.01).  In contrast, rats in the 10 Day Fendiline (Fig. 17B, n=12) or 2 Day Late 
Fendiline (Fig. 6D, n=14) treatment groups did not express a preference for the 
Meth-paired chamber after an acute challenge of fendiline.  For the 10 Day 
Fendiline group, a two-way repeated measures ANOVA revealed a significant 
Chamber x Test interaction (F(1,22)=14.483, p=0.001) with non significant effects 
of Chamber (F(1,22)=3.063, p=0.094) or Test (F(1,22)=0.011, p=0.916).  Likewise, a 
two-way repeated measures ANOVA of rats in the 2 Day Late Fendiline group 
demonstrated a significance for the effect of Chamber (F(1,26)=7.105, p=0.013) 
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and Chamber x Test interaction (F(1,36)=8.574, p=0.007) but no effect of Test 
(F(1,26)=0.036, p=0.851).  A Post-hoc Newman-Keuls test revealed significant 
preference for the drug-free CPP Test 3 (p<0.01) and no preference during the 
fendiline challenged CPP Test 4 (p>0.05) for both groups.  Throughout each CPP 
test, time spent in the middle chamber did not significantly change in any 
treatment group throughout any of the experiments.  These findings indicate that 
there may be a critical time that is later in the post-conditioning period, when 
fendiline causes neuroadaptive alterations that subsequently render an acute 
fendiline challenge effective in reducing expression of Meth-induced CPP. 
 
As the CPP study indicated that brain adaptations may have occurred following 
fendiline administration, we also examined motor activity measured during the 
CPP Test 4 to determine if this behavior also showed changes indicative of 
neuronal adaptations.  A between group comparison, Fendiline injection 
administered prior to CPP Test 4 significantly altered horizontal motor activity 
(horizontal beam breaks; one-way ANOVA, p<0.0001).  A post-hoc Newman-
Keuls revealed that horizontal beam breaks were significantly decreased for all 
fendiline-treated groups (independent of treatment history) compared to the 
vehicle treated rats (10 Day and 2 Day Late Fendiline history, p<0.0001; 2 Day 
Early Fendiline, p<0.001).  While all groups had significantly reduced motor 
activity, it did not impede the capacity of rats to express a preference for the 
Meth-paired chamber as rats with a treatment history of 2 Day Early Fendiline 
expressed a preference for the Meth-paired chamber in spite of decreased motor 
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activity.  Illustrated in Fig 17E is horizontal activity but this was representative for 
all behaviors including total distance and vertical activity. 
 
Discussion 
The current study revealed that three conditioning sessions with Meth (alternated 
with three saline-condition sessions) induced a preference for the Meth-paired 
chamber that persisted for at least 16 days, and that this preference was not 
diminished by the home cage injections or repeated CPP testing.  The memory of 
this preference was disrupted by repeated fendiline treatment in a duration-
dependent and post-conditioning time-related manner. 
 
To the best of our knowledge, this is the first evaluation of the ability of fendiline 
to alter behavioral effects of a psychostimulant.  Consequently, it was prudent to 
demonstrate that the dose employed did not alter motivated (i.e., rotarod) motor 
behavior in Meth-conditioned rats, and that it was not rewarding or aversive.  Ten 
days of fendiline treatment proved to be more important than the post-
conditioning phase during which fendiline was administered, as two, once-daily 
injections of fendiline given either at the early or late post-conditioning phase of 
the 10 Day protocol failed to diminish the maintenance of Meth-induced CPP.  
Furthermore, the duration of time between terminating two days of fendiline 
treatment and the test for preference (compare Experiment 3, three days; 
Experiment 4, 2 Day Early Fendiline, 11 days) had no effect on the ability of rats 
to express a preference for the Meth-paired chamber.  The findings may reflect 
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sustained interruptions of mechanisms critical for maintenance and/or 
adaptations that only occur with repeated treatments (i.e., >2 treatments and 
does not reflect actions of fendiline administered at the beginning or the end of 
the 10 day treatment period) of fendiline which serve to weaken the conditioned 
response memory.   
 
The maintenance of associative memories involves a variety of neurotransmitter 
systems (e.g., dopamine and glutamate receptors) and concomitant changes in 
ion channels (e.g., calcium and sodium channels) (Alberini et al., 2006; Bailey et 
al., 2004; Wang et al., 2006; Vianna et al., 2000).   Fendiline, acting as a 
GABABR PAM (Kerr et al., 2002; Ong et al., 2005; Ong and Kerr, 2005) as well 
as an L-type calcium channel blocker (Bayer and Mannhold, 1987; Nawrath et 
al., 1998; Tripathi et al., 1993), has dual mechanisms that may serve to alter 
memory maintenance.  Indeed, augmented GABABR signaling (via decreased 
cAMP/PKA) (Knight and Bowery, 1996; Malcangio and Bowery, 1993) and 
calcium channel blockade (via calcium calmodulin kinase and ERK) 
(Rajadhyaksha and Kosofsky, 2005) influence CREB-mediated gene 
transcription of proteins that are important for psychostimulant-induced and 
neuronal plasticity as well as learning and memory (Berke and Hyman, 2000; 
Nestler, 2001; Kelley, 2004).  The specific adaptations are dependent on duration 
of time after the last psychostimulant administration.  For example, following 
repeated Meth administration the activated form of CREB (pCREB) is increased 
in the cortex at three and not at 14 days withdrawal.  In the current study, we 
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were not able to identify post-conditioning withdrawal time dependent effects of 
two fendiline injections on the maintenance of Meth-induced CPP when tested in 
a drug-free state.  Future studies focused on molecular and electrophysiological 
consequences of repeated fendiline are needed to verify the mechanisms that 
underlie the ability of fendiline to disrupt memory maintenance. 
 
Treatment history is critically important in the ability of an acute fendiline injection 
to inhibit the expression of Meth-induced CPP.  Here, two (2 Day Late Fendiline) 
and ten fendiline injections both terminating on protocol day 19, but not the 2 day 
treatment which terminated on protocol day 11, both rendered the acute fendiline 
challenge effective in blocking preference expression.  One explanation is that 
two once-daily fendiline injections is sufficient to induce an adapted brain state 
that persists for at least 19 days (2 Day Late Fendiline) but less than 25 days (2 
Day Early Fendiline).  This adapted brain state is vulnerable to the inhibitory 
effects of fendiline on the expression of Meth-induced associative learning.  The 
fact that fendiline treatments can produce effects which persist is functionally 
important, and determining if this reflects pharmacodynamic and/or 
pharmacokinetic mechanisms is another area that will need to be addressed.  
The adaptations engendered by two fendiline injections were also maintained 
after 10 injections which indicate that desensitization and/or down-regulation has 
not occurred over the additional eight fendiline injections; therefore, this 
compound may be a viable long-term treatment.  Regardless of the underlying 
mechanisms, it is clear that fendiline treatment history dictated the capacity of a 
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fendiline challenge to inhibit the expression of Meth-induced CPP, and the time 
of the treatment, not the number of injections, was the critical factor.   
 
Re-exposure to cues associated with abused substances increases neuronal 
activity in a region specific manner in humans (Childress et al., 2008; Childress 
et al., 1999; Kilts et al., 2004; Kilts et al., 2001) and rodents (Brown et al., 1992; 
Ciccocioppo et al., 2001; Franklin and Druhan, 2000; Zombeck et al., 2008; 
Rhodes et al., 2005).  This activation is also observed with memory recall 
processes and thus we can infer that blunting neuronal activity may result in an 
inability to express Meth-induced CPP.  Administration of fendiline prior to the 
CPP test may have blunted the hyper-responsive state that occurs during re-
exposure to Meth-associated contextual cues through mechanism such as 
activation of inwardly rectifying potassium channels (GABABR mediated GIRK 
activation) and inhibition of L-type calcium channels.  Indeed, if neuronal activity 
is blunted by augmenting GABA receptor signaling (via administration of gamma 
vinyl GABA), the expression of Meth-primed reinstatement of CPP is blunted 
(DeMarco et al., 2009).  However, the treatment history dependent effects 
suggest that prior fendiline-induced adaptations must have occurred in order for 
the acute fendiline successfully inhibit the expression of the behavior.   
 
An alternative explanation is that the later post-conditioning time (protocol days 
18 & 19) is vulnerable to fendiline-induced effects whereas the early post-
conditioning time (protocol days 10 & 11) are not.  Withdrawal is a dynamic 
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process with different brain states occurring in the days and weeks following 
psychostimulant administration.  For example, functional coupling of the GABABR 
is decreased in the nucleus accumbens and increased in the cortex at 14 days 
withdrawal from repeated amphetamine, an effect that is not observed at one day 
withdrawal (Zhang et al., 2000).  Similarly, cocaine-induced sensitization induced 
subunit-specific and withdrawal-time dependent effects on L-type calcium 
channel expression and distribution in the cortex; the increase was more 
profound at 21 days than at three days withdrawal (Ford et al., 2009).  Thus, 
fendiline administered during the different withdrawal time may have different 
effects on brain function and this factor may have contributed to the effects of 
treatment history on fendiline inhibition of the expression of Meth-induced CPP. 
 
The goal of this study was to evaluate the ability of fendiline, an L-type Ca++ 
channel blocker and GABABR PAM, to disrupt mnemonic processes necessary to 
maintain and subsequently express the learned associations established during 
CPP.  The results suggest that fendiline successfully disrupted the learned 
associations between the drug and the cues which is of value as an anti-
addiction therapy; both long-term and recent fendiline treatment appears to 
provide a protective effect in reducing the salience of drug-associated cues 
and/or the maintenance of the associative memory.  Fendiline is clinically 
available in Europe as a coronary vasodilator and therefore may be repurposed 
and rapidly translated into the clinic as an anti-addiction therapy.   
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Figure 10.  Illustration of treatment protocols.  A. Fendiline conditioned place 
preference/conditioned place aversion.  For the pre-test (day -1), drug-free rats 
were allowed to explore the apparatus for 30min; these data were used to 
counterbalance rats based on unconditioned preference.  Conditioning occurred 
twice daily for 10 days; fendiline vehicle was paired with one chamber in the 
morning and fendiline was paired in the opposite chamber in the afternoon.  
Three days after the last conditioning session (day 13), drug-free rats were 
tested for rewarding or aversive subjective effects of fendiline.  B & C. Rats were 
pre-tested as described previously, and assigned to receive Meth in the chamber 
in which the least amount of time was spent during the pre-test.  Conditioning 
occurred for six days; Meth was paired with one chamber on days 1, 3, & 5, and 
saline-paired in the opposite chamber on days 2, 4, & 6.  Three days later (day 
9), rats were tested to confirm the development of CPP (CPP Test 1).  Rats were 
then assigned to one of the following treatment groups.  B. Experiment 1 
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evaluated the effects of two home cage injections (days 10 & 11) of fendiline or 
its vehicle on the maintenance of Meth-induced CPP.  Three days after the home 
cage treatments (day 14), drug-free rats were tested for the expression of Meth-
induced CPP (CPP Test 2).  C. Experiment 2 evaluated the effect of fendiline on 
the maintenance of Meth-induced CPP by administering 10 once-daily home 
cage injections (days 10-19): 10 injections of vehicle (10 Day Veh), 10 injections 
of fendiline (10 Day Fend), two injections of fendiline followed by eight injections 
of vehicle (2 Day Early Fend), or eight injections of vehicle followed by two 
injections of fendiline (2 Day Late Fend).  Rats were subsequently tested in a 
drug-free state three days after the last home cage injection (CPP Test 2, day 
22).  Experiment 3 evaluated the effects of an acute fendiline injection on the 
expression of Meth-induced CPP.  Rats were re-conditioned to re-establish CPP 
and prevent extinction of the behavior that can occur due to repeated testing.  
CPP Test 3 was used to verify that rats expressed CPP.  Three days later, rats 
were given an injection of fendiline and immediately tested for the expression of 
Meth-induced CPP (CPP Test 4).  Ø, no drug; V or Veh, vehicle (1ml/kg); F or 
Fend, fendiline (5mg/kg), M, Meth (1mg/kg); S, saline (1ml/kg). 
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Figure 11.  Motivated motor behavior assessed on the rotarod was not inhibited 
by 5mg/kg fendiline.  Rats were trained on the rotarod to meet minimum criterion 
for inclusion in the study; a repeated measures design was employed such that 
each rat (n=10) was tested with each ligand or it‟s vehicle (i.e., saline, fendiline 
(5mg/kg), fendiline vehicle (25% EtOH, 1ml/kg), baclofen (4mg/kg), and 
pentobarbital (10mg/kg).  Latency to fall from the rotating drum (which was 
accelerated from 5-40rpm over 5min) was recorded at the following times 0 
(immediately prior to injection), 20, 60, 60, 180, 360min, and 24hr.  Two way 
repeated measures ANOVA followed by a post-hoc Newman-Keuls revealed that 
the positive controls, baclofen (p<0.05, filled square) and pentobarbital (p<0.01, 
star), significantly impaired motivated motor function compared to saline treated 
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rats (open square) at 20 and 40min post injection; an effect that was not 
observed for fendiline (p>0.05, filled triangle) or fendiline vehicle rats (p>0.05, 
open triangle).
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Figure 12.  Fendiline (5mg/kg) was neither rewarding nor aversive.  Time spent 
in each chamber was recorded before (Pre-Test) and after 10 days of fendiline 
(5mg/kg) conditioning (CPP/CPA test).  Two-way repeated measures ANOVA 
followed by a post-hoc Newman-Keuls revealed no significant changes between 
time spent in each chamber during the Pre-Test and the test for preference (n=8, 
p>0.05) (center chamber was not included in the statistical analysis).  Filled 
diamonds, time spent in the fendiline-paired chamber; open square, time spent in 
the fendiline vehicle-paired chamber; filled triangle, time spent in the center 
chamber. 
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Figure 13.  Fendiline administered during the early post-conditioning phase did 
not inhibit short-term memory maintenance.   After six days of conditioning a 
CPP test was conducted to verify the development of CPP (CPP Test 1); home 
cage injections were then administered and a drug-free test was subsequently 
conducted (CPP Test 2).  A. Rats administered two fendiline vehicle injections 
(25% EtOH, n=8) expressed CPP on both test days (CPP Test 1 & 2).  B. Rats 
that received two once-daily fendiline injections (4mg/kg, n=9) also expressed a 
preference for the Meth-paired chamber during both tests.  Two-way repeated 
measures ANOVA followed by a post-hoc Newman-Keuls test was used to 
determine between chamber differences (center chamber not included in the 
statistical analysis), ** p<0.01, * p<0.05.  Filled diamond, time spent in the Meth-
paired chamber; open square, time spent in the saline-paired chamber; filled 
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triangle, time spent in the center chamber.
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Figure 14.  The maintenance of Meth-induced CPP was inhibited by 10 
injections but not two post-conditioning injections of fendiline.  After six days of 
conditioning a CPP test was conducted to verify the development of CPP (CPP 
Test 1); home cage injections were then administered and a drug-free test was 
subsequently conducted (CPP Test 2).  A. Rats administered 10 fendiline vehicle 
injections (25% EtOH, n=11) expressed CPP on both test days (CPP Test 1 & 2).  
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B. Rats administered 10 once daily fendiline injections (n=12) did not express a 
preference for the Meth-paired chamber on CPP Test 2.  Rats administered 2 
once-daily injections of fendiline corresponding to the first two days (C, n=14) or 
the last two days (D, n=16) of the 10 day treatment expressed CPP during both 
CPP Test 1 and CPP Test 2.  Two-way repeated measures ANOVA followed by 
a post-hoc Newman-Keuls test was used to determine between chamber 
differences (center chamber not included for statistical analysis), ** p<0.01.  
Filled diamonds, time spent in the Meth-paired chamber; open squares, time 
spent in the saline-paired chamber; filled triangles, time spent in the center 
chamber. 
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Figure 15.  The expression of Meth-induced CPP was inhibited by a fendiline 
injection administered immediately prior to the CPP test only in rats with a 
treatment history of 10 injections and two injections corresponding to the last two 
injections of the 10 day treatment.  Rats were re-conditioned to prevent the 
extinction that can occur after repeated testing and re-establish CPP in the 10 
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Day Fendiline treated group.  CPP Test 3 was conducted drug-free state to verify 
the expression of CPP.  Three days later rats were tested for the expression of 
Meth-induced CPP after an acute injection of fendiline (5mg/kg) or fendiline 
vehicle (25% EtOH, 1ml/kg).  A. Rats with a treatment history of 10 fendiline 
vehicle injections (n=9) expressed CPP during the drug-free test and after a 
fendiline vehicle injection (CPP Test 3 & 4).  C. Likewise, rats with a treatment 
history of two once-daily fendiline injections corresponding to the first two days of 
the 10 day treatment expressed CPP during both tests (n=12).  In contrast, rats 
with a treatment history of 10 once daily fendiline injections (B, n=12) as well as 
rats with a treatment history of two once-daily injections of fendiline 
corresponding to the last two days of the 10 day treatment (D, n=14) expressed 
CPP during the drug-free test (CPP Test 3) but not after the acute fendiline 
injection (CPP Test 4).  Two-way repeated measures ANOVA followed by a post-
hoc Newman-Keuls test was used to determine between chamber differences 
(center chamber not included for statistical analysis), ** p<0.01.  Filled diamonds, 
time spent in the Meth-paired chamber; open squares, time spent in the saline-
paired chamber; filled triangles, time spent in the center chamber.  E. Horizontal 
Activity assessed during CPP Test 4 revealed that fendiline injection, 
independent of treatment history, significantly decreased motor activity.  One-
way ANOVA followed by post-hoc Newman-Keuls, ## p<0.001, # p<0.01.  
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CHAPTER VI 
ADMINISTRATION OF GABAB RECEPTOR POSITIVE ALLOSTERIC 
MODULATORS GS39783 AND CGP7930 BUT NOT BACLOFEN 
INHIBIT THE MAINTENANCE OF PREVIOUSLY  
ESTABLIHSED METHAMPHETAMINE- 
INDUCED CONDITIONED PLACE 
PREFERENCE 
Abstract 
Little is known about the role of GABABR in the maintenance of memories 
associated with abused substances.  The current study determined if baclofen, 
and/or GABABR positive allosteric modulators, GS39783 and CGP7930, could 
negate previously established conditioned place preference (CPP) induced by 
methamphetamine.  Post-conditioning, home-cage treatments with GS39783 or 
CGP7930 antagonized the expression of methamphetamine-induced CPP but 
baclofen did not.  These data indicate that selectively augmenting GABABR 
signaling in areas where GABA is endogenously released after repeated 
methamphetamine administration may reduce the maintenance and/or the 
salience of drug-associated cues. 
 
Introduction 
Cues associated with the use of abused substances can activate limbic brain 
regions (Childress et al., 1999; Childress et al., 2008) and elicit drug-craving and  
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drug-seeking behavior (O'Brien et al., 1992; Ehrman et al., 1992).  This powerful, 
long-lasting associative learning process that occurs in addicts is modeled in 
rodents using conditioned place preference (CPP) with high face, construct, and 
predictive validity (Childs and deWit H., 2009; Tzschentke, 1998; Tzschentke, 
2007).  The current study evaluated CPP induced by the psychostimulant, 
methamphetamine (Meth).     
 
There is no FDA-approved pharmacotherapy for psychostimulant addiction.  
However, literature suggests that the GABABR system is a viable target (Brebner 
et al., 2002; Xi and Gardner, 2008).  Administration of the GABABR agonist 
baclofen inhibits the development and expression of CPP induced by Meth (Li et 
al., 2001) as well as the development and expression of amphetamine-induced 
motor sensitization (Bartoletti et al., 2004; Bartoletti et al., 2005).  Baclofen also 
decreases several aspects of Meth (Ranaldi and Poeggel, 2002), amphetamine 
(Brebner et al., 2005) and cocaine self-administration (Filip et al., 2007) in 
rodents and cocaine-primed reinstatement of cocaine-seeking in baboons 
(Weerts et al., 2007).  These data demonstrate that baclofen prevents the 
development of psychostimulant-induced behaviors and subsequent stimulant-
seeking.  Moreover, imaging studies indicate that baclofen blunts the limbic 
activation associated with visual drug cues in drug-addicted humans (Brebner et 
al., 2002).  Clinical studies also demonstrate the efficacy of baclofen to reduce 
cocaine craving (Ling et al., 1998) and reduce cocaine (Shoptaw et al., 2003) 
and Meth use (Heinzerling et al., 2006).  While the use of GABABR agonists as a 
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therapy for addiction has considerable support (Xi and Gardner, 2008; Rose and 
Grant, 2008), the side effects associated with agonist administration (e.g., 
sedation and motor impairment) is a drawback to their practical application 
(Cryan et al., 2004; Ling et al., 1998; Shoptaw et al., 2003; Heinzerling et al., 
2006; Jacobson and Cryan, 2005).  Positive allosteric modulators (PAMs) of the 
GABABR provide an alternative means to augment GABAergic signaling.  GABA-
BR PAMs do not directly activate receptors; instead they increase the efficacy of 
endogenous GABA (Bettler et al., 2004; Urwyler et al., 2001; Gjoni et al., 2006; 
Urwyler et al., 2005).  While GABABRs are located throughout the brain, 
expression levels differ greatly among regions with high expression levels found 
in brain regions important for reward and motivated behavior (e.g., ventral 
tegmental area, substantial nigra, and the thalamus) (Margeta-Mitrovic et al., 
1999).  The differential expression of GABABRs and the temporal and regional 
specificity of GABA release afford PAMs considerable therapeutic discretion 
compared to GABABR agonists. 
 
Recent reports reveal the ability of GABABR PAMs to reduce reward-mediated 
behaviors.  The PAM CGP7930 reduces cocaine self-administration (Smith et al., 
2004; Filip et al., 2007) and both cocaine- and cue-induced reinstatement of 
cocaine-seeking (Filip and Frankowska, 2007).  The PAM GS39783 blunts 
locomotion induced by acute cocaine, blocks the development of cocaine-
induced motor sensitization, and normalizes molecular adaptations resulting from 
repeated cocaine administration (Lhuillier et al., 2007).  These studies 
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demonstrate the capacity of GABABR PAMs to modulate cocaine-mediated 
effects; yet, the capacity of PAMs to modify Meth-induced behaviors is unknown. 
 
Administration of GABAergic ligands during the development and expression 
phases of reward-mediated behaviors provides insight into the role of the 
GABABR system in these behaviors; however, there are limited therapeutic 
applications for these treatment protocols.  A more relevant approach is to 
administer a potential therapy after the brain and behavioral adaptations have 
taken place.  Using this treatment strategy, baclofen successfully inhibits the 
expression of previously established amphetamine-induced motor sensitization 
(Bartoletti et al., 2004).  We have revealed that a similar strategy with the atypical 
antidepressant mirtazapine which inhibits the expression of Meth-induced CPP 
(Herrold et al., 2009) and Meth-induced motor and cellular sensitization (McDaid 
et al., 2007).  These studies illustrate the feasibility of post-conditioning 
treatments to nullify previously established Meth-induced behavioral effects.  The 
current study used this approach to determine if baclofen and/or PAMs would 
inhibit the expression of Meth-induced CPP when administered after the 
development of the behavior.  
 
The GABA system undergoes many temporal and region specific adaptations 
following psychostimulant administration including changes in GABA turnover 
and receptor-mediated function.  These adaptations are influenced by neuronal 
phenotype, number of drug exposures, and withdrawal duration.  During early 
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withdrawal (<10 days) the GABABR system is down-regulated which includes 
decreased receptor expression (Frankowska et al., 2008b; Frankowska et al., 
2008a), uncoupling of the GABABR from the G-protein (Kushner and Unterwald, 
2001), and increased extracellular GABA concentrations (Jayaram and Steketee, 
2005; Jayaram and Steketee, 2005; Bustamante et al., 2002).  In the current 
study, the GABABR ligands baclofen, GS39783, and CGP7930 were 
administered during the early withdrawal phase (days 5 and 6) and we 
hypothesized that augmenting GABABR signaling during this phase would reduce 
the salience of Meth-associated cues.   
 
Materials and Methods 
Animals 
Male Sprague-Dawley rats (n=73, Harlan, Indianapolis, IN) weighing 250-300g at 
the start of the study were acclimated to the vivarium for at least one week prior 
to the onset of the experiments.  Rats were housed in pairs in a climate-
controlled environment on a 12 hr light/dark cycle and allowed ad libitum access 
to food and water.  Cage mates were given identical pharmacological treatments.  
Housing facilities at Rush University are accredited through the Association for 
Assessment and Accreditation of Laboratory Animal Care, and all experiments 
were carried out in accordance with the conditions set forth by the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals (National 
Research Council, 1996) and with the approval of the local Institutional Animal 
Care and Use Committee.  
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Drugs 
Conditioning: (+)Methamphetamine HCl (Sigma-Aldrich, St. Louis, MO) was 
dissolved in 0.9% sterile saline and administrated as 1mg/ml/kg.  We have 
demonstrated that this dose (as opposed to, e.g., 0.1mg/kg) reliably produces an 
enduring CPP (unpublished data).  Saline was administered as 1ml/kg.  Home 
cage injections: baclofen (2mg/kg; Sigma, St Louis, MO), baclofen vehicle (0.9% 
saline; 1ml/kg), GS39783 and CGP7930 (30mg/kg; gift from Novartis Pharma 
AG, Basel, Switzerland), PAM vehicles (10% propylene glycol in sterile water; 
1ml/kg).  All injections were given intraperitoneally (i.p.).   
 
Doses of GABAergic ligands were selected based on the following behavioral 
endpoints in laboratory rats.  The dose of 30mg/kg GS39783 and CGP7930 
successfully reduces cocaine self administration when administered 10 min prior 
to the session (Smith et al., 2004) (3, 10, 30mg/kg i.p.).  The dose of 2mg/kg 
baclofen was selected because it was within the range of doses found to 
successfully i) attenuate the development and expression of Meth-induced CPP 
when administered 30min prior to each daily conditioning session or CPP test, 
respectively (doses tested were 1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001), ii) inhibit 
the reinstatement of nicotine-induced CPP and self-administration when 
administered 5min prior to testing (0.612, 1.25, 2.5mg/kg, i.p.) (Fattore et al., 
2009), iii) reduce cocaine self-administration when administered 10min prior to 
the session (2.5mg/kg, i.p.) (Smith et al., 2004), iv) reduce amphetamine self-
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administration break point when administered 30min prior to testing (doses 
tested were 1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005), and v) inhibit the 
maintenance of amphetamine-induced motor sensitization (2mg/kg, i.p.) 
(Bartoletti et al., 2004).  In addition, we determined that motivated motor behavior 
assessed on the rotarod was inhibited by 4mg/kg baclofen (20 and 40min 
collapsed results were as follows; latency to fall 209±24sec (n=5), vs. 355±29sec 
for vehicle (n=11); Student’s t-test, p<0.01).  Additionally, while 3mg/kg baclofen 
produced an impairment in spontaneous motor activity, 2mg/kg baclofen resulted 
in no difference from vehicle (horizontal activity, photobeam breaks over 75min 
post injection for vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388; 
baclofen 3mg/kg (n=6), 1067±258; ANOVA p=0.012, post-hoc Dunnett’s).  
 
Apparatus  
The apparatus used to monitor activity consisted of three chambers divided by 
opaque Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two 
large conditioning chambers (25cm x 30cm x 30cm) separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct visual (horizontal or 
vertical stripes or a solid color wall) and tactile cues (textured floors).  Motor 
activity and time spent in each chamber was monitored via two sets of 
photobeams (24 horizontal and 12 vertical). 
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Conditioned Place Preference 
The behavioral testing room was dimly lit (54-108lux) with white noise 
continuously present.  The rats were transported from the vivarium to the test 
room (located across the hall, in the same animal facility suite) at least 30min 
prior to the start of the experiment.  The protocol consisted of four phases (refer 
to Figure 18): pre-test, conditioning, home-cage intervening treatments, and a 
CPP test.  A 30min pre-test, verified that the box configuration did not result in a 
significant group preference for either chamber (time spent left: 789±42s, time 
spent right: 883±42s, p=0.265).  Individual rats tended to spend unequal amounts 
of time in each chamber; thus, for conditioning, rats were administered Meth in 
the chamber in which they spent the least amount of time during the pre-test.  
Conditioning occurred over 6 days.  During the conditioning phase, rats were 
given a Meth injection (1mg/kg, i.p.) every other day (days 1, 3, and 5) and 
immediately placed into the appropriate chamber for 45min.  On the alternate 
days (2, 4, and 6), rats were given a saline injection (1ml/kg, i.p.) and 
immediately placed into the opposite chamber for 45min.  In half the rats, the 
order of Meth or saline pairing occurring first was switched such that saline was 
administered on days 1, 3, and 5 and Meth on days 2, 4, & 6.  A drug-free CPP 
test was performed on day 9, (termed CPP Test 1) to confirm that the preference 
developed.  This was accomplished by placing rats into the center chamber and 
the sliding doors were immediately removed allowing free access to the entire 
CPP box.  The test session lasted 30min and time spent in each chamber was 
determined.  There were no differences between those rats which received the 
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Meth or the saline pairing first thus they were pooled for the analysis.  Rats that 
did not increase time spent in the Meth-paired chamber on CPP Test 1 compared 
to the same chamber during the pre-test by at least 10% (180s) were excluded 
from the study.  This culling procedure, as previously shown by others (Paolone 
et al., 2009) helps assure that only those rats that clearly acquired the task were 
used to determine the potential for GABABR ligands to subsequently reduce the 
acquired preference.  Based on the results generated during CPP Test 1, rats 
were assigned to one of the following once-daily home cage treatments (days 10 
& 11) such that the expression of the preference was approximately equal across 
all treatment groups which included: vehicle, baclofen, GS39783, or CGP7930.  
Selection of the early withdrawal time treatment (days 10 & 11) was based on 
literature demonstrating that the GABABR system is down-regulated during early 
withdrawal times (Frankowska et al., 2008b; Kushner and Unterwald, 2001) and 
therefore might benefit from augmented GABABR signaling.  While the 
pharmacokinetics of GS39783 and CGP7930 are unknown, orally administered 
baclofen (5mg/kg) elicits centrally mediated events including hypothermia (Cryan 
et al., 2004) within one hour after baclofen administration suggesting that the 
onset of action is relatively short.  Plasma and brain concentrations of baclofen 
are reported to be relatively consistent for at least 180min after a single bolus i.v. 
injection of baclofen in the rat (50mg/kg) (Deguchi et al., 1995) which aligns with 
enduring effects of GABAergic ligands on drug-induced behaviors.  Baclofen 
(2.5mg/kg), GS39783 (3mg/kg), and CGP7930 (30mg/kg) significantly reduce 
cocaine self administration for at least 10 hours, indicating that these ligands may 
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actively alter brain processes for several hours after a single administration 
(Smith et al., 2004).  Therefore, in the current study the administration of ligands 
once-daily for two days likely altered GABAergic signaling for a sustained period 
of time.  Three days after the home cage treatments (day 14), rats were tested 
for the expression of CPP in a drug-free state (termed CPP Test 2).  This period 
aided in clearing the GABABR compounds from the rat prior to CPP testing to 
avoid any potential influences of residual drug on the expression of CPP.  Thus, 
this approach allowed us to more confidently interpret the effects of GABABR 
ligands in terms of memory maintenance.    
 
Statistical Analysis 
CPP was defined as spending significantly more time in the Meth-paired vs. 
saline-paired chamber.  This was accomplished by two-way repeated measures 
ANOVA (factors were Chamber and CPP Test) followed by post-hoc Newman-
Keuls for between chamber differences for each test.  All data are shown as 
mean ± SEM.  Statistical outliers were determined as those rats that spent 
greater than two standard deviations above or below the mean time spent in any 
chamber.  
 
Results 
The 6 day conditioning protocol resulted in a significant preference for the Meth-
paired chamber.  As a group, the 73 rats tested expressed CPP on Test 1 (day 9) 
(time spent Meth-paired chamber, 970±33sec; time spent saline-paired chamber, 
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675±32sec; paired t-test: p<0.0001); however, 13 rats were not tested for 
antagonism by GABABR ligands because time spent in the Meth-paired chamber 
on CPP Test 1 was not least 10% (180s) more than time spent in the same 
compartment during the pre-test.  This culling procedure helped assure that only 
those rats that clearly acquired the task were used to determine the potential for 
GABABR ligands to subsequently reduce the acquired preference (see Materials 
& Methods). 
 
Post-conditioning administration of the vehicle solutions did not impact the ability 
of drug-free rats to express a preference for the Meth-paired chamber (Figure 19, 
Baclofen Vehicle (n=9): Chamber, F(1,16)=23.850, p=0.0002; Test, F(1.16)=0.0001, 
p=0.994; Chamber x Test Interaction, F(1,16)=2.572, p=0.128.  Figure 20, PAM 
Vehicle (n=14): Chamber, F(1,26)=18.759, p=0.0002; Test, F(1,26)=0.065, p=0.801; 
Chamber x Test Interaction, F(1,26)=2.05, p=0.164). This demonstrated that the 
acquired preference demonstrated three days after conditioning did not diminish 
for at least five days, due to repeated CPP testing, or with the intervening home 
cage injections. 
 
Rats administered baclofen as an intervening treatment maintained CPP (Figure 
19, Baclofen (n=8): Chamber, F(1,14)=25.326, p=0.0002; Test, F(1,14)=0.055, 
p=0.818; Chamber x Test Interaction, F(1,14)=6.167, p=0.026).  In contrast, 
administration of the GABABR PAMS, GS39783 and CGP7930 nullified 
previously established preference; i.e., the preference for the Meth-paired 
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chamber observed on CPP Test 1 was no longer evident on CPP Test 2 (Figure 
3. GS39783 (n=11): Chamber, F(1,20)=11.141, p=0.003; Test, F(1,20)=0.0002, 
p=0.989; Chamber x Test Interaction, F(1,20)=6.947, p=0.016.  CGP7930 (n=9): 
Chamber, F(1,16)=3.506, p=0.080; Test, F(1,16)=0.002, p=0.965; Chamber x Test 
Interaction, F(1,16)=9.108, p=0.008.)    
 
Throughout each test, (Pre-Test, CPP Test 1, CPP Test 2) time spent in the 
middle chamber did not significantly change in any treatment group (Figures 19 & 
20).   
 
These data reveal the unique ability of post-conditioning injections of the 
GABABR PAMS (administered while the rats remained in the home cage) to 
diminish the expression of the previously established preference.   
 
Discussion 
This study revealed that GABABR PAMs administered to rats in the neutral 
environment of the home cage was sufficient to nullify the previously expressed 
preference for the Meth-paired chamber.  This outcome was not obtained with 
the direct GABABR agonist, baclofen.  At the dose selected, GS39783 and 
CGP7930 are thought to act only at GABABRs that are occupied by endogenous 
GABA (Gjoni et al., 2006; Urwyler et al., 2001).  Therefore, these findings 
indicate that augmenting the efficacy of occupied GABABRs during early phases 
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of withdrawal is sufficient to disrupt the maintenance of the acquired salience for 
the Meth-associated context. 
 
There are numerous studies demonstrating the efficacy of baclofen, GS39783, 
and CGP7930 to modulate the development and expression of behaviors 
induced by psychostimulants when administered during conditioning, or within 
30min prior to testing (Li et al., 2001; Bartoletti et al., 2005; Filip et al., 2007; Filip 
and Frankowska, 2007; Weerts et al., 2007; Smith et al., 2004; Lhuillier et al., 
2007; Brebner et al., 2005; Fattore et al., 2009).  However, to date only Bartoletti 
and colleagues (Bartoletti et al., 2004) have demonstrated efficacy of a GABABR 
ligand to modify the maintenance of a previously established psychostimulant-
induced behavior.  These authors report that the maintenance of amphetamine-
induced motor sensitization is blunted when 10 administrations of 2mg/kg 
baclofen were initiated 36 days after the behavior developed and terminated 20 
days prior to the amphetamine challenge.  Our research efforts are expanding 
this literature by evaluating GABABR influences on the maintenance of place 
preference memory induced by Meth.  The inhibitory effects previously observed 
for baclofen on the maintenance of amphetamine-induced motor sensitization 
were not observed in the current study for the maintenance of Meth-induced CPP 
when 2mg/kg baclofen treatments were initiated 4 days after Meth, and given 
once-daily for two days after conditioning.    This discrepancy may be due to 
several factors including different behavioral endpoints (motor sensitization vs. 
CPP), different psychostimulant (amphetamine vs. Meth), different treatment 
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duration, and/or different withdrawal time for initiating the baclofen treatment (36 
days vs. 4 days).  Thus, the possibility still remains that a different treatment 
regimen might afford a viable window of opportunity by which baclofen may be 
able to interrupt the maintenance of place preference memories for Meth. 
 
The PAMs GS39783 and CGP7930 successfully inhibited the maintenance of 
previously established CPP.  As PAMs act by positively modulating GABA-
occupied receptors, this suggests that during the early withdrawal period, regions 
that endogenously release GABA have a sufficient number of functional 
GABABRs to allow PAMs to inhibit the maintenance of place preference memory.  
This conclusion is consistent with the recent demonstration that enhancing GABA 
levels (via reducing its metabolism with gamma vinyl GABA, an irreversible 
inhibitor of GABA transaminase), inhibits the expression of Meth-primed 
reinstatement of CPP (administered 2.5hr prior to the Meth challenge) (DeMarco 
et al., 2009).  Thus, it may be that augmenting GABABR signaling in brain regions 
where GABA is tonically released is particularly important for disrupting memory 
maintenance.   
 
Several laboratories report region specific changes in GABA turnover, GABABR 
expression, and receptor-mediated function during the early days following 
repeated psychostimulant exposure.  Examples of increased GABAergic tone 
occurring within the first seven days of withdrawal include increased extracellular 
GABA levels in the medial prefrontal cortex after repeated cocaine administration 
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(Jayaram and Steketee, 2005) and enhanced substantia nigra and striatum K+-
evoked GABA release after repeated Meth administration (Bustamante et al., 
2002).   These observations may be the consequence of the brain attempting to 
maintain homeostasis (i.e., blunt the neuronal hyper-excitability associated with 
psychostimulant use).  Possibly contributing to the hyper-excitability associated 
with psychostimulant administration, GABABRs are reduced throughout the brain 
of rats after cocaine self-administration (Frankowska et al., 2008b) and in the 
ventral tegmental area a decrease in the functional coupling of GABABRs is 
observed (Kushner and Unterwald, 2001).  Changes such as these may 
contribute to the hyper-excitable state of the brain observed during 
psychostimulant withdrawal (Hu, 2007).  Behavioral observations made the 
current study suggest that the “new brain state’ induced by Meth conditioning 
includes GABA-occupied GABABRs in regions critical for the maintenance of 
Meth-associated memories that are selectively enhanced by PAMs.  The 
negative findings for baclofen then suggest that activating GABABRs throughout 
the brain (regardless of endogenous GABAergic tone) overrides the selective 
augmentation of occupied GABABRs achieved by administration of the PAMs.   
 
The current study focused on the short-term maintenance of Meth-associated 
memories, a phase of mnemonic processing that is not widely studied with 
regard to GABABR influences.  In contrast, there is ample literature 
demonstrating that administration of baclofen alters other mnemonic processes 
including acquisition (Nakagawa et al., 1995; McNamara and Skelton, 1996), 
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consolidation (Castellano et al., 1989; Swartzwelder et al., 1987; Castellano et 
al., 1989; Zarrindast et al., 2002; Zarrindast et al., 2004), and expression 
(Stackman and Walsh, 1994; Stackman and Walsh, 1994; Levin et al., 2004; Li et 
al., 2001) of spatial and/or associative learning tasks.  We determined that a 
dose of baclofen that was subthreshold to impairing motor function was not 
sufficient to inhibit the maintenance of CPP when given as two once-daily 
injections.  Therefore, while moderate doses of baclofen effectively inhibit 
memory acquisition, consolidation, and expression it does not appear to be 
effective to inhibit memory maintenance during the first few days of withdrawal.  
Phase-dependent effects also observed with the PAM GS39783 which was 
shown to inhibit the acquisition but not the expression of nicotine-induced CPP 
(Mombereau et al., 2007).   The current work extended this literature by 
demonstrating that selective positive modulation of activated GABABRs by 
GS39783 and CGP7930 can also inhibit the early phase maintenance of drug-
associated memories. 
 
In summary, we have identified two structurally distinct GABABR PAMs, 
GS39783 and CGP7930, which inhibit the expression of Meth-induced CPP 
when administered during the early withdrawal phase.  This information allows us 
to infer that GABABR expressing neurons in regions that have endogenous 
GABAergic tone are critical for the maintenance of the associative memory that 
forms during Meth-induced CPP.  Thus, GABABR PAMs may be a viable 
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therapeutic alternative to direct acting GABABR agonists for the treatment of 
psychostimulant addiction. 
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Figure 16.  Illustration of the treatment protocol.  A drug-free pre-test was 
conducted and rats were assigned to receive Meth (1mg/kg, i.p.) in the initially 
non-preferred chamber.  Conditioning occurred on days 1–6.  A drug-free CPP 
test was conducted on day 9 to verify the development of CPP (CPP Test 1).  
Vehicle, baclofen, or a PAM was administered in the home cage on days 10 & 
11.  A final drug-free CPP test (CPP Test 2) was conducted on day 14 to 
determine the capacity of GABAergic ligands to influence the expression of Meth-
induced CPP.  M, methamphetamine (1mg/kg), S, saline (1mg/kg), Veh, vehicle 
(1ml/kg), Bac, baclofen (2mg/kg), PAM, positive allosteric modulator: GS39783 
(30mg/kg), CGP7930 (30mg/kg) 
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Figure 17.  Meth-induced CPP was not inhibited by post-conditioning 
administration of baclofen.     Rats assigned to the baclofen vehicle (0.9% saline) 
group (n=9) expressed CPP on both test days (CPP Test 1 & 2).  Rats that 
received baclofen treatment (2mg/kg; n=8) also expressed a preference for the 
Meth-paired chamber on both test days.  Post-hoc Newman-Keuls test was used 
to determine between chamber differences (center chamber not included for 
statistical analysis), ** p<0.01.  Solid line, time spent in the Meth-paired chamber; 
dashed line, time spent in the saline-paired chamber; grey line, time spent in the 
center chamber 
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Figure 18.  Meth-induced CPP is inhibited by post-conditioning administration of 
the PAMs GS39783 and CGP7930.     Rats assigned to the PAM vehicle (10% 
propylene glycol) group (n=14) expressed CPP on both test days (CPP Test 1 
&2).  Rats administered GS39783 (n=11) or CGP7930 (n=9) as an intervening 
treatment did not express a preference for the Meth-paired chamber on CPP 
Test 2.  Post-hoc Newman-Keuls test was used to determine between chamber 
differences (center chamber not included for statistical analysis), ** p<0.01.  Solid 
line, time spent in the Meth-paired chamber; dashed line, time spent in the 
saline-paired chamber; grey line, time spent in the center chamber 
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CHAPTER VII 
POST-CONDITIONING ADMINISTRATION OF BACLOFEN INTO THE MEDIAL 
DORSAL THALAMUS INHIBTS METHAMPHETAMINE-INDUCED 
CONDITIONED PLACE PREFERENCE 
Abstract 
The medial dorsal nucleus of the thalamus (MDT) is connected to brain regions 
important in the regulation of psychostimulant-induced behaviors and mnemonic 
processes.  However, the role of the MDT in the maintenance of 
psychostimulant-induced associative learning is unclear.  The MDT expresses 
moderate to high levels of GABABR; which modulate psychostimulant-induced 
neurotransmitter release and downstream molecular adaptations.  The present 
study evaluated the role of GABABRs in the MDT in the maintenance of 
methamphetamine (Meth)-induced associative learning using conditioned place 
preference (CPP).  After the development of Meth (1mg/kg)-induced CPP, rats 
were administered two once-daily injections of baclofen (0.5nmol/0.5μl/side) or 
vehicle into the MDT, or the overlying hippocampus (HC) which served as a site 
control.  The following day, place preference was determined for drug-free rats 
by comparing time spent in the Meth-paired chamber during the CPP test to the 
same chamber during the pre-test.  Intra-MDT administration of vehicle and intra-
HC administration of either the vehicle or baclofen did not impact the ability of  
rats to demonstrate significant CPP.  In contrast, rats that received intra-MDT 
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injections of baclofen did not show CPP.  These results implicate GABABRs in 
the MDT as regulators of short term processes that allow for subsequent 
expression of Meth-induced CPP. 
 
Introduction 
When psychostimulants are administered in a unique context or environment, 
that context may become associated with the positive attributes of the stimulant.  
Once this drug-context association is made, re-exposure to the context, in the 
absence of the drug, can increase in neuronal activity in limbic brain regions 
(Childress et al., 1999; Childress et al., 2008; Rhodes et al., 2005; Brown et al., 
1992; Zombeck et al., 2008; Franklin and Druhan, 2000; Ciccocioppo et al., 
2001) and induce drug-craving, drug-seeking during cue re-exposure which can 
lead to relapse to drug use (Ehrman et al., 1992; Hartz et al., 2001; O'Brien et al., 
1992).    The enhanced salience of drug-associated cues can be studied in the 
laboratory with conditioned place preference (CPP) paradigms (Childs and deWit 
H., 2009; Tzschentke, 1998; Tzschentke, 2007).  CPP measures the tendency to 
spend more time in an environmental context previously coupled with the 
rewarding effects of an unconditioned stimulus.  Methamphetamine (Meth) is a 
potent and highly abused psychostimulant with no FDA-approved 
pharmacotherapies available.  Drug-associated cues can hinder abstinence in 
addicts; therefore, understanding the brain circuits and transmitter systems that 
are involved in responsiveness to these cues might help identify targets for 
relapse reduction pharmacotherapy.   
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Though largely ignored by the addiction field, the MDT is connected with regions 
known to regulate drug-induced behaviors and mnemonic processes (Kalivas et 
al., 1999; Kalivas et al., 2001).  Through glutamatergic (Pirot et al., 1994; Kuroda 
et al., 1995; Kuroda et al., 1998; Giguere and Goldman-Rakic, 1988; Pirot et al., 
1995) and GABAergic (Churchill et al., 1996b; Groenewegen, 1988; Mogenson et 
al., 1987; Zahm et al., 1996) connections, the MDT modulates the medial 
prefrontal cortex (mPFC) (Ferron et al., 1984) and ventral pallidum (VP) 
(Churchill et al., 1996b; Churchill et al., 1996a; Churchill and Kalivas, 1999), 
respectively.   Given the involvement of the mPFC in associative learning it is not 
surprising that neuronal activity in the MDT is correlated with associative learning 
tasks (Oyoshi et al., 1996); lesions of the MDT disrupt the acquisition of sucrose-
induced associative learning (McAlonan et al., 1993), blockade of mu-opioid 
receptors in the MDT inhibits the acquisition of morphine-induced associative 
learning (Guo et al., 2008b), and baclofen administration into the MDT inhibits 
working memory (e.g., short-term memory) (Floresco et al., 1999; Romanides et 
al., 1999).  Based on these observations, we sought to determine the yet 
unexplored role of the MDT in the maintenance of Meth-induced associative 
learning. 
 
Systemic administration of the GABABR agonist baclofen inhibits the 
development and expression of Meth-induced behaviors including CPP (Li et al., 
2001) and self-administration (Ranaldi and Poeggel, 2002).  GABABRs are 
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located throughout the brain (Margeta-Mitrovic et al., 1999; Charles et al., 2003); 
however, moderate to high expression levels are observed in the thalamus, 
including the MDT (Margeta-Mitrovic et al., 1999; Charles et al., 2003).  Thus, 
effects of systemically administered baclofen likely reflect, at least in part, 
activation of GABABRs in the MDT.  Indeed, activating GABABRs within the MDT, 
via intra-cerebral injections of GABABR agonists, disrupts working memory 
(Floresco et al., 1999; Romanides et al., 1999) and GABABR expression within 
the MDT is significantly decreased following cocaine self-administration 
(Frankowska et al., 2008b; Frankowska et al., 2008a).  The current project was 
designed to expand this literature to ascertain if activating MDT GABABRs can 
reduce the maintenance of place preference memory that was induced by Meth.     
 
Materials and Methods 
Animals 
Forty male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-275g at 
the start of the study were acclimated to the vivarium (a climate-controlled 
environment on a 12hr light/dark cycle), for at least one week prior to the onset of 
the experiments.  Rats were housed in pairs and allowed ad libitum access to 
food and water.  Cage mates were given identical pharmacological treatments.  
The rat housing room was in the same animal facility suite as, and adjacent to, 
the behavioral testing room.  Loyola University Medical Center and Rush 
University Medical Center housing facilities are accredited through the 
Association for Assessment and Accreditation of Laboratory Animal Care, and all 
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experiments were carried out in accordance with the conditions set forth by the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals 
(National Research Council, 1996) and with the approval of the Loyola University 
Medical Center and Rush University Medical Center Institutional Animal Care 
and Use Committee.  
 
Drugs 
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile 
saline and the dose, 1mg/ml/kg, was calculated as the salt and administered 
intraperitoneally (i.p.).  Vehicle (0.9% saline; 0.5μl/side) or baclofen 
(0.5nmol/0.5μl/side; Sigma, St Louis, MO) were administered via intracerebral 
(i.c.) injections.  The dose of baclofen selected was because it is within the range 
of MDT-injected doses found to be behaviorally relevant to inhibit working 
memory (doses used were 0.03-0.3nmol) (Romanides et al., 1999) and influence 
motor activity (doses used were 0.003-1.0nmol) (Churchill et al., 1996a) . 
 
Surgical Procedures for intracerebral implantation of guide cannula 
To allow direct delivery of vehicle or baclofen into the MDT of awake, behavior 
rats, the rats were surgically fitted with guide cannulae overlying the MDT prior to 
initiating the study. To do so, 41 rats were allowed one week of acclimation to the 
vivarium, and then were anesthetized with pentobarbital (50mg/kg, i.p., Ovation 
Pharmaceuticals, Inc., Deerfield, IL) and placed in a stereotaxic apparatus (David 
Kopf Instruments, Tujunga, CA).  After the skull was exposed, guide cannulae 
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(28 gauge, 1.2mm wide, 11.4mm long) were lowered into the brain 1.2mm 
posterior to bregma, +/- 0.6mm off the midline, and 4.4mm below dura 
(Pellegrino et al., 1979) as has been used previously (Churchill et al., 1996a).   
For placement controls, guide cannulae were implanted into the hippocampus 
(HC) which is dorsal to the MDT that was 2.4mm below dura (2mm dorsal to the 
MDT).  Stainless steel mounting screws and dental acrylic were used to fix the 
cannulae to the skull.  The skin incision was closed with sutures.  Each guide 
cannula was fitted with dummy cannula (33 gauge, which did not extend below 
the tip of the implanted guide cannula), and was changed daily to prevent 
obstruction of the cannula and to acclimate the rats to having the cannula 
manipulated.  At least five days of recovery were allowed between the surgery 
and the initiation of the experiment. 
 
Behavioral Evaluations  
The behavioral test room was dimly lit (54-108lux) with white noise (San Diego 
Instruments, San Diego, CA) continuously present.  The small animal activity box 
used for CPP (AccuScan Instruments, Inc., Columbus, OH) was 63cm x 30cm x 
30cm and consisted of three chambers divided by Plexiglas sliding doors; two 
large conditioning chambers (25cm x 30cm x 30cm) separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct visual and tactile 
cues.  Chamber A had vertical stripes on the walls and a textured floor with an 
overturned paint dish glued to the center, the opposite, chamber B, had 
horizontal stripes and a textured floor with a flat rectangle glued to the center, 
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and the center chamber had solid color walls and a smooth, slightly raised 
platform floor.  Time spent in each chamber and motor activity was monitored via 
two sets of photobeams (24 in the horizontal plane and 12 vertical). 
 
The rats were transported from the animal housing room to the adjacent test 
room at least 30min prior to the start of the experiment for habituation.  Rats 
were subjected to a 30min pre-test (refer to the timeline in Fig.21A) which verified 
that there was not a significant preference for either chamber (data presented in 
Results); however, individual rats tended to spend more time in one chamber 
compared to the other.  Thus, for conditioning, rats were administered Meth 
(1mg/kg) in the chamber in which they spent the least amount of time during the 
pre-test.  Conditioning occurred over five days; Meth was paired with one of the 
chambers on days 1, 3, & 5 and a saline (1ml/kg) was paired in the opposite 
chamber on days 2 & 4.  Pairing occurred immediately after each injection and 
lasted for 45min.  During the withdrawal period after conditioning, baclofen or 
vehicle was administered in the home cage, once-daily for two days (days 6 & 7).  
One day later (day 8), rats were tested for expression of CPP in a drug-free 
state.  To do so, the rats were placed into a small neutral, center chamber and 
the sliding doors were immediately removed allowing the rats free access to the 
entire CPP box.  The test session lasted 30min and time spent in each chamber 
was determined.   
 
Intracerebral Microinjection Procedure 
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For the intracerebral injections (which occurred in the housing room), dummy 
cannulae were removed and injectors which extended 1.0mm below the guide 
cannulae were inserted.  The injectors were connected to a Hamilton syringe 
(Reno, NV) via polyethylene tubing, and the syringes were held in a CMA/100 
microinjection pump (Carnegie Medicine, Stockholm, Sweden).  Baclofen 
(0.5nmol/0.5μl/side, dose based on (Churchill et al., 1996a; Romanides et al., 
1999)) or vehicle (0.5μl/side) was administered to behaving, unrestrained rats at 
a rate of 0.1µl/min for 5min for a total volume of 0.5μl/side.  Injectors were left in 
place for 1min to allow for diffusion of the drug away from the injector tip after 
which time the injectors were removed, dummy injectors were replaced, and rats 
returned to the home cage. 
 
Histology 
After the completion of behavioral testing, pontamine sky blue (Sigma, St. Louis, 
MO) was injected to allow for visualization of injector tip placement.  The brains 
were removed, fresh frozen and cut in 50µm sections.  Sections were mounted 
on subbed slides and stained with pyronin-Y or cresyl violet.  The intracerebral 
infusion site (marked by blue dot or lesion) was agreed on by two treatment-blind 
observers using light microscopy and reconstructed onto a rat stereotaxic brain 
map (Paxinos and Watson, 1998) (Fig. 22) 
 
Statistics 
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A two-way repeated measures ANOVA (treatment x test) was employed to 
determine shifts in chamber preference across time (pre-test vs. CPP test).  
Post-hoc Newman-Keuls was used to identify between test differences.  All data 
are presented as mean ± SEM.  Statistical outliers were determined as those rats 
that spent greater than two standard deviations above or below the mean time 
spent in any chamber during the pre-test or CPP Test.   
 
Results 
Results of the 30min pre-test demonstrated that, before conditioning, there was a 
significant group preference for chamber A (n=41, time spent in chamber A, 
1025±45sec vs. chamber B 643±44sec; paired t-test, p<0.001, center chamber 
time was 133±8sec).  Based on pre-test results, rats were assigned to receive 
Meth in the chamber in which the least amount of time was spent during the pre-
test such that time spent in the chamber to be paired with Meth was 
approximately equal across all treatment groups.  Rats were assigned to one of 
the following Meth-conditioned treatment groups: HC vehicle, HC baclofen, MDT 
vehicle, or MDT baclofen.   
 
Figure 22 shows the injection sites within the MDT and HC for the intracerebral 
injections administered during the post-conditioning period; out of the total of 41 
rats used for the study one was excluded due to the cannula blockage and four 
for placement outside of the MDT and HC.  Rats receiving HC injections 
demonstrated significant CPP independent of treatment history (i.e., vehicle or 
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baclofen) (Fig. 23A), a two-way repeated measures ANOVA revealed a 
significant effect of Test (F(1,11)=22.068, p=0.001) and no effect of Treatment 
(F(1,11)=0.467, p=0.508) or Treatment x Test interaction (F(1,11)=1.274, p=0.283).  
A Post-hoc Newman-Keuls test showed that time spent in the Meth-paired 
chamber during the CPP test (day 8) was significantly increased from time spent 
in the same chamber during the pre-test (day -1) for both treatment groups (HC 
vehicle, n=8; HC baclofen, n=5; p<0.05).  In contrast, treatment history 
significantly impacted CPP outcomes for MDT injected rats (Fig. 23B), a two-way 
repeated measures ANOVA revealed a significant effect of Test (F(1,21)=26.822, 
p<0.0001) and a Treatment x Test interaction (F(1,21)=4.614, p=0.044) but no 
effect of Treatment (F(1,21)=1.327, p=0.262).  A Post-hoc Newman-Keuls test 
revealed that time spent in the Meth-paired chamber during the CPP test (day 8) 
was significantly increased from time spent in the same chamber during the pre-
test (day -1) for the MDT vehicle treated rats (n=13, p<0.01) but not for those rats 
which received MDT baclofen (n=10, p>0.05).   
 
 
 
Discussion 
Repeated pairing of Meth with a unique context results in robust associations 
between Meth (unconditioned stimulus) and the context in which it is 
administered (conditioned stimulus) (Tzschentke, 1998; Tzschentke, 2007).  In 
the current study, preference for the Meth-paired chamber was not disrupted by 
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intra-cerebral vehicle injections into the MDT or HC indicating that the injection 
procedure did not impact the preference for the Meth context.  Baclofen 
administered into the MDT, and not the overlying HC, inhibited the expression of 
Meth-induced CPP when tested in a drug-free state 24hr after the last 
intracerebral injection.  These findings demonstrate that pharmacological 
augmentation of GABABR signaling in the MDT disrupted the processes 
necessary to maintain and subsequently express a preference for the Meth-
paired chamber.   
 
Prior work has demonstrated that the GABABR agonist, baclofen, modifies the 
development (administered immediately after training) and expression 
(administered as a pretreatment prior to behavioral testing) of mnemonic  
processes including spatial memory (Levin et al., 2004; McNamara and Skelton, 
1996; Nakagawa et al., 1995) and fear conditioning (Castellano et al., 1989; 
Swartzwelder et al., 1987; Zarrindast et al., 2004).  Baclofen also antagonizes 
the expression of conditioned behaviors; baclofen administered as a pre-
treatment prior to testing for the expression of Meth-induced CPP (Li et al., 2001) 
or amphetamine-induced conditioned motor sensitization (Hotsenpiller and Wolf, 
2003) inhibits the expression of these behaviors.  The current study 
demonstrated that intra-MDT administration of baclofen in Meth-conditioned rats 
resulted in a reduction of CPP drug-free rats one day after the last MDT 
treatment an effect which was not observed with two once-daily systemic 
injections of 2mg/kg baclofen (Chapter VI) indicating a selective influence of the 
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MDT on the maintenance of Meth-induced CPP rather than globally activating 
GABABRs via systemic baclofen administration.  The behavioral effects of locally 
injected baclofen can be antagonized by co-administration of GABABR 
antagonists (i.e., CGP35348 or saclofen) (Zarrindast et al., 2002; Churchill et al., 
1996a) indicating the involvement of the GABABR in the observed behavioral 
phenomenon; however, future studies with a GABABR antagonist will be 
necessary to validate the involvement of GABABRs in the observed behavioral 
effects. 
 
The MDT expresses moderate to high levels of GABABRs (Margeta-Mitrovic et 
al., 1999; Charles et al., 2003); therefore, it is possible that augmented GABABR 
signaling within the MDT may be responsible, at least in part, for mediating the 
effects of the systemically administered ligands.  The MDT is important for 
learning and memory processes; neuronal activity in the MDT is enhanced during 
the recall of associative tasks (Oyoshi et al., 1996), lesions of the MDT inhibit the 
acquisition of sucrose-induced associative learning (McAlonan et al., 1993) as 
well as working memory (Floresco et al., 1999), morphine-induced associative 
learning is disrupted by blockade of μ-opioid receptors in the MDT (Guo et al., 
2008b), and baclofen administered into the MDT disrupts working memory 
(Romanides et al., 1999).  We have now demonstrated that the maintenance of 
associative memories is regulated by the MDT.  The current study demonstrated 
that intra-MDT administration of baclofen in Meth-conditioned rats inhibited the 
maintenance of CPP when drug-free rats were tested one day after the last MDT 
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treatment.  As this outcome was not obtained when the overlying HC was 
exposed to the same treatment this helped verify that the effect of baclofen 
reflected actions within the MDT, and not via back diffusion of baclofen up the 
cannulae track to more dorsal structures.  Although the HC has long been 
implicated in learning and memory processes (Jarrard, 1993); the current study 
found that augmenting GABABR signaling in the HC 24 and 48hr after 
conditioning had no effect on memory maintenance.  When baclofen was 
administered into the HC immediately after passive avoidance training 
subsequent expression of the behavior was inhibited, this observation is 
consistent with the involvement of the HC in early memory mnemonic events 
(<24hr) (Arolfo et al., 1998; Bourtchouladze et al., 1998; Packard and Teather, 
1997).  Taken together, these studies suggest that augmenting GABABR 
signaling within the MDT, but not the HC, during the early phases after Meth-
conditioning is sufficient to weaken the maintenance of Meth-induced associative 
learning.  
 
The MDT is anatomically positioned to influence a number of brain regions that 
are known to influence drug-induced behaviors and mnemonic processes; one 
such region is the medial prefrontal cortex (mPFC) which receives dense 
glutamatergic projections from the MDT (Kuroda et al., 1995; Churchill et al., 
1996b; Kuroda et al., 1998; Pirot et al., 1994; Groenewegen, 1988).  Glutamate 
in the mPFC is a critical regulator of memory processes (Wang et al., 2006) and 
neuronal activity in the mPFC is increased by electrical stimulation of the MDT 
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(Ferron et al., 1984; Bubser et al., 1998).  Thus a decrease in MDT (e.g., due to 
administration of baclofen as in the current study) activity might be expected to 
reduce glutamate release in the mPFC and blunt neuronal activity.  This effect 
may account for inhibiting working memory (Romanides et al., 1999) and 
disrupting the maintenance of Meth-induced associative memory in the current 
study.   
 
In conclusion, these results implicate GABABRs in the MDT as critical regulators 
of processes that are necessary to maintain and subsequently express Meth-
induced CPP.  
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Figure 19.  Illustration of treatment the protocol.  For the pre-test (day -1), drug-
free rats were allowed to explore the entire CPP box for 30min.  Conditioning 
occurred for five days; Meth was paired with one chamber on days 1, 3, & 5, and 
the saline was paired with the opposite chamber on days 2 & 4).  Baclofen 
(0.5nmol/0.5μl/side) or its vehicle (0.9% saline, 0.5μl/side) was administered on 
days 6 and 7.  One day later (day 8), rats were tested for the expression of Meth-
induced CPP in a drug-free state.  M, methamphetamine (1mg/kg); S, saline 
(1mg/kg); Ø, no drug.   
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Figure 20.  Brain map Illustrating location of intra-cerebral injection sites.  A.  
Illustration of the injector tip location for all intra-cerebral sites tested.  Stereotaxic 
maps were adapted from the atlas of Paxinos and Watson (Paxinos and Watson, 
1998).  The numbers refer to the coronal level of the section, in mm relative to 
bregma.  B.  Representative photomicrographs of Nissl-stained coronal brain 
sections showing injector tips into the medial dorsal thalamus.  
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Figure 21.  The maintenance of Meth-induced CPP was inhibited by two-once 
daily injections of baclofen into the medial dorsal thalamus (MDT).  Data were 
analyzed with a two-way repeated measures ANOVA followed by a post-hoc 
Newman-Keuls test to identify between test (pre-test vs. CPP test) differences.  
Post-hoc test values are illustrated, * p<0.05, ** p<0.01, ns, not significant.  The 
dashed line indicates 900sec; 50% of the total CPP test time (1800sec).  B.  
Intra-hippocampus (HC) injections of vehicle (open bars, n=8, p<0.05) or 
baclofen (filled bars, n=5, p<0.05) did not impact the ability of rats to demonstrate 
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CPP.   C.  Rats that received intra-MDT injections of vehicle demonstrate a 
significant CPP (open bars, n=13, p<0.01), whereas those rats which received 
baclofen did not (filled bars, n=10, p>0.05).   
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CHAPTER VIII 
ANALYSIS OF GABAB RECEPTOR EXPRESSION AND DISTRIBUTION USING 
THE CROSS-LINKING TECHNIQUE IN RAT BRAIN FOLLOWING  
REPEATED METHAMPHETAMINE ADMINISTRATION 
 
Abstract 
Repeated psychostimulant administration creates persistent molecular, cellular, 
and circuit adaptations which are manifested as altered neuronal function and 
behavior.  These adaptations are the consequence of adaptations in a number of 
neurotransmitter systems including the inhibitory GABABR system; however, little 
is known about the GABABR at a time when psychostimulant-induced behaviors 
are expressed.  To provide an ex vivo snap-shot of an in vivo brain state we 
applied the bis(sulfosuccinimidyl)suberate (BS3) cross-linking technique to 
assess GABABR expression and distribution, the first time that such an 
evaluation has been conducted with a metabotropic receptor in psychostimulant-
treated brain tissue.  Using this technique, we evaluated GABABR expression 
and distribution within brain regions involved in psychostimulant-induced 
behaviors at a time when methamphetamine (Meth)-induced conditioned place 
preference (CPP, Experiment 1) and motor sensitization (MS, Experiment 2) 
were expressed.  For CPP, we used a six-day conditioning protocol (Meth-paired  
on days 1, 3, & 5 and saline-paired on days 2, 4, & 6) which was sufficient to 
induce CPP and MS.  Brain tissue was harvested one day after rats  
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demonstrated Meth-induced CPP (day 10).  In spite of the robust behavioral 
effects, we observed no significant changes in the expression or distribution of 
the GABABR in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), 
ventral pallidum, or medial dorsal thalamus.  Likewise, 14 days after three once-
daily Meth injections, at a time when rats expressed Meth-induced MS, GABABR 
expression or distribution was unaltered in the mPFC and NAc.  Thus, we 
conclude that in the expression of Meth-induced CPP and MS in the current 
studies was not dependent on a change in the expression and or distribution of 
the GABABR in limbic brain regions evaluated.  However, future studies 
evaluating downstream mediators of the GABABR and/or receptor function will be 
of value to determine if there is a down-regulation of the GABABR system 
contributing to the psychostimulant-induced behaviors such as CPP and motor 
sensitization.  These studies also suggest that the BS3 cross-linking technique 
will likely be of value to assess a wide variety of surface proteins. 
 
Introduction 
Psychostimulants, including methamphetamine (Meth), induce long-lasting 
changes in neuronal function (Chen et al., 2009; Nestler, 2001; McDaid et al., 
2007).  These adaptations are highly dynamic and paradigm-specific, with 
different brain states occurring during the hours, days, and weeks following 
psychostimulant administration (Kalivas and Hu, 2006).  While the basal brain 
state is highly variable, it is clear that brain regions/neurons that are withdrawn 
from repeated exposure to psychostimulants are hyper-responsive to re-
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exposure to cues which are associated with drug-administration (Brown et al., 
1992; Zombeck et al., 2008; Franklin and Druhan, 2000; Ciccocioppo et al., 
2001; Rhodes et al., 2005; Childress et al., 1999; Childress et al., 2008; Lin et al., 
2007) as well as subsequent psychostimulant administration (Robinson et al., 
1988; Kazahaya et al., 1989; Nishikawa et al., 1983; McDaid et al., 2006b; 
McDaid et al., 2007).  This hyper-excitable brain state can be observed 
behaviorally in the laboratory using conditioned place preference (CPP) and 
motor sensitization (MS).  These behaviors model different aspects of 
psychostimulant-induced brain adaptations but both behaviors indicate persistent 
alterations in neuronal function that persist long-after psychostimulant 
administration. 
 
The GABABR modulates neuronal excitability, signal transduction, and protein 
expression; thus, changes in the GABABR system will significantly affect brain 
function and resulting behavior.  Effects on neuronal excitability are mediated by 
G-protein dependent activation of inwardly rectifying K+ channels and inhibition of 
high voltage activated Ca++ channels (Mott and Lewis, 1994; Bowery, 1993); the 
GABABR regulates neuronal activity and the release of a neurotransmitters 
including dopamine (Gong et al., 1998; Kalivas et al., 1993; Santiago et al., 
1993a; Santiago et al., 1993c; Smolders et al., 1995).  Indeed, pharmacological 
augmentation of GABABR signaling blunts stimulus-evoked release of dopamine 
(Fadda et al., 2003) and glutamate (Hotsenpiller and Wolf, 2003).  In addition, 
GABABRs also mediate effects on protein expression and signal transduction via 
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a G-protein dependent mechanism (e.g., cAMP) to regulate the activity of the 
transcriptional regulator cAMP response element binding protein (CREB).  Thus, 
a down-regulation in GABABR system function may contribute to neuronal hyper-
responsivity observed after repeated psychostimulant administration.  Indeed, the 
GABABR system is down-regulated after robust psychostimulant administration 
protocols including decreased GABABR expression following a minimum of six 
days of stable cocaine self-administration (average of 15-18mg/kg/day) 
(Frankowska et al., 2008b; Frankowska et al., 2008a) and functional coupling of 
the receptor to the Gi/o G-protein is reduced after chronic cocaine (Kushner and 
Unterwald, 2001) and after a sensitizing regimen of amphetamine (Zhang et al., 
2000).  Furthermore, these effects are withdrawal time dependent; which makes 
it of value to determine withdrawal time dependent effects on the GABABR 
system which may contribute to the development, maintenance, and/or 
expression of Meth-induced behaviors.  Thus, the current study sought to 
determine the expression and distribution of the GABABR at a time when Meth-
induced CPP and MS are expressed. 
 
Trafficking of GABABRs is a dynamic process that can profoundly influence 
stimulant-medicated behaviors and learning and memory.  Several methods have 
been used to determine the cellular distribution of GABABRs including 
biotinylation (Fairfax et al., 2004), α-bungarotoxin tag (Wilkins et al., 2008), and 
florescent protein tags (Fairfax et al., 2004).  However, each of these techniques 
has aspects which make them less than ideal.  The cross-linking technique used 
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in the current study, pioneered by Boudreau and Wolf (Boudreau and Wolf, 2005) 
to evaluate the surface expression of AMPA receptor subunits, provides an ex 
vivo snapshot of an in vivo brain state and is an efficient method to determine the 
distribution and expression of surface proteins.  The membrane impermeable 
cross-linking agent bis(sulfosuccinimidyl)suberate (BS3) binds to extracellular 
basic residues (via an amide bond) of proteins inserted into the membrane 
resulting in a high molecular weight aggregate that is easily differentiated from 
the intracellular protein by using an antibody for protein detection targeted to the 
carboxy-terminal region of the receptor.   In order for the cross-linking technique 
to work there must be an adequate number of extracellular basic resides for BS3 
to bind to in the extracellular domain.  The GABABR is part of the Class C family 
of receptors which has a very large extracellular domain (Brauner-Osborne et al., 
2007) making it amenable to the cross-linking procedure.  Using this technique, 
we were able to successfully evaluate the expression and distribution of 
GABABRs in brain regions critical for regulating psychostimulant-induced 
behaviors (i.e., medial prefrontal cortex, mPFC; nucleus accumbens, NAc; 
ventral pallidum, VP; and medial dorsal thalamus, MDT) at a time when Meth-
induced CPP and MS are demonstrated.  These experiments demonstrate, for 
the first time, that the cross-linking procedure can be used to assess expression 
and cellular distribution of a metabotropic receptor in brain tissue.  Applying this 
technique, these experiments were designed to assess behavior- (CPP vs. MS) 
and/or withdrawal-time (4 or 14 days after the last Meth administration) 
dependent effects on the GABABR. 
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Materials and Methods 
Animals 
A total of 70 male Sprague-Dawley rats weighing between 250-275g at the start 
of the study were acclimated to the vivarium for at least one week prior to the 
onset of the experiment.  Rats were housed in pairs in a climate-controlled 
environment on a 12hr light/dark cycle and allowed ad libitum access to food and 
water.  Cage mates were given identical treatments.  Housing facilities were 
accredited through the Association for Assessment and Accreditation of 
Laboratory Animal Care, and all experiments were carried out in accordance with 
the conditions set forth by the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (National Research Council, 1996) and with the 
approval of the Loyola University Medical Center and Rush University Medical 
Center Institutional Animal Care and Use Committee.  
 
Drugs 
(+)Methamphetamine HCl (Meth; Sigma, St. Louis, MO) was dissolved in 0.9% 
sterile saline and the dose, 1mg/ml/kg, was calculated as the base (Experiment 
1) or as the salt (Experiment 2).  Meth and Meth vehicle (0.9% saline) were given 
at a volume of 1ml/kg via subcutaneous (s.c.) or intraperitoneal (i.p.) injection, as 
indicated. 
 
Conditioned Place Preference Apparatus 
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The test room was dimly lit (54-108lux) with white noise (white noise generator, 
San Diego Instruments, San Diego, CA) continuously present.  The CPP 
apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by 
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large 
conditioning chambers (25cm x 30cm x 30cm) were separated by a small center 
chamber (13cm x 30cm x 30cm).  Each chamber had distinct visual and tactile 
cues.  Chamber A, vertical stripes on walls and an overturned paint dish glued to 
the center of a patterned floor; Chamber B, horizontal stripes on walls and a grid 
floor; Center chamber, solid color walls and a smooth, slightly raised platform 
floor. Time spent in each chamber and motor activity was monitored via two sets 
of photobeams (24 horizontal and 12 vertical). 
 
Behavioral Experiment 1: Repeated Meth administration, four days post-
conditioning 
The rats were transported from the animal housing room to the adjacent test 
room at least 30min prior to the start of the experiment.  The behavioral paradigm 
consisted of three phases: pre-test, conditioning, and CPP test (Fig. 24A).  Rats 
were given a 15min pre-test to determine, initial, unconditioned chamber bias 
(time spent Chamber A, 348±26s vs. time spent Chamber B, 459±24s, Student’s 
t-test, p=0.034).  Rats were assigned to one of two treatment groups (i.e., Meth 
or saline conditioned) such that unconditioned preference was approximately 
equal for each group.  For conditioning, rats were counterbalanced wherein half 
of the rats were assigned to receive the day 1 pairing in the chamber in which 
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they spent the greatest amount of time during the pre-test and the other half were 
assigned to receive the day 1 pairing in the chamber in which they spent the 
least amount of time during the pre-test.  Rats were subsequently conditioned for 
six days; Meth (1mg/kg, as the base, i.p.) administered on days 1, 3, & 5 and 
saline on the alternate days (termed Meth conditioned group; Meth Grp) or saline 
was administered on days 1-6 (saline conditioned group; Sal Grp).  During 
conditioning, rats were injected (Meth or saline) and were immediately placed 
into the appropriate chamber of the CPP box for 45min; motor activity was 
assessed during this time (illustrated is vertical time which represent sensitized 
motor activity induced by psychostimulants including Meth, Figs. 24B & C).  The 
rats were evaluated for chamber preference three days after the last conditioning 
session (day 9).  To do so, rats were placed into the center chamber and sliding 
doors immediately removed allowing free access to the entire CPP box.  The test 
session lasted 15min and time spent in each chamber was evaluated to 
determine preference.  Brain tissue was harvested one day after the CPP test as 
described below. 
 
Behavioral Experiment 2: Repeated Meth administration, 14 days post-
administration 
The rats were transported from the animal housing room to the behavior room at 
least 30min prior to the start of the experiment.  The behavioral paradigm 
consisted of three phases: repeated treatment, withdrawal, and motor 
sensitization test (Fig. 25A).  For the repeated treatment (days 1-3), rats were 
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administered a once-daily injection of Meth (1mg/kg, as the salt, s.c.) or vehicle 
(1ml/kg) and placed into a chamber of the CPP box (which was used to measure 
motor activity and not used for conditioning) and motor activity was monitored for 
60min.  During the 14 day withdrawal period, rats remained in the home cage 
undisturbed.  To ascertain if motor sensitization was expressed on day 17, rats 
were given an acute challenge of Meth (1mg/kg, as the salt, s.c.) immediately 
prior to being placed into the CPP box for 60min.  Vertical activity reliably 
represents sensitized motor activity induced by psychostimulants including Meth, 
illustrated are vertical beam breaks and vertical time.  Brain tissue was harvested 
(described below) from a separate group of rats on the same day as the 
behavioral sensitization test (day 17). 
 
Biochemical assessments  
Tissue Preparation 
The surface receptor cross-linking method was adapted from that of Boudreau 
and Wolf (Boudreau and Wolf, 2005).  Rat mPFC, VP, NAc, and MDT tissues 
were harvested one day after the CPP test (Fig. 3).  After being dissected, each 
brain region was chopped into 400µm slices with a McIlwain tissue chopper 
(Mickle Laboratory Engineering Co. LTD, Goose Green, UK) and immediately 
placed into artificial cerebrospinal fluid (aCSF) with 2mM 
Bis(sulfosuccinimidyl)suberate (BS3; Thermo Scientific, Rockford, IL).  The cross-
linking reaction took place for 30min with gentle agitation at 4°C and the reaction 
was terminated by administration of 100mM glycine (10min at 4°C).  The tissue 
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pellet was separated from the supernatant by centrifugation at 14,000rpm for 
2min (4oC); supernatant was removed and the pellet was re-suspended in lysis 
buffer containing: 25mM HEPES, 500mM NaCl, 2mM EDTA, 20mM NaF, 0.1% 
Nonidet P-40, 1mM DTT, 1mM PMSF, protease inhibitor cocktail (Calbiochem, 
La Jolla, CA), phosphatase inhibitor cocktail I (Sigma-Aldrich), and phosphatase 
inhibitor cocktail II (Sigma-Aldrich).  Cellular membranes were disrupted by 
sonication.  Tissues were spun at 14,000rpm for 2min at 4°C and subsequently 
aliquoted and frozen at -80°C for future use.  Protein concentrations were 
determined via the Bradford method (Bradford, 1976). 
 
Non-cross-linked samples (Non CL, Fig. 27A) were hand dissected and 
immediately fast-frozen on dry ice then kept at -80°C until tissue preparation.  For 
tissue preparation, brain regions were Dounce homogenized and sonicated in 
homogenation/lysis buffer (25mM HEPES, 1mM EGTA, 1mM EDTA, 100nM 
okadaic acid, 1mM sodium orthovanadate, 100μM PMSF, 10µg/ml of pepstatin, 
leupeptin & aprotinin in cocktail form).  Protein concentrations were determined 
via the Bradford method (Bradford, 1976) and samples were prepared with 
sample buffer (NuPAGE LDS Sample Buffer, Invitrogen, Carlsbad, CA) and 
reducing agent (NuPAGE Sample Reducing Agent, Invitrogen), aliquoted and 
frozen until use at -80°C.    
 
Immunoblotting   
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Tissue homogenate samples for cross-linking experiments were prepared with in 
1:1 dilution of Laemmli sample buffer (Bio-Rad, Hercules, CA) with β-
mercaptoethanol (volume determined based on protein assay result) and 
subsequently heated to 100°C for 3-5min.  Protein (20µg) was loaded into a 4-
15% Tris-HCl linear gradient gel (Bio-Rad) and electrophoresed at 200V for 
45min.  The gels were then transferred to a Hy-Bond PVDF membrane (GE 
Healthcare Limited, Buckinghamshire, UK) for 1.5hr at a current of 1.25 amperes.  
Nonspecific binding was blocked by incubation of the membrane with TBST 
(0.05% Tween 20, Sigma-Aldrich), 1% normal donkey (GABABR1-R20) or 1% 
normal goat (GABABR1-R300) serum for at least 1hr.  Membranes were then 
incubated with GABABR1-R20 (1:300 in TBST, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA), GABABR1-R300 (1:500 in TBST, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), or actin (1:20,000 in TBST and 5% non-fat dry milk, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA) primary antibody overnight at 4°C with 
gentle agitation.  Membranes were washed repeatedly with TBST and then 
incubated with the appropriate HRP-conjugated secondary antibody for 
GABABR1-R20 (donkey anti-goat 1:50,000 in TBST; Jackson ImmunoResearch, 
West Grove, PA), GABABR1-R300 (goat anti-rabbit 1:15,000 in TBST; Jackson 
ImmunoResearch, West Grove, PA), or actin (goat anti-rabbit 1:20,000 in TBST 
and 5% non-fat dry milk; Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  
Membranes were subsequently washed with TBST, TBS, and distilled water.  
Chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific, 
Rockford, IL) was applied to the membrane to visualize protein of interest by light 
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sensitive film (HyBlot CL, Denville Scientific, Inc., Metuchen, NJ).  Optical density 
was determined via densitometric analysis with Un-Scan-It Software (Silk 
Software,Inc., Orem, UT).   
 
Preabsorption Assay 
Immunoblotting was conducted as stated above with the following adaptations.  
The PVDF membrane was cut in half.  One half was incubated with antibody plus 
the blocking peptide (pre-incubated for 1hr at room temperature) and the other 
half was processed as described previously; membranes were incubated 
overnight at 4°C.  The GABABR blocking peptide (1:60 in 1xTBST; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) specific to the epitope of the anti-
GABABR1-R20 goat immunoaffinity purified IgG primary antibody (1:300 in 
1xTBST; Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  Immunoblots were 
subsequently washed, incubated with the appropriate secondary antibody and 
developed as described previously. 
 
Quantification and Data Summary 
Optical density of the high molecular weight aggregate (>400kD) corresponding 
to receptors located at the neuronal surface (S), the intracellular components (I) 
which were located at the expected molecular weights (GABAB1aR ~130kD, 
GABAB1bR ~100kD), and actin (A, ~43kD) were determined.  Using these data 
the following were calculated: 1) the ratio of surface to intracellular protein (S/I 
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ratio), 2) total surface protein (S/A), 3) total intracellular protein (I/A), and 4) total 
protein ((S+I)/A).   
 
Statistics 
All data are represented as mean ± SEM.  Statistical outliers were determined as 
more than two standard deviations above or below the mean for any data set. 
 
Behavior 
Conditioned place preference: Significant preference was achieved when a 
significantly greater amount of time was spent in the Meth-paired compared to 
the saline-paired chamber during the CPP test as assessed with a paired t-test 
(Bonferroni adjustment set significance at p<0.025).  Development of motor 
sensitization: A within group comparison of vertical activity between the first and 
the last Meth treatment (Paired t-test, p<0.05).  Expression of motor sensitization: 
A between groups analysis of vertical activity following a Meth challenge (saline 
vs. Meth) (Student’s t-test, significance set at p<0.05).   
 
Immunoblotting 
The surface to intracellular ratio (S/I ratio), total protein, surface (S), and 
intracellular (I) values were normalized to the average saline within each gel and 
multiplied by 100 to determine optical density as a % Average Saline.  Student’s 
t-tests (significance set at p<0.05) were used to determine differences between 
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GABABR distribution and expression in Meth and saline treatment groups for S/I 
ratio, total protein, S, and I.   
 
Results 
Experiment 1: Repeated Meth administration, four days post-conditioning 
(Refer to Fig. 24A for conditioning protocol) 
 
Meth-conditioned rats demonstrated a significant preference for the Meth-paired 
chamber (n=16, p=0.0004; Fig. 24C) while saline-conditioned rats did not show 
preference for either chamber (n=16, p=0.304, Fig. 24B).  The conditioning 
procedure was also sufficient to induce motor sensitization; vertical time 
(p=0.040) was significantly greater on day 5 compared to first conditioning day 
(day 1) which was representative of other vertical parameters as well.  Saline 
conditioned rats demonstrated a significant decrease in vertical time (p<0.001) 
when comparing the first and last conditioning days which is consistent with 
habituation to the environment and the conditioning procedure.  Together these 
data indicate that the Meth administration protocol induced brain adaptations 
which were sufficient to induce Meth-induced associative learning and MS; thus 
to determine the status of the GABABR at a time when the behavior was 
expressed brain tissue was harvested one day after the CPP test.  No 
differences in GABABR expression or distribution were observed in any brain 
region comparing Meth-conditioned rats which expressed a preference for the 
Meth-paired chamber when compared to saline-conditioned rats (representative 
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blots in Fig. 27C; Table 1); this was true when evaluating the GABAB1aR (130kD) 
and GABAB1bR (100kD) isoforms separately (data not shown) or when included 
together (100+130kD).  Meth conditioning did not alter GABABR 
surface/intracellular ratio, total protein, surface, or intracellular in the mPFC, NAc, 
VP, or MDT (Table 1).  Furthermore, the magnitude of the preference was not 
correlated with biochemistry outcomes. 
 
Experiment 2: Repeated Meth administration, 14 days post-administration 
(Refer to Figure 25A for repeated treatment protocol) (Behavioral data, 
collected by Amanda Mickiewicz, Ph.D.) 
 
These data revealed that three once-daily treatments of 1mg/kg Meth 
(administered as the salt, s.c.) was sufficient to induce brain changes that 
manifested themselves as the development (Figs. 25B & C) and expression (Fig. 
25D) of Meth-induced MS.  Vertical parameters (which reliably represent the 
profile of psychostimulant motor sensitization in rodents) including vertical time 
(time spent in the vertical position) which was significantly increased during the 
repeated treatment period (day 1 vs. day 3) for rats which received repeated 
Meth (Fig. 25C, n=8, paired t-test, p=0.005) but not for those repeatedly 
administered saline (Fig. 25B, n=8, paired t-test, p=0.527).  In addition, 
significant between group differences were observed on day 17 following a Meth 
challenge injection; with the Meth repeated treatment rats spending more time in 
the vertical position (Student’s t-test, p=0.018).  Analysis of tissue collected on 
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day 17 revealed no differences in GABABR expression or distribution in the 
mPFC or NAc when comparing rats repeatedly treated with saline or Meth 
(representative blots in Fig. 27D; Table 2); this was true when evaluating the 
GABAB1aR (130kD) and GABAB1bR (100kD) and 130kD isoforms separately (data 
not shown) or when included together (100+130kD).  Repeated Meth 
administration sufficient to induce behavioral sensitization did not alter GABABR 
expression or distribution (i.e., surface/intracellular ratio, total protein, surface, or 
intracellular) in the mPFC or NAc (Table 2). 
 
Cross-linking of the GABAB receptor 
The GABABR was identified as the first receptor to function as an obligate 
heterodimer (Kaupmann et al., 1998; White et al., 1998; Jones et al., 1998; 
Kuner et al., 1999); the receptor is comprised of a ligand-binding GABAB1R 
(Kaupmann et al., 1998) (which has two isoforms (GABAB1aR & GABAB1bR) 
which differ from one another by the presence of a sushi domain repeat ) 
(Kaupmann et al., 1997) and a GABAB2R which couples to the G-protein (Gi/o) 
(Bettler et al., 2004; Pin et al., 2004).  In addition, the dimerization is critical for 
the trafficking of the functional receptor to the neuronal surface; the binding of the 
GABAB2R masks the endoplasmic reticulum retention signal located on the 
GABAB1R (Couve et al., 1998; Kaupmann et al., 1997).  For the current study, 
evaluation of the GABAB1R would be expected to mirror changes that also 
occurred for the GABAB2R; thus, it is appropriate to evaluate the GABAB1R in the 
current study. 
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Using the cross-linking technique we have been able to differentiate between the 
high molecular weight aggregate corresponding to receptor inserted into the 
neuronal membrane bound to BS3 (>400kD) and the intracellular protein which 
ran at the expected molecular weight (~130 & 100kD) in the same tissue sample.  
This is illustrated in Fig. 27A which demonstrates the difference between 
Western blot results obtained from cross-linked (CL) and non-cross-linked (Non 
CL) samples.  The high molecular aggregate is not present in the Non CL tissue.  
The ability to cross-linked receptor proteins is not ubiquitous, the inwardly 
rectifying potassium channel (GIRK, a major downstream mediator of the 
GABABR) could not be cross-linked due to a relatively small extracellular domain, 
and resulting lack of basic amino acid residues for BS3 to bind to (data not 
shown).  Using antibodies targeting toward the intracellular portion of the 
receptor we were able to reliably assess expression and distribution of the 
GABABR.  We then validated that the antibodies used were specific for the 
GABABR using a blocking peptide which inhibited all antibody binding (illustrated 
in Fig. 27B).  Results obtained in this assay revealed small inter-sample 
variability making the results highly reproducible. 
 
 
 
Discussion 
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In the current study, the cross-linking technique revealed no changes in the 
expression or distribution of the GABABR at a time when Meth-induced CPP and 
MS are expressed.  This result conflicts with the decreased GABABR-selective 
radioligand binding observed throughout the brain, including regions evaluated in 
the current study (i.e., cortex, NAc, MDT) of rats repeatedly self-administered 
cocaine (Frankowska et al., 2008b; Frankowska et al., 2008a); however, the 
amount of cocaine that was administered (15-18mg/day for more than 6 days) far 
exceeded the Meth administered (1mg/kg/day for 3 days) in the current study.  
Our possibility to account for the divergent results between our study and the 
previous self-administration study, a more robust psychostimulant administration 
paradigm might be required to obtain significant changes in GABABR expression 
and/or distribution.  Our findings are in agreement with an earlier study which 
demonstrated that during a time when amphetamine-induced behavioral 
sensitization was expressed (14 days after 5mg/kg x 5 days) GABABR density 
was unchanged although there was a change in the functional coupling of the 
receptor to the G-protein (Zhang et al., 2000).  This is not the first report to 
demonstrate that GABABR expression does not always correlate with GABABR 
function (Enna and Bowery, 2004).  Based on these data, we may conclude that 
adaptations in GABABR expression and distribution are not necessary for the 
expression of psychostimulant-induced behaviors or an alternative conclusion 
may be that there was a functional down-regulation of the GABABR system which 
was not detected in these assays.  Our laboratory has previously demonstrated 
that the inhibitory effects of GABA are diminished in the VP following a 
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sensitizing regimen of Meth (McDaid et al., 2005) which may reflect a change in 
the functional coupling of the GABABR to the G-protein or one of the downstream 
mediators of the GABABR including the expression or function of GIRKs and/or 
Ca++ channels (Bettler et al., 2004; Mott and Lewis, 1994; Barthel et al., 1996).  
Taken together psychostimulant-induced behaviors which appear to not involve 
alterations in GABABR expression or distribution may be the consequence of a 
functional down-regulation of the GABABR system.  Further analysis will be 
required to validate this possibility. 
 
These findings indicate that one day after the expression of Meth-induced CPP 
the expression and distribution of the GABABR are not altered in rats that learned 
to associate the rewarding properties of Meth with the contextual cues of the 
chamber.  Likewise, 14 days after repeated Meth administration, at a time when 
Meth-induced behavioral sensitization is expressed, the expression and 
distribution of the GABABR were unaltered.  While we were not able to identify 
changes in GABABR expression or distribution at a time when Meth-induced CPP 
or MS were expressed, this report describes a re-purposing of a technique to 
assess changes in cellular distribution of a metabotropic receptor for the first 
time.   This technique allows for a reliable and efficient means to assess 
expression and distribution of surface proteins which may be applied to a wide 
variety of proteins inserted into the neuronal surface.  
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Figure 22.  A six-day conditioning protocol was sufficient to induce 
methamphetamine-induced conditioned place preference and behavioral 
sensitization.  A.  Illustration of treatment protocol.  A drug-free Pre-test was 
conducted (day 0) and rats were counterbalanced (half were given the day 1 
treatment in chamber in which rats spent the least amount of time during the Pre-
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test and the other half in the chamber in which the greatest amount of time was 
spent during the Pre-test).  Conditioning occurred on days 1–6; saline 
conditioned group was administered saline on days 1-6 (n=16) and the Meth 
conditioned group was administered Meth on days 1, 3, & 5 and saline on the 
alternate days (n=16).  A drug-free CPP test was conducted on day 9 to verify 
the development of CPP (CPP Test 1) and tissue was collected from drug-free 
rats one day later (day 10).  Sal Grp, saline conditioned group; Meth Grp, 
methamphetamine conditioned group; M, methamphetamine (1mg/kg, as the 
base); S, saline (1mg/kg); Ø, no drug.  During conditioning, the saline group 
exhibited a significant decrease in time spent in the vertical position (s) (day 1 vs. 
day 5) consistent with habituation (B; Paired t-test, p<0.001) whereas the Meth 
group had a significant increase in time spent in the vertical position (seconds) 
when comparing the first to the last Meth injection (day 1 vs. day 5) 
demonstrating the development of behavioral sensitization (C; Paired t-test, 
p<0.05).  The drug-free CPP test conducted on day 9 revealed that saline 
conditioned rats had no preference for either chamber (D; Paired t-test, p>0.05) 
while the Meth-conditioned rats demonstrated a significant preference for the 
chamber paired with Meth (E; Paired t-test, p<0.01).  S, saline-paired chamber; 
M, methamphetamine-paired chamber.   
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Figure 23.  Three once-daily injections of methamphetamine induced behavioral 
sensitization which was expressed at 14 days withdrawal.  A.  Illustration of 
treatment protocol.  Three once-daily injections of saline or vehicle were 
administered (day 1-3) and 14 days later (day 17) rats were either given an acute 
challenge or tissue was harvested from drug-free rats.  Sal Grp, saline repeated 
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treatment group; Meth Grp, methamphetamine repeated treatment group; M, 
methamphetamine (1mg/kg, as the salt); S, saline (1mg/kg); Ø, no drug.  During 
repeated treatment, the saline-treated rats did not exhibit a significant change in 
vertical time (seconds spent in the vertical position) (day 1 vs. day 3) (B; Paired t-
test, p>0.05) whereas the Meth group had a significant increase in time spent in 
the vertical time when comparing the first to the last Meth injection (day 1 vs. day 
3) demonstrating the development of behavioral sensitization (C; Paired t-test, 
p<0.01).  On day 17, rats with a treatment history of Meth (n=20, filled bars) had 
significantly higher motor activity than rats repeatedly administered saline (n=18, 
open bars) over the 60min post Meth injection time period.  D.  Vertical time; 
Student’s t-test, p<0.05. 
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Figure 24.  Anatomical illustration of the brain regions dissected for 
immunoblotting.  Sections were redrawn from Paxinos and Watson (1998) and 
the numbers illustrate the distance in millimeters from Bregma.  mPFC, medial 
prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; MDT, medial 
dorsal thalamus. 
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Figure 25.  Validation of the cross-linking technique and GABAB receptor anti-
body specificity.  A. Immunoblotting of cross-linked (CL) and non-cross-linked 
(Non CL) mPFC tissues demonstrated a high molecular weight aggregate 
(~400kD) which corresponds to BS3 bound GABABR inserted into the neuronal 
membrane in the CL tissue which is not present in the Non CL tissue.  Bands 
corresponding to receptors contained in the intracellular compartment were found 
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at the expected molecular weights of the two isoforms, GABAB1aR (~130kD) and 
GABAB1bR (~100kD) in CL and Non CL samples.  A band corresponding to the 
dimerized receptor (GABAB1R & GABAB2R) was also observed in CL and Non CL 
samples.  B. Pre-incubation of the antibody with blocking peptide inhibited all 
antibody binding, indicating antibody specificity.  Representative blots from CL 
tissue used for quantification in behavioral studies.  C.  Experiment 1 (GABABR1-
R20), tissue was collected one day after the test for chamber preference in which 
Meth (1mg/kg, as the base, i.p.) conditioned rats demonstrate a preference for 
the Meth-paired chamber and saline (1ml/kg) conditioned rats did not.  D.  
Experiment 2 (GABABR1-R300), tissue was collected 14 days after three once 
daily treatments of saline (1ml/kg) or Meth (1mg/kg, as the salt, s.c.).  mPFC, 
medial prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; MDT, 
medial prefrontal cortex; M, methamphetamine treated rats; S, saline treated 
rats. 
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Table 1.  There were no significant changes in GABAB receptor expression 
or distribution after Meth conditioning (Experiment 1). 
 Saline Conditioned Meth Conditioned Student’s t-test 
Surface/Intracellular Ratio: S/I 
mPFC 100±6, n=15 115±6, n=15 p=0.077 
NAc 100±4, n=11 96±6, n=12 p=0.583 
VP 100±3, n=9 110±6, n=11 p=0.202 
MDT 100±5, n=14 98±8, n=13 p=0.804 
Total Protein: (S+I)/A 
mPFC 100±3, n=12 94±5, n=13 p=0.338 
NAc 100±4, n=7 101±7, n=7 p=0.930 
VP 100±4, n=10 107±6, n=11 p=0.353 
MDT 100±3, n=13 94±3, n=10 p=0.182 
Surface: S/A 
mPFC 100±4, n=13 104±7, n=15 p=0.636 
NAc 100±3, n=7 105±9, n=7 p=0.625 
VP 100±4, n=11 102±8, n=9 p=0.859 
MDT 100±2, n=14 100±6, n=13 p=0.944 
Intracellular: I/A 
mPFC 100±4, n=14 89±5, n=15 p=0.100 
NAC 100±8, n=8 103±8, n=7 p=0.824 
VP 100±3, n=10 109±6, n=7 p=0.139 
MDT 100±4, n=14 96±4, n=13 p=0.543 
 
Table 2.  There were no significant changes in GABAB receptor expression 
or distribution 14 days after repeated Meth administration (Experiment 2). 
 
Saline Repeated 
Treatment 
Meth Repeated 
Treatment 
Student’s t-test 
Surface/Intracellular Ratio: S/I 
mPFC 100±5, n=8 98±6, n=9 p=0.839 
NAc 100±8, n=7 92±7, n=5 p=0.529 
Total Protein: (S+I)/A 
mPFC 100±9, n=9 92±6, n=8 p=0.459 
NAc 100±5, n=10 101±3, n=9 p=0.839 
Surface: S/A 
mPFC 100±6, n=7 101±6, n=9 p=0.955 
NAc 100±4, n=11 98±3, n=10 p=0.653 
Intracellular: I/A 
mPFC 100±7, n=7 106±10, n=8 p=0.619 
NAc 100±5, p=12 105±6, n=10 p=0.465 
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CHAPTER IX 
BACLOFEN FACILITATES THE EXTINCTION OF 
METHAMPHETAMINE-INDUCED CONDITIONED 
PLACE PREFERENCE IN RATS 
Abstract  
Exposure to cues associated with abused drugs can trigger drug-craving, 
seeking and relapse in the abstinent addict.  The powerful, long-lasting 
association between the rewarding effects of a drug and contextual cues 
associated with drug administration can be studied in laboratory rats using 
conditioned place preference (CPP).  Extinction therapy is based on the concept 
that repeated exposure to drug-associated cues in the absence of the drug 
reduces the significance of cues and the likelihood of cue-induced relapse.  
Extinction processes engage multiple brain systems that are modulated by GABA 
and baclofen, the GABABR agonist, which has been shown to facilitate the 
extinction of morphine-induced CPP in mice.  The current study extended this 
work by determining if baclofen could enhance the extinction of 
methamphetamine (Meth)-induced CPP in rats.  Meth-induced CPP was 
established using a six day conditioning protocol.  Rats were subsequently 
administered baclofen (2mg/kg i.p. or its vehicle) in conjunction with six once-
daily extinction training sessions followed by a CPP test (collectively termed an  
extinction training cycle).  Our results demonstrate that CPP persisted for at least 
four extinction cycles in vehicle-treated rats.  In contrast, the expression of Meth- 
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induced CPP was completely inhibited following the first extinction training cycle 
in which baclofen was administered immediately after each daily extinction 
training session.  These data indicate that Meth-induced CPP was resistant to 
extinction, but extinction training combined with baclofen administration rapidly 
extinguished the preference for the Meth-paired chamber.  These findings 
converge with the prior demonstration of baclofen facilitating the extinction of 
morphine-induced CPP indicating that GABABR actions are independent of the 
primary (unconditioned) stimulus (i.e., the opiate or the stimulant) and likely 
reflect mechanisms engaged by extinction learning processes per se.  Thus, 
baclofen administered in conjunction with extinction training may be of value for 
addiction therapy in abstinent addicted humans regardless of the class of drug 
being abused. 
 
Introduction 
 
Methamphetamine (Meth) is a highly abused psychostimulant.  Even after long 
periods of abstinence, cues associated with the rewarding properties of 
psychostimulants can elicit drug-craving and seeking (O'Brien et al., 1992; 
Ehrman et al., 1992; Hartz et al., 2001).  Thus, relapse to drug use remains a 
major challenge for psychostimulant-addicted individuals.  These responses are 
attributed at least in part to the robust associative learning that occurs between 
contextual cues (conditioned stimulus) and the rewarding effects of abused 
substances (unconditioned stimulus) as well as the enduring nature of the drug-
context memory.  This long-lasting association can be demonstrated in the 
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laboratory with conditioned place preference (CPP) (Childs and deWit H., 2009; 
O'Brien et al., 1998; Tzschentke, 1998; Tzschentke, 2007).  Unwanted 
associative memories can be disrupted by purposefully employing extinction 
learning procedures.  For example, extinction procedures can reduce anxiety 
associated with post traumatic stress disorder in humans (McCleery and Harvey, 
2004; Brunet et al., 2008).  However, extinction of reward-related memories is 
not particularly efficacious in reducing relapse in abstinent drug-dependent 
humans (Conklin and Tiffany, 2002) or in rodent models of addiction (Crombag 
and Shaham, 2002; Di Ciano P. and Everitt, 2004); but there is evidence that 
combining extinction therapy with a pharmacotherapy may reduce cue-elicited 
relapse in humans (O'Brien et al., 1990) and mice (Heinrichs et al., 2010).  
 
Currently there are no FDA-approved pharmacotherapies for Meth addiction; 
however, the GABABR has received considerable attention as a potential 
pharmacotherapeutic target (Xi and Gardner, 2008; Rose and Grant, 2008; 
Brebner et al., 2002).  GABABRs negatively regulate neurotransmitter systems 
important for reward-mediated behaviors and mnemonic processes, including 
glutamate (Yamada et al., 1999; Lei and McBain, 2003; Porter and Nieves, 2004; 
Harte and O'Connor, 2005) and dopamine (Santiago et al., 1993c; Santiago et 
al., 1993b; Smolders et al., 1995; Westerink et al., 1996).  Cues associated with 
drug reward activate limbic brain regions in drug-addicted humans (Childress et 
al., 1999; Childress et al., 2008) and rodents (Brown et al., 1992; Zombeck et al., 
2008; Franklin and Druhan, 2000; Ciccocioppo et al., 2001; Rhodes et al., 2005).  
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This activation is attributed to the hyper-responsiveness of glutamatergic (Bell et 
al., 2000; Hotsenpiller et al., 2001) and dopaminergic (Lin et al., 2007) systems.  
Imaging studies indicate that baclofen, a GABABR agonist, blunts the limbic 
activation associated with visual drug cues in drug-addicted humans (Brebner et 
al., 2002).  Baclofen also inhibits the expression of many psychostimulant-
induced behaviors in rodents including CPP (Li et al., 2001), conditioned motor 
sensitization (Hotsenpiller and Wolf, 2003), motor sensitization (Bartoletti et al., 
2004; Frankowska et al., 2009; Lhuillier et al., 2007), and self-administration 
(Ranaldi and Poeggel, 2002; Brebner et al., 2005; Campbell et al., 1999; Filip et 
al., 2007; Roberts and Andrews, 1997; Smith et al., 2004; Weerts et al., 2007).  It 
is clear that baclofen can alter learning and memory process.   Particularly 
relevant to the current study is the recent demonstration that baclofen 
administered immediately after extinction training facilitated the extinction of 
morphine-induced CPP (Heinrichs et al., 2010).  As baclofen modulates 
neurotransmitter systems that are critical for the expression of psychostimulant-
induced behaviors as well as the extinction of opiate-induced CPP, we sought to 
determine the efficacy of baclofen to facilitate the extinction of Meth-induced 
associative learning.   This experimental endeavor also determined if the 
baclofen effect seen with morphine-induced CPP generalized to the 
psychostimulant Meth.     
 
Materials and Methods 
Animals 
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Forty male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-300g at 
the start of the study were acclimated to the local vivarium (a climate-controlled 
environment on a 12hr light/dark cycle) for at least one week prior to the onset of 
the experiments.  Rats were housed in pairs and allowed ad libitum access to 
food and water.  Cage mates were given identical pharmacological treatments.  
Rush University Medical Center housing facilities are accredited through the 
Association for Assessment and Accreditation of Laboratory Animal Care, and all 
experiments were carried out in accordance with the conditions set forth by the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals 
(National Research Council, 1996) and with the approval of the Rush University 
Medical Center Institutional Animal Care and Use Committee.  
 
Drugs 
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile 
saline, and the dose, 1mg/ml/kg, was administered as the base.  Baclofen was 
also dissolved in 0.9% saline and administered at a dose of 2mg/ml/kg (Sigma, 
St Louis, MO).  Saline vehicle injections were administered as 1ml/kg.  All 
injections were given intraperitoneally (i.p.).   
 
The baclofen dose of 2mg/kg is within the range of doses used in laboratory rats 
to successfully attenuate psychostimulant-induced behaviors, including Meth-
induced CPP (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001), cocaine self-administration 
(2.5mg/kg, i.p.) (Smith et al., 2004), break point of amphetamine self-
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administration (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005), and amphetamine-
induced motor sensitization (2mg/kg, i.p.) (Bartoletti et al., 2004).  In addition, in 
pilot studies, we determined that motivated motor behavior assessed on the 
rotarod (San Diego Instruments, San Diego, CA) was inhibited by 4mg/kg 
baclofen and spontaneous motor activity was decreased by 3mg/kg baclofen but 
not by 2mg/kg (unpublished data).  
 
Apparatus for Assessing Behavior 
The test room was dimly lit (54-108lux) with white noise (San Diego Instruments, 
San Diego, CA) continuously present.  The CPP apparatus (63cm x 30cm x 
30cm) consisted of three chambers divided by Plexiglas sliding doors (AccuScan 
Instruments, Inc., Columbus, OH); two large conditioning chambers (25cm x 
30cm x 30cm) separated by a small center chamber (13cm x 30cm x 30cm).  
Each chamber had distinct, yet neutral, visual and tactile cues.  Chamber A had 
white vertical stripes and chamber B had white horizontal stripes on walls.  These 
chambers were randomly fitted with floors that were either a textured surface with 
an overturned paint dish glued to the center or different textured floor with a 
smooth, flat rectangle glued to the center.  The center chamber had white walls 
and a smooth, slightly raised platform floor.  Time spent in each chamber and 
motor activity was monitored via two sets of photobeams (24 in the horizontal 
plane and 12 vertical). 
 
Conditioned Place Preference 
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The rats were transported from the animal housing room to the adjacent test 
room at least 30min prior to the start of the experiment for habituation.  Rats 
were subjected to a 30min pre-test (refer to the timeline in Fig.28A) which verified 
that there was not a significant preference for either chamber (data presented in 
Results); however, individual rats tended to spend more time in one chamber 
compared to the other.  Thus, for conditioning, rats were administered Meth 
(1mg/kg) in the chamber in which they spent the least amount of time during the 
pre-test.  Conditioning occurred over six days; Meth was paired with a unique 
context (i.e., chamber) on days 1, 3, & 5 and a saline (1ml/kg) was paired with a 
different context on days 2, 4, & 6.  Pairing occurred immediately after each 
injection and lasted for 45min.  In order to confirm that the preference developed, 
a drug-free CPP test was conducted on day 9 (termed CPP Test 1; Fig. 28A).  
For this test, rats were placed into the center chamber and the sliding doors were 
immediately removed allowing free access to the entire CPP box.  The test 
session lasted 30min and time spent in each chamber was determined.  Rats 
that did not increase time spent in the Meth-paired chamber on CPP Test 1 
compared to the same chamber during the pre-test by at least 10% (180s) were 
excluded from the studies.  This culling procedure, as previously shown by others 
(Paolone et al., 2009) helps assure that only those rats who clearly acquired the 
task were used to determine the potential of the GABABR agonist baclofen to 
facilitate the extinction of CPP.  Rats were assigned to either the baclofen or 
baclofen vehicle treatment group such that the magnitude of the preference 
during CPP Test 1 was approximately equal between the two groups.  Each 
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extinction cycle consisted of six consecutive once-daily forced extinction 
sessions (45min) followed by a CPP test three days later (referred to as the 
“Extinction Test”, Ext Test; Fig. 28A).  The once-daily forced extinction sessions 
consisted of pairing a saline (1ml/kg) treatment with each chamber for 45min 
(termed “Pre-Training Injection”; Fig. 28A), alternating between the previously 
Meth- or saline-paired chamber (as done during conditioning), a commonly used 
approach for forced extinction training (Mueller and Stewart, 2000; Heinrichs et 
al., 2010; Schroeder and Packard, 2004).  Immediately after each daily extinction 
session, baclofen vehicle (1ml/kg) or baclofen (2mg/kg) was administered 
(termed “Post-Training Injection”; Fig. 28A) and rats were returned to the home 
cage.  Four extinction cycles (each including six once-daily forced extinction 
sessions and the Ext test) were conducted (Fig. 28A).   
 
Statistical Analysis 
A two-way repeated measures ANOVA was employed using the within group 
factor of chamber and the repeated measure of test.  Post-hoc Newman-Keuls 
was used to identify between chamber differences; significant preference was 
achieved when time spent in the Meth-paired chamber was significantly greater 
than time spent in the saline-paired chamber for any CPP/Ext Test.  This 
approach has been used by Stewart and colleagues for similar evaluations 
(Paolone et al., 2009; Botreau et al., 2006).  All data are presented as mean ± 
SEM.  Statistical outliers were determined as those rats that spent greater than 
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two standard deviations above or below the mean time spent in any chamber 
during any of the CPP or Ext tests. 
 
Results 
Results of the 30min pre-test demonstrated that, before conditioning, rats spent 
approximately equal amount of time in each chamber (time spent in chamber A, 
868±64s vs. chamber B 810±63s; paired t-test, p=0.652 center chamber time 
was 122±9s; n=40).  After conditioning (CPP Test 1, day 9), rats expressed a 
significant preference for the Meth-paired chamber compared to the saline-paired 
chamber (time spent in the Meth-paired chamber, 958±41s vs. time spent saline 
chamber 672±43s; paired t-test, p=0.0003; center chamber time was 170±8sec; 
n=40).  Of these rats, 28 met the learning criteria detailed in the methods, and 
these rats with a strong preference for the Meth-chamber (i.e., robust learners) 
were subsequently assigned to receive either baclofen or baclofen vehicle in 
order to assess the ability of baclofen to facilitate the extinction of Meth-induced 
CPP.  As detailed in the methods, rats that were outliers for any of the tests (CPP 
Test-Ext Test 4) were excluded (n=7) thus a total of 10 and 11 rats were included 
in the baclofen vehicle and baclofen groups, respectively.  
 
Significant preference was expressed on CPP Test 1 and it persisted through 
four extinction cycles when vehicle was administered in conjunction with 
extinction training (n=10, Fig. 28B).  A two-way repeated measures ANOVA 
revealed a significant effect of Chamber (F(1,18)=15.966, p=0.001) but no effect of 
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Test (F(4,72)=0.022, p=0.999) and no Chamber x Test interaction (F(4,72)=1.011, 
p=0.407).  A post-hoc Newman-Keuls test revealed significant CPP (significantly 
greater amount of time spent in the Meth-paired than the saline-paired chamber) 
for the CPP test and all subsequent extinction tests (Fig. 1B; p<0.05 or p<0.01).  
In contrast, baclofen administered immediately after each daily extinction session 
during extinction cycle 1 nullified preference for the Meth-paired chamber during 
all subsequent preference tests (n=11; Fig. 28C, Ext Test 1-4).  A two-way 
repeated measures ANOVA revealed a significant Chamber x Test interaction 
(F(4,80)=2.799, p=0.031) with no effect of Chamber (F(1,20)=2.950, p=0.101) or Test 
(F(4,80)=0.057, p=0.994).  A post-hoc Newman-Keuls test revealed significant 
preference for the Meth-paired chamber compared to the saline-paired chamber 
only during CPP Test 1 (p<0.01).  Although time spent in the center chamber was 
not included in the statistical analyses reported above, we verified that time spent 
in the center chamber did not significantly change for either treatment group 
during any of the preference tests (CPP Test-Ext 4) (one-way ANOVA; vehicle 
treated rats F(4,45)=1.300, p=0.284, baclofen treated rats F(4,50)=1.185, p=0.329). 
 
Motor activity was monitored during each of the preference tests (CPP and Ext 
Tests).  Examination of these data revealed no significant between group 
differences during any test for horizontal or vertical activity (Student’s t-test, 
p>0.05; Table 1). 
 
Discussion 
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The Meth-induced preference observed in the current study was highly resistant 
to extinction; repeated re-exposure to the chambers over four extinction cycles 
did not extinguish the Meth-induced preference in vehicle treated rats.  In 
contrast, baclofen administered immediately after chamber re-exposure inhibited 
the preference for the Meth-paired chamber after the first extinction cycle 
(Extinction Test 1).  This inhibitory effect was produced even in rats which 
demonstrated robust preference during CPP Test 1 (see culling procedure in 
Methods).  Motor activity was not significantly altered by repeated baclofen 
treatment; thus, the place preference results do not reflect a change in the 
capacity of rats to successfully execute the task.  These findings indicate that 
augmenting GABABR signaling facilitates the extinction of Meth-induced CPP.   
 
These results corroborate the recent publication by Heinrichs and colleagues 
which demonstrates that baclofen facilitates the extinction of morphine-induced 
CPP in mice (Heinrichs et al., 2010).  This suggests that baclofen is working via 
an overlapping mechanism(s) engaged during the extinction of morphine- and 
Meth-induced CPP.  During extinction training, rats were re-exposed to 
contextual cues (i.e., the conditioning chambers) that were previously associated 
with Meth- as well as those paired with saline.  Re-exposure to cues associated 
with Meth (Rhodes et al., 2005; Chiang et al., 2009) and morphine (Guo et al., 
2008a; Schroeder et al., 2003; Schroeder and Kelley, 2002; Schroeder et al., 
2000) increases neuronal activity (e.g., amygdala and orbitofrontal cortex).  This 
may reflect hyper-responsive glutamatergic (Bell et al., 2000; Hotsenpiller et al., 
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2001) neurotransmission.  Indeed, blocking glutamatergic AMPA receptors 
inhibits the increase in Fos expression that occurs during re-exposure to cocaine 
cues in limbic and cortical brain regions (Zavala et al., 2007).  In the current 
study, blunting the cue-induced brain hyperactivity immediately after re-exposure 
to the Meth-paired context is a credible candidate mechanism by which baclofen 
facilitates the extinction of Meth-induced CPP with the same argument holding 
true for the extinction of opiate-induced CPP.  If true, this indicates that the 
persistence of drug-induced associative memories is dependent on hyper-
responsive glutamate neurotransmission in the time period after re-exposure to 
contextual conditioning cues which influences protein expression and neuronal 
structure. 
 
Extinction of a memory is believed to involve new learning; the new memory 
becomes stronger than the previously established memory resulting in a different 
conditioned response (Quirk and Mueller, 2008).  For example, memory 
consolidation can be facilitated by augmenting glutamatergic neurotransmission 
(Ungerer et al., 1998); the extinction of cocaine-induced CPP is enhanced by 
administering a mGluR5 positive allosteric modulator prior to extinction training 
(Gass et al., 2009) or a NMDA receptor agonist immediately after extinction 
training (Botreau et al., 2006).    In the current study, baclofen was administered 
immediately after each daily extinction session (i.e., after re-exposure to the 
saline- or Meth-paired chamber), thus the extinction enhancing effects of 
baclofen may be due to enhanced consolidation of the extinction memory likely 
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involving mechanisms including PKA and CREB.  Although not typically thought 
of as memory enhancing, the GABABR agonist baclofen has been reported to 
improve passive avoidance learning when administered immediately after 
training (Georgiev et al., 1988; Saha et al., 1993) and recognition memory 
deficits induced by repeated Meth administration when administered prior to 
training (Arai et al., 2009).  GABABRs blunt glutamatergic (Yamada et al., 1999; 
Lei and McBain, 2003; Porter and Nieves, 2004) and dopaminergic (Santiago et 
al., 1993c; Santiago et al., 1993b; Smolders et al., 1995; Westerink et al., 1996) 
neurotransmission and this effect would serve to inhibit rather than facilitate 
memory consolidation.  Antagonism of NMDA glutamate receptors impairs the 
extinction of fear conditioning (Liu et al., 2009) as well as the extinction of 
cocaine self-administration (Feltenstein and See, 2007) and similar impairing 
effects on the extinction of fear conditioning are observed with dopamine 
receptor antagonisms (Holtzman-Assif et al., 2010; Hikind and Maroun, 2008).  
Therefore, while baclofen has been reported to have positive influences on 
memory consolidation, the negative regulation of glutamate and dopamine does 
not account for the extinction facilitating effects observed in the current study. 
 
Extinction of a previously established memory can occur when a memory is 
recalled (which makes the memory labile and sensitive to disruption) but not 
successfully reconsolidated (McGaugh, 2000; Tronson and Taylor, 2007; Taylor 
et al., 2009; Bevilaqua et al., 2008).  Inhibiting reconsolidation as a practical 
means to reduce cue-induced cocaine seeking has been successfully 
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demonstrated (Lee et al., 2006; Lee et al., 2005).  GABABR-induced decrease in 
glutamatergic neurotransmission (Yamada et al., 1999; Lei and McBain, 2003; 
Porter and Nieves, 2004; Harte and O'Connor, 2005) should serve to blunt 
memory reconsolidation as administration of an NMDA receptor antagonist 
inhibits reconsolidation of cocaine-induced CPP memory (Brown et al., 2008; 
Itzhak, 2008).  Dopamine receptor antagonism has been reported to have both 
no effect on the extinction of cocaine CPP (Yim et al., 2009) but has been 
reported to facilitate the extinction of conditioned fear (an effect that may be 
attributed to the disruption of re-consolidation mechanisms) (Ponnusamy et al., 
2005).  In the current protocol, we cannot determine if baclofen enhanced 
extinction learning or inhibited memory re-consolidation, a task made more 
difficult by the fact that these processes have many overlapping mechanisms 
(Alberini, 2005), these avenues need further exploration to determine how 
baclofen facilitated the extinction of Meth-induced CPP. 
 
Baclofen effects on memory maintenance, independent of re-exposure to the 
conditioning cues, should also be considered for the current behavioral 
outcomes.  To date only Bartoletti and colleagues (Bartoletti et al., 2004) have 
demonstrated efficacy of baclofen to modify the maintenance of a previously 
established psychostimulant-induced behavior.  These authors reported that the 
maintenance of amphetamine-induced motor sensitization is diminished by 10 
home cage administrations of 2mg/kg baclofen.  In the current study, baclofen 
may have inhibited memory maintenance independent of re-exposure to the 
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conditioning cues.  However, while we have observed that the maintenance of 
Meth-induced CPP was not inhibited with two once-daily baclofen treatments 
(2mg/kg) (Chapter VI) the maintenance of the behavior can be inhibited by two 
once-daily injections of negative allosteric modulators of the metabotropic 
glutamate receptor subtype 5 (mGluR5).  Likewise, 10 administrations of 
baclofen in the home cage inhibited the maintenance of Meth-induced CPP 
(Chapter IV); however, we contend that the inhibitory effects of baclofen on the 
maintenance of Meth-induced CPP may be more therapeutically efficacious by 
combining baclofen treatment with extinction training.  
 
In summary, we have found that baclofen administered in conjunction with 
extinction training resulted in rapid and complete extinction of Meth-induced 
CPP.  While the mechanism is unclear this exciting study provides insight into the 
role of the GABABR in memory processes engaged after re-exposure to salient 
drug-associated contextual cues and may be of value as an addiction therapy for 
abstinent, Meth-addicted individuals.   
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Table 3.  Motor activity recorded during testing revealed no significant 
differences between vehicle- (n=10) and baclofen- (n=11) treated rats. 
 CPP Test 
1 
Ext Test 1 Ext Test 2 Ext Test 3 Ext Test 4 
Horizontal Activity 
Vehicle 4242±226 3306±115 3098±198 3296±356 2876±152 
Baclofen 4003±259 3291±252 3239±263 2899±201 2773±126 
Vertical Activity 
Vehicle 746±51 528±44 519±49 446±33 406±32 
Baclofen 757±82 569±62 527±60 380±32 398±26 
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Figure 26.  Extinction of Meth-induced CPP was facilitated by baclofen.  A.  
Illustration of treatment protocol.  A drug-free pre-test was conducted and rats 
were assigned to receive Meth in the chamber in which the least amount of time 
was spent during the pre-test.  Conditioning occurred on days 1–6.  A drug-free 
CPP test was conducted on day 9 to verify the development of CPP.  Daily 
extinction sessions consisted of a saline injection prior to being placed into either 
the previously saline- or Meth-paired chamber.  Immediately following each 
extinction training session, baclofen vehicle or baclofen was administered before 
the rats were returned to the home cage.  Each six-day extinction cycle was 
followed by a drug-free test for preference three-days after the last extinction 
session (denoted Ext Test 1-4, on days 18, 30, 46 and 55).  M, 
methamphetamine (1mg/kg); S, saline (1mg/kg); Veh, vehicle (0.9% saline, 
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1ml/kg); Bac, baclofen (2mg/kg); Ø, no drug.  B.  Meth-induced CPP established 
by 6 days of conditioning and subsequently expressed during CPP Test 1 was 
not altered by post-conditioning administration of vehicle; significant CPP was 
expressed on CPP Test 1 through Ext Test 4 (Vehicle, n=10).  C.  CPP Test 1 
validated that rats expressed a preference prior to initiating extinction training.  
The preference evident during CPP Test 1 was not present after the first 
extinction cycle with baclofen (Baclofen, n=11).  Post-hoc Newman-Keuls was 
used to determine between chamber differences ** p<0.01.  Solid line, time spent 
in the Meth-paired chamber; dashed line, time spent in the saline-paired 
chamber; grey line, time spent in the center chamber. 
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CHAPTER X 
GENERAL DISCUSSION 
Relapse to drug use is a major problem for abstinent drug-addicted individuals; 
cues associated with drug use can precipitate drug-craving, -seeking, and –
relapse (Childress et al., 1993; Ehrman et al., 1992; O'Brien et al., 1998).  Thus, 
a mechanism to functionally ‘uncouple’ the cue from the response (i.e., drug-
craving and –seeking) may reduce the propensity of individuals to relapse to drug 
use.  Towards that end, this dissertation project explored the role of the GABABR 
in the maintenance of Meth-induced CPP.  The maintenance of CPP, compared 
to the development and expression phases, is a relatively unexplored area which 
has significant clinical applications, for it is those individuals who are already 
addicted who require treatment and will struggle with the consequences of being 
re-exposed to drug-associated cues.  Thus, disrupting processes necessary to 
maintain the previously acquired drug-cue association may be of value as an 
anti-relapse therapy.  This dissertation project was developed to assess if 
augmenting GABABR signaling was sufficient to alter brain circuits necessary to 
maintain and subsequently expresses Meth-induced CPP.  The collective results 
from this project demonstrate that the maintenance of Meth-induced learned 
associations are sensitive to disruption by augmenting GABABR signaling.  
GABABRs regulate the development and expression of drug-induced behaviors 
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 (e.g., CPP and MS) as well as learning and memory; however, the influence of 
these receptors in the maintenance of drug-induced behaviors is largely 
unexplored.  To date, only Bartoletti and colleagues have demonstrated that 10 
once-daily injections of baclofen administered after the development of 
amphetamine- (Bartoletti et al., 2005) or morphine- (Bartoletti et al., 2007) 
induced motor sensitization inhibits the subsequent expression of the behavior 
and Heinrichs and colleagues have demonstrated that baclofen facilitates the 
extinction of morphine-induced CPP (Heinrichs et al., 2010).  Findings from the 
current project extend these previous results by revealing that i) 10 once-daily 
systemic injections of baclofen or fendiline, ii) two once-daily systemic injections 
of GS39783 and CGP7930, iii) two once-daily intra-MDT injections of baclofen 
administered in the context of the home cage altered brain processes necessary 
to maintain Meth-induced CPP, and iv) six systemic injections of baclofen 
administered in conjunction with extinction training accelerated the disruption of 
the preference.  GABABR activation influences neuronal function via several 
different mechanisms which may disrupt Meth-induced CPP; below, I have 
overviewed the most plausible theories that help define these mechanisms and 
which dovetail into the findings from the current project. 
 
Repeated administration of psychostimulants has significant effects on neuronal 
excitability.  Studies overwhelmingly support the notion that the brain is hyper-
excitable during re-exposure to drug-associated cues.  This hyper-excitability 
was measured as an increase in i) Fos expression (Brown et al., 1992; 
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Ciccocioppo et al., 2001; Franklin and Druhan, 2000; Rhodes et al., 2005; 
Zombeck et al., 2008; Miller and Marshall, 2005), ii) neuronal firing (Rebec and 
Sun, 2005) iii) metabolic activity (Childress et al., 2008; Childress et al., 1999), 
and iv) extrasynaptic concentrations of neurotransmitters glutamate (Bell et al., 
2000; Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002) and dopamine (Lin 
et al., 2007).  These studies consistently demonstrate neuronal hyper-excitability 
within the amygdala, thalamus, and PFC (especially the anterior cingulate and 
the orbitofrontal cortices) when the psychostimulant withdrawn individual is re-
exposed to drug-associated stimuli.  Both the amygdala and the thalamus send 
glutamatergic projections to the PFC; therefore, the PFC may be a site of 
convergence for multiple brain circuits which respond to drug-associated stimuli.  
Thus, restoring the inhibitory/excitatory balance in the PFC (which plays an 
important role in learning/memory processes as well as executive function) and 
associated circuits may reduce the maintenance and subsequent expression of 
Meth-induced CPP.  Outcomes obtained in Chapter VIII indicate that any putative 
adaptations did not involve the level of expression or cellular distribution of the 
GABABR, in several limbic regions at times when Meth-induced behaviors (which 
presumably involve neuronal hyper-excitability) were expressed (i.e., cue-
induced hyper-responsivity (CPP) and drug-induced hyper-excitability (MS)).  
Thus, it does not appear that changes in GABABR expression and/or distribution 
are responsible for rats to demonstrate Meth-induced behaviors, and that down-
regulation of some other component of the GABABR system may have occurred.  
For example, decreased G-protein expression is observed after chronic cocaine 
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(Nestler et al., 1990) and functional coupling of the GABABR to the G-protein 
after a sensitizing regimen of amphetamine (Zhang et al., 2000) or chronic 
cocaine (Kushner and Unterwald, 2001).  It might be that overt changes in the 
expression of the GABABR only occur with robust psychostimulant exposure (> 
10 days, 15-18mg/kg i.v. cocaine/day) as was observed previously (Frankowska 
et al., 2008b; Frankowska et al., 2008a) and not with the more modest Meth-
treatment protocols which induced CPP and MS (1mg/kg x 3 days).  Although no 
changes were observed in the current project, a previous report has 
demonstrated that GABABR expression does not predict function of the GABABR 
system (Enna and Bowery, 2004).  Determination of such changes in GABABR 
system function at a time when Meth-induced behaviors are observed will require 
further study.  Independent of the status of the GABABR system, this project has 
demonstrated that augmenting GABABR signaling inhibited the maintenance of 
Meth-induced CPP.   
 
Activating GABABRs inhibits Ca
++ influx via high voltage activated Ca++ channels 
(Gong et al., 1998; Kalivas, 1993; Santiago et al., 1993c; Santiago et al., 1993b; 
Smolders et al., 1995; Westerink et al., 1996; Harte and O'Connor, 2005; Lei and 
McBain, 2003; Porter and Nieves, 2004; Yamada et al., 1999; Bonanno et al., 
1997; Huston et al., 1990; Amico et al., 1995; Cardozo and Bean, 1995; Mintz 
and Bean, 1993; Scholz and Miller, 1991; Takahashi et al., 1998).  This effect 
would oppose the enhanced excitatory response to drug-stimuli (i.e., subsequent 
drug exposure or re-exposure to cues) caused by repeated psychostimulant 
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administration which increases the expression of L-type Ca++ channels 
(Shibasaki et al., 2010; Ford et al., 2009; Nasif et al., 2005a; Nasif et al., 2005b; 
Hu, 2007).  Whether attenuated inhibition or augmented excitation underlies 
maintenance, increasing GABABR signaling effectively disrupted mechanisms 
necessary to maintain and subsequently express Meth-induced CPP. 
 
Baclofen administered in conjunction with extinction training rapidly disrupted the 
Meth-induced preference beyond that achieved with extinction training alone 
(Chapter IX).  This experimental protocol highlights events which occur during re-
exposure to Meth-associated cues; it suggests that blunting neuronal activity 
and/or down-stream signaling events at a time when neuronal activity was 
increased (i.e., during re-exposure to cues) rapidly disrupted the Meth-induced 
preference.  GABABRs directly influence neurotransmitter release via inhibition of 
high-voltage activated Ca++ channels (Gong et al., 1998; Kalivas, 1993; Santiago 
et al., 1993c; Santiago et al., 1993b; Smolders et al., 1995; Westerink et al., 
1996; Harte and O'Connor, 2005; Lei and McBain, 2003; Porter and Nieves, 
2004; Yamada et al., 1999; Bonanno et al., 1997; Huston et al., 1990; Amico et 
al., 1995; Cardozo and Bean, 1995; Mintz and Bean, 1993; Scholz and Miller, 
1991; Takahashi et al., 1998), neuronal excitability via activation of GIRKs 
(Tabata et al., 2005; Luscher et al., 1997; Nicoll, 2004; Chen and Johnston, 
2005; Takigawa and Alzheimer, 1999), and down-stream molecular events via 
inhibition of cAMP and CREB (Bettler et al., 2004; Bowery et al., 2002; Bowery, 
1993).  Thus, the GABABR has multiple mechanisms that may underlie the 
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observed behavioral outcomes.  GABABR-mediated reduction in excitatory 
neurotransmitter release, is akin to blunting neuronal excitation via 
pharmacological antagonism of glutamate receptors; a well documented means 
to impair mnemonic processes (i.e., consolidation and reconsolidation) (Liu et al., 
2009; Feltenstein and See, 2007; Brown et al., 2008; Itzhak, 2008; Holtzman-
Assif et al., 2010; Hikind and Maroun, 2008; Ponnusamy et al., 2005).  In 
addition, GABABR-mediated reduction in cAMP (Bettler et al., 2004) may reduce 
the activity of the transcription factor CREB (Barthel et al., 1996; Bettler et al., 
2004; Mott and Lewis, 1994; Lhuillier et al., 2007; Yin et al., 2006).  Indeed, 
augmenting GABABR signaling at the same time as psychostimulant 
administration pharmacologically antagonizes events leading to psychostimulant-
induced changes in the transcription factor CREB (Yin et al., 2006; Lhuillier et al., 
2007) and also inhibits downstream consequences of changes in gene 
transcription including ΔFosB (Lhuillier et al., 2007) and neuropeptide gene 
expression (Zhou et al., 2004).  This transcriptional regulation by the GABABR 
may also reduce the expression of proteins that regulate mnemonic processes, 
e.g., NMDA receptors which are known to be regulated by CREB (Mayr and 
Montminy, 2001; McClung and Nestler, 2003).  In addition, GABABR mediated 
inhibition PKA (via cAMP) would be expected to negatively impact memory 
processes as direct inhibition of PKA impairs the maintenance of spatial, fear 
conditioned, and recognition memory (Abel and Nguyen, 2008; Wang et al., 
2006) as well as memory consolidation (Bourtchouladze et al., 1998; Quevedo et 
al., 2004; Vianna et al., 2000; Isiegas et al., 2006) and reconsolidation (Micheau 
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and Riedel, 1999) when administered immediately before or after 
training/testing/re-exposure to cues.  GABABR G-protein independent 
mechanisms, where transcription factors bind directly to the receptor, may also 
be involved (e.g., CREB2) (White et al., 2000; Nehring et al., 2000; Vernon et al., 
2001).  Thus, there are multiple avenues by which augmenting GABABR 
signaling can disrupt the cue-activated brain state which may account for the 
behavioral inhibition observed when baclofen was administered in conjunction 
with extinction training.   
 
In contrast to the cue-activated brain produced during re-exposure to drug-
associated cues (e.g., during extinction training) (Brown et al., 1992; Ciccocioppo 
et al., 2001; Franklin and Druhan, 2000; Rhodes et al., 2005; Zombeck et al., 
2008; Miller and Marshall, 2005; Rebec and Sun, 2005; Bell et al., 2000; 
Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002; Lin et al., 2007), the 
remaining studies primarily evaluated the effects of baclofen given without re-
exposure to conditioning cues.  Thus, administration of PAMs, which are highly 
dependent on extracellular GABA concentrations, may function quite differently in 
a cue-activated brain vs. a ‘non-activated’ brain.  Although these brain states are 
quite different, results from this project demonstrated that augmented GABABR 
signaling during the maintenance period is also sufficient to disrupt processes 
necessary to maintain Meth-induced CPP.   This effect may be the consequence 
of the highly dynamic brain state that exists during the days and weeks following 
psychostimulant administration and learning with different kinases, transcription 
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factors, and proteins being expressed and activated in a time dependent manner 
(Lonze and Ginty, 2002; Selcher et al., 2002; Wang et al., 2006; Bailey et al., 
1996; Nestler, 2001; Chen et al., 2009; Berke and Hyman, 2000; Carlezon et al., 
2005; McDaid et al., 2006b; Ford et al., 2009; Alberini, 2009).  Based on results 
obtained with the PAMs, regions which are critical for the maintenance of Meth-
induced CPP express GABABRs and have endogenous GABAergic tone. 
 
While it is difficult to predict what brain regions systemic administration of 
baclofen, fendiline, GS39783, or CGP7930 might most influence; guided several 
criterion we chose to explore the MDT as a critical mediator of the effects of 
systemically administered ligands.  The MDT i) expresses moderate to high 
levels of GABABRs (Margeta-Mitrovic et al., 1999; Charles et al., 2003), ii) is 
tonically regulated by endogenous GABA (Churchill et al., 1996a), iii) sends a 
glutamatergic projection to the PFC which is known to regulate drug-induced 
behaviors and mnemonic processes (in fact the orbitofrontal cortex is defined 
almost entirely as a projection region of the MDT) (Goldman-Rakic, 1995; Kuroda 
et al., 1995; Krettek and Price, 1977; Sesack et al., 1989) which alters PFC 
neuronal activity (Bubser et al., 1998; Pirot et al., 1994; Ferron et al., 1984; Gigg 
et al., 1992), and iv) studies which demonstrate an involvement of the MDT in 
drug-induced behaviors (Churchill and Kalivas, 1999) and mnemonic processes 
(Romanides et al., 1999; Floresco et al., 1999; McAlonan et al., 1993; Kalivas et 
al., 1999; Kalivas et al., 2001; Oyoshi et al., 1996).  As this anatomical 
connectivity would predict, augmenting GABABR signaling in the MDT, which 
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should reduce glutamate release in the cortex (Bubser et al., 1998; Pirot et al., 
1994; Ferron et al., 1984; Gigg et al., 1992), was sufficient to disrupt processes 
necessary to maintain Meth-induced CPP (Chapter VII).  Glutamate in the PFC is 
a critical regulator of mnemonic processes (Wang et al., 2006).  Administration of 
baclofen into other regions which provide significant glutamatergic input to the 
PFC would be expected to have similar behavioral outcomes.  The HC provides 
glutamatergic input to the PFC and intra-HC baclofen inhibits passive avoidance 
memory retention (Zarrindast et al., 2002) as well as the acquisition of spatial 
memories (Arolfo et al., 1998).  In contrast to these results, baclofen injected into 
the HC in the current study did not inhibit the maintenance of Meth-induced CPP 
(Chapter VII).  Thus, intra-HC baclofen does influence mnemonic processes, but 
this effect may be a task-specific (i.e., associative learning vs. spatial or passive 
avoidance learning), phase specific (i.e., acquisition vs. maintenance), or dose-
specific.  It is interesting that the HC, which does provide glutamate to the PFC, 
was not identified by Rhodes and colleagues as a region which is engaged 
during re-exposure to Meth-associated cues in a Meth-CPP protocol (Rhodes et 
al., 2005).  Future studies evaluating the amygdala which does provide a 
glutamatergic input and is activated during cue re-exposure would be of value in 
determining the neurocircuitry underlying the maintenance of Meth-induced CPP. 
 
Our results suggest that brain region-selective augmentation of GABABR 
signaling disrupts Meth-induced CPP more rapidly than non-selective activation 
of GABABRs throughout the brain.  This conclusion is drawn from the observation 
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that two once-daily systemic injections of the selective PAMs GS39783 and 
CGP7930 (Chapter VI), and local injection of baclofen into the MDT (Chapter 
VII), inhibited the maintenance of Meth-induced CPP, whereas two 
administrations of baclofen (Chapters IV & VI) or the PAM/L-type Ca++ channel 
blocker fendiline did not (Chapter V).  Thus, global activation of GABABRs by 
baclofen or the global inhibition of L-type Ca++ channels by fendiline may negate 
the effects of selectively augmenting GABABRs in areas where GABA is 
endogenously released.  That is, the GABABR influence on neuronal activity in 
particular brain regions appears to have been overridden by global inhibition 
throughout the brain.  This effect was independent of the post-conditioning time 
during which the two once-daily injections of baclofen and fendiline were 
administered (i.e., early post-conditioning time vs. a later post-conditioning time).  
Although the brain is highly dynamic during the days and weeks following 
repeated psychostimulant administration (Camp et al., 1997; Ernst and Chang, 
2008; Jayaram and Steketee, 2005; McDaid et al., 2006b; McGregor et al., 2005; 
Zhang et al., 2000; Zhang et al., 2001; Giorgetti et al., 2002; Ford et al., 2009) 
and memory acquisition (Abel and Kandel, 1998; Alberini, 2009; Bailey et al., 
1996), we did not observe time-dependent effects of baclofen or fendiline on the 
maintenance of Meth-induced CPP.  Rather, the inhibitory effects of baclofen and 
fendiline appeared to be dependent on the number of treatments (i.e., protocol 
duration) and not on the post-conditioning withdrawal time during which the 
ligands were administered. 
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 These findings indicate that persistent adaptations engendered by repeated 
GABABR activation and/or Ca
++ channel inhibition are needed to disrupt the place 
memory.  Alterations in neuronal function resulting from two fendiline injections 
were not sufficiently robust to inhibit maintenance and subsequent expression of 
Meth-induced CPP when rats were tested in a drug-free state whereas drug-free 
inhibition of the preference was observable after 10 injections.  Reports 
underscore that such adaptations are long lasting; e.g., 10 once-daily injections 
of baclofen inhibits the expression of amphetamine- and morphine-induced motor 
sensitization when evaluated 28 (Bartoletti et al., 2004) and 30 (Bartoletti et al., 
2007) days after the last administration, respectively.  Such persistent effects 
may reflect long term changes in gene expression which do not occur with two 
injections.  Evidence for this effect can be found in Chapter V, two once-daily 
injections of fendiline rendered the brain vulnerable to an acute injection of 
fendiline; however, this effect was only observed for those rats which received 
fendiline during the late post-conditioning phase and not when fendiline was 
administered during the early post-conditioning phase.  This indicates that the 
adaptations engendered by two injections of fendiline were not sufficiently robust 
(i.e., they are not observable in drug-free rats) nor did they persist (i.e., note 
behavioral differences between two injections during the early vs. late post-
conditioning phase).   
 
It should be noted that we interpret these effects in terms of ‘maintenance of 
previously acquired associations’ but the behavioral outcomes also might reflect 
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changes in motivation (Ma et al., 2010).  Future studies evaluating the 
maintenance of other learned behaviors (e.g., Morris water maze, fear 
conditioning, novel object recognition) vs. tasks that more directly assess 
motivation (e.g., assess break point) are necessary to conclusively determine the 
mechanism underlying the observed behavioral effects.  This will be especially 
important in light of the observation that in a progressive ratio experiment, 
baclofen (3.2mg/kg, i.p.) reduces cocaine self-administration break point when 
given 30min prior to the test while having no effect on food self-administration 
(Brebner et al., 2000).  Thus, it will be informative to conduct a similar test with 
GABABR agonists and/or PAMs administered during the post-acquisition phase 
on a drug-free test for break point. 
 
While many of the exact underlying mechanisms are conjecture it is clear that the 
GABABR is an exciting and highly therapeutically relevant target for an anti-
addiction therapy.  Results from this project suggest that not only do PAMs have 
an improved side effect profile over the agonist baclofen but also that they may 
afford significant therapeutic advantage wherein the selective PAMs GS39783 
and CGP7930 were able to disrupt the maintenance of CPP with fewer 
administrations than baclofen or the non-selective PAM fendiline.  Thus, it will 
certainly be of value to explore the use of the selective GABABR PAMs GS39783 
and CGP7930 as anti-addiction therapies.   
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